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This thesis describes a new approach to disrupting signaling of oncogenic proteins, 
specficially of Ras proteins. Ras is one of the major oncogenes, and it is mutated 
in 20% of all human cancers. Despite numerous efforts, targeting Ras directly 
in cancer has proven unsuccessful. We have taken a new approach to targeting 
Ras, namely targeting its localization and organization into nanoclusters in the 
cell membrane. By utilizing Förster resonance energy transfer (FRET)-based 
methods, we have screened chemical libraries to identify compounds that affect 
Ras nanoclustering. One of the main findings is that known cancer stem cell 
(CSC) inhibitors affect K-ras nanoclustering. We identify a K-ras-associated gene 
signature predicts response of cancer cells to CSC inhibitors. In addition, we were 
also able to identify novel compounds that target CSCs. The results give new 
insights into the role of Ras nanoclusters as promising new molecular targets in 
cancer and in stem cells.
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 ABSTRACT	
Cancer affects more than 20 million people each year and this rate is increasing 
globally. The Ras/MAPK-pathway is one of the best-studied cancer signaling 
pathways. Ras proteins are mutated in almost 20% of all human cancers and despite 
numerous efforts, no effective therapy that specifically targets Ras is available to date. 
It is now well established that Ras proteins laterally segregate on the plasma 
membrane into transient nanoscale signaling complexes called nanoclusters. These 
Ras nanoclusters are essential for the high-fidelity signal transmission. Disruption of 
nanoclustering leads to reduction in Ras activity and signaling, therefore targeting 
nanoclusters opens up important new therapeutic possibilities in cancer. This work 
describes three different studies exploring the idea of membrane protein 
nanoclusters as novel anti-cancer drug targets. It is focused on the design and 
implementation of a simple, cell-based Fo ̈rster Resonance Energy Transfer (FRET)-
biosensor screening platform to identify compounds that affect Ras membrane 
organization and nanoclustering. Chemical libraries from different sources were 
tested and a number of potential hit molecules were validated on full-length 
oncogenic proteins using a combination of imaging, biochemical and 
transformation assays.  
In the first study, a small chemical library was screened using H-ras derived 
FRET-biosensors. Surprisingly from this screen, commonly used protein synthesis 
inhibitors (PSIs) were found to specifically increase H-ras nanoclustering and 
downstream signalling in a H-ras dependent manner. Using a representative PSI, 
increase in H-ras activity was shown to induce cancer stem cell (CSC)-enriched 
mammosphere formation and tumor growth of breast cancer cells. Moreover, PSIs 
do not increase K-ras nanoclustering, making this screening approach suitable for 
identifying Ras isoform-specific inhibitors.  
In the second study, a nanoncluster-directed screen using both H- and K-ras 
derived FRET biosensors identified CSC inhibitor salinomycin to specifically inhibit 
K-ras nanocluster organization and downstream signaling. A K-ras nanoclustering-
associated gene signature was established that predicts the drug sensitivity of cancer 
cells to CSC inhibitors. Interestingly, almost 8% of patient tumor samples in the The 
Cancer Genome Atlas (TCGA) database had the above gene signature and were 
associated with a significantly higher mortality. From this mechanistic insight, an 
additional microbial metabolite screen on H- and K-ras biosensors identified 
ophiobolin A and conglobatin A to specifically affect K-ras nanoclustering and to act 
as potential breast CSC inhibitors.   
In the third study, the Ras FRET-biosensor principle was used to investigate 
membrane anchorage and nanoclustering of myristoylated proteins such as 
heterotrimeric G-proteins, Yes- and Src-kinases. Furthermore, Yes-biosensor was 
validated to be a suitable platform for performing chemical and genetic screens to 
identify myristoylation inhibitors. 
The results of this thesis demonstrate the potential of the Ras-derived FRET-
biosensor platform to differentiate and identify Ras-isoform specfic inhibitors. The 
results also highlight that most of the inhibitors identified predominantly perturb 
Ras subcellular distribution and membrane organization through some novel and 
yet unknown mechanisms. The results give new insights into the role of Ras 
nanoclusters as promising new molecular targets in cancer and in stem cells.  
 
Keywords: cancer stem cells, caveolin, drug screening, FRET, nanoclusters, Ras 
  
 SAMMANFATTNING	(Swedish	Abstract)	
Cancer påverkar mera än 20 miljoner människor årligen och mängden människor 
som insjuknar i cancer ökar globalt. Ras/MAPK-signaleringsräckan är en av de mest 
studerade signaleringsräckorna i cancer. Ras proteinerna är muterade i nästan 20 % 
av alla humana cancer, men trots otaliga försök har man i nuläget inte lyckats hitta 
effektiva läkemedel som specifikt påverkar Ras. Det är nu etablerat att Ras proteiner 
återfinns i plasmamembranen i små tillfälliga signaleringskomplex som kallas 
nanoklusters. Dessa Ras nanoklusters är väsentliga för överföringen av information 
till de signaleringskaskader som är nedströms från Ras. En störning i bildandet av 
nanoklusters minskar Ras-aktiviteten och -signaleringen. Hämmare och aktiverare 
av nanokluster-bildningen kan således vara nya potentiella cancerläkemedel. Detta 
arbete beskriver tre olika studier var vi undersöker idén om rikta in anti-cancer 
läkemedelsbehandlingen mot olika membranproteiners nanoklusterbildning. 
Avhandlingen fokuserar på konstrueringen och implementeringen av en enkel cell-
baserad FRET-biosensor metod för att screena för och identifiera läkemedel som 
påverkar Ras-proteinernas organisation i membranen och deras nanoklusters. Olika 
kemiska bibliotek testades, varefter ett antal potentiella molekyler validerades med 
hjälp av en kombination av mikroskopiering, biokemiska  och  biologiska analyser. 
I den första studien screenades ett litet kemikaliebibliotek med hjälp av 
FRET-biosensorer som härletts från H-ras proteinet. Till vår överraskning upptäckte 
vi att proteinsyntesinhibitorer (PSI) specifikt ökar bildandet av H-ras nanoklusters 
och således även H-ras beroende nedströmssignalering. Vi kunde dessutom visa att 
den cycloheximid-inducerade ökningen i H-ras aktiviteten medförde att både 
bildandet av cancerstamcell (CSC)-mammosfärer och in ovo tumörtillväxten ökade. 
Nämnvärt är att PSI inte ökar mängden K-ras nanoklusters, vilket visar att denna 
screening-metod också är användbar för att identifiera isoform-specifika inhibitorer 
för Ras. 
I den andra studien använde vi biosensorer som härletts från både H- och K-
ras och vi upptäckte att CSC inhibitorn salinomycin specifikt inhibierar bildandet av 
K-ras nanoklusters och således dess nedströms signalering. Ut över detta upptäckte 
vi en specifik genisgnatur som predicerar hur känsliga cancercellerna är för CSC 
inhibitorer. Intressant nog återfanns denna gensignatur i cirka 8 % av tumörerna i 
The Cancer Genome Atlas (TCGA)-databasen och den korrelerade med en 
signifikant högre dödlighet. Genom att använda oss av denna gensignatur kunde vi 
identifiera ytterligare två ämnen, ophiobolin A och congoblatin A som hämmar 
tillväxten av CSCs. Dessa ämnen inhiberar specifik K-ras nanoklustering och verkar 
som potentiella bröst CSC-inhibitorer. 
I den tredje studien använde vi oss av samma FRET-biosensor princip för att 
studera hur myristoylerade proteiner, t.ex. heterotrimeriska G-proteiner, Yes- och 
Src-kinaser, bildar nanokluster och hur de är förankrade i membranen. Vidare 
validerades Yes-biosensorerna som en passande platform för att utföra kemiska- och 
genetiska screener för att identifiera ämnen som inhiberar myristoylering.  
Resultaten från denna avhandling visar tydligt att Ras-härledda FRET-
biosensorer kan användas för att identifiera isoformspecifika Ras-inhibitorer. 
Resultaten påvisar även att de flesta nya inhibitorer som identifierades främst stör 
den subcellulära distributionen av Ras och dess organisering i membranen genom en 
fortfarande oupptäckt mekanism. Dessa resultat ger en djupare förståelse för Ras 
nanoklustrens roll som lovande nya molekylära mål i kampen mot cancer och 
cancerstamceller.  
Nyckelord: cancerstamceller, caveolin, FRET, läkemedel screening, nanoklusters, 
Ras 
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INTRODUCTION	
I n t r o d u c t i o n 	
According to the World Health Organization around 15% of all deaths worldwide 
are caused by cancer. In 2012, 14.1 million new cancer cases and 8.2 million cancer 
deaths were registered worldwide. These numbers are expected to rise due to the 
changing lifestyles, growth and aging of the world population. This has gathered 
great attention and efforts from the academic and pharmaceutical industry to 
identify and develop anti-cancer agents. Cancer is defined as a group of diseases 
characterized by uncontrolled cell growth and spreading of cancer cells.  
A number of strategies have been employed over the last century to treat cancer. 
They range from surgery, chemotherapy, radiation, hormone therapy, and immune 
therapy to targeted therapy, which employs drugs against specific molecules in 
cancer cells. However, success of these different therapeutic strategies varies widely. 
The pioneers of molecular oncology identified a collection of genes that when 
mutated lead to uncontrolled cell proliferation and cancer. Many of these oncogenes 
and oncoproteins are now known to be drivers of human cancers. Several anti-
cancer agents have been developed in the past few decades against human cancers. 
Cisplatin, a first-class of anti-cancer drugs, is a DNA-binding agent that induces cell 
death. Natural product-derived anti-cancer drugs such as paclitaxel (Taxol) that 
deregulate cell division, have potent anti-cancer properties. However, these drugs 
and their counterparts affect many cellular pathways and they are not specific for 
cancer cells, thus causing severe side effects. The identification of oncogenes and the 
molecular level understanding of their function have resulted in the identification of 
more specific anti-cancer drugs, such as the Abl kinase inhibitor imatinib (Gleevec) 
that is effective in treating chronic myeloid leukemia. In addition to small molecules, 
antibodies against kinase receptors have also been developed. For example, 
bevacizumab (Avastin), a humanized monoclonal antibody against the vascular 
endothelial growth factor A (VEGF-A) that targets angiogenesis has been in use for 
treating several cancers.  
Ras proteins are an important class of anti-cancer targets that are frequently mutated 
in cancers. Yet, after thirty years of intense efforts to target these mutant proteins, no 
safe drugs have been developed successfully. However, these efforts have 
substantially increased our understanding of Ras function and regulation in normal 
and cancer cells. Today, we know that Ras forms nanoscale signaling domains called 
nanoclusters on the plasma membrane that are critical for Ras signaling. 
This thesis summarizes efforts to identify chemical modulators of Ras membrane 
anchorage and nanoclustering, and postulates nanoclustering as a general 
characteristic of lipid-bound proteins.  
Review of the Literature – The Ras Superfamily of Small GTPases 
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REVIEW	OF	THE	LITERATURE	
R e v i e w 	 o f 	 t h e 	 L i t e r a t u r e 	 – 	 T h e 	 R a s 	 S u p e r f a m i l y 	 o f 	 S m a l l 	 G T P a s e s 	 	 	
1 Ras	Superfamily	of	Small	GTPases	
 
Small guanosine triphosphatases (GTPases) are proteins that bind and hydrolyze 
guanosine triphosphate (GTP). The human Ras-superfamily of small GTPases 
consists of 160 proteins that are subdivided based on function and sequence 
similarities into five classical families consisting of 39 Ras proteins, 30 Arfs, 22 Rhos, 
65 Rabs, 1 Ran and some ‘unclassified’ sequences  (Figure 1). These families of 
proteins are involved in functions ranging from cellular signaling, proliferation, 
differentiation, cytoskeletal organization, vesicular trafficking to nuclear transport 
(Rojas et al., 2012). 
 
 
 
Small GTPases act as molecular binary switches and they have the following 
characteristics that form a common biochemical paradigm for the whole 
superfamily: they cycle between an active GTP-bound ‘On’ and an inactive GDP-
bound ‘Off’ state, they have high affinities for GDP and GTP, they all contain the G-
domain that binds GTP or GDP, and they undergo large conformational changes 
following nucleotide binding (Wennerberg et al., 2005). The G-domain contains five 
conserved G box fingerprint motifs called G1-G5. Guanine nucleotide binding-
induced structural changes happen in the ‘switch’ regions - switch I (Ras residues 30-
38) and switch II (Ras residues 59-67). In short, activation of Ras proteins begins as 
the γ-phosphate of the GTP interacts with switch I (at threonine 35) and II (at 
glycine 60) pulling them close to the nucleotide into what is interpreted as the 
“loaded spring” mechanism (Vetter and Wittinghofer, 2001). This induces a 
conformational change to form an interaction surface that favors effector binding in 
Ran
Ras
Rho
Arf
Rab
Figure	1.	The	Ras	Superfamily	of	GTPases.	Adapted	from	(Rojas	et	al.,	2012)	
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a GTP-dependent fashion.  When the γ-phosphate is cleaved-off by the GTPase 
activity, it releases the “loaded spring” yielding the GDP-bound form. The 
GDP/GTP state of Ras is regulated by the guanine nucleotide exchange factors 
(GEFs) that turn “on” the molecular switch by promoting the dissociation of bound 
GDP in exchange for a new GTP (Figure 2). Since the cytosolic GTP concentration is 
much higher than GDP, GTP replaces GDP and changes Ras to an active state 
(Antonarakis and Van Aelst, 1998). Conversely, this active state of Ras is regulated 
by its very low intrinsic GTPase activity that is accelerated strongly by the GTPase-
activating proteins (GAPs) that cause the hydrolysis of GTP to GDP and promote 
the formation of the inactive GDP-bound Ras. This cycling of Ras between the GDP 
and the GTP bound states is known as the GTPase cycle (Figure 2) (Vigil et al., 
2010).  
 
 
1.1 Ras	as	founding	members	of	the	Ras	superfamily	
Ras has the distinction of being the first oncogene to be identified in human cancers 
(Der et al., 1982; Parada et al., 1982; Santos et al., 1982). This observation came to 
fruition from the early discoveries of acutely transforming retroviruses that caused 
sarcomas in infected animals. This was followed by the discovery of the oncogenic 
Harvey murine sarcoma virus (Harvey, 1964) and Kirsten murine sarcoma virus 
(Kirsten and Mayer, 1967) and their ability to cause Rat Sarcomas (Ras). The viral 
genes were named HRAS and KRAS and their corresponding proteins came to be 
known as Ha-Ras or H-ras and Ki-Ras or K-ras. By 1980s, studies from Scolnick and 
colleagues made it clear that the HRAS and KRAS genes encode a membrane bound, 
Ras
GTP
Ras
GDP
GEFGAP
Effector
Pi GTP
GDP
Figure	2.	 The	GTPase	 cycle.	 Ras	 is	 a	 low-molecular	weight	 guanine	nucleotide	binding	protein	 that	
acts	 as	 a	molecular	switch	cycling	between	a	GDP-	and	GTP-bound	state,	which	 is	 regulated	by	the	
guanine	 nucleotide	 exchange	 factors	 (GEFs)	 and	 GTPase	 activating	 proteins	 (GAPs).	 Inactive	 GDP-
bound	Ras	is	activated	by	GEFs	that	catalyze	GTP	binding	of	Ras.	Consequently,	GTP-bound	active	Ras	
interacts	with,	 and	activates,	 the	downstream	 signaling	 effector	proteins.	 The	 active	 state	of	Ras	 is	
regulated	 by	 its	 low	 intrinsic	 GTPase	 activity,	 which	 is	 accelerated	 strongly	 by	 GAPs	 leading	 to	
hydrolysis	of	GTP	to	GDP.	
Review of the Literature – The Ras Superfamily of Small GTPases 
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21 kDa protein that binds GDP and GTP. They also identified that the cellular 
equivalent of these viral genes had similar properties and their preferential GTP 
binding is key for transformation (Cox and Der, 2010). In 1982, three laboratories 
made the milestone discovery of identifying the transforming gene from human 
cancers to be homologues of the viral Harvey and Kristen-RAS genes (Der et al., 
1982; Parada et al., 1982; Santos et al., 1982). This was followed by the identification 
of NRAS  - named after the oncogene found in a human neuroblastoma cell line 
(Ireland, 1989). Today these Ras proteins are considered the founding members of 
the Ras superfamily of proteins.  The Ras family has received much attention as it 
occupies a central role in many cellular signaling processes including cell growth, 
differentiation and apoptosis. 
 
1.2 Ras	isoforms	have	high	sequence	identity	
 After more than 30 years since the original finding, we now know that mammalian 
cells have three ‘classical’ RAS genes encoding four distinct clinically relevant 
isoforms of Ras – H-ras, K-ras4A and 4B (two splice variants of the K-ras gene) and 
N-ras. These four Ras isoforms are 188–189 amino acid long with an almost 82-90% 
overall sequence identity. The first 164 residues comprise the highly conserved G-
domain, with the first 80 amino acids being identical and the next 85 amino acids 
display over 95% sequence identity (Figure 3). All the four Ras isoforms differ almost 
exclusively in the 25 amino acids of the carboxyl-terminal known as the 
hypervariable region (HVR) (Figure 3). Therefore, it is suggested that the functional 
differences between the Ras isoforms is due to the HVR. As discussed later, HVR 
contains the targeting information needed for Ras membrane anchorage that is 
essential for Ras function (Cox and Der, 2010).  
 
Figure	3.	Ras	overall	domain	structure.	The	four	Ras	isoforms	(H-,	N-,	K-ras4A	and	4B)	that	are	188-
189	amino	acid	 long	share	82-90%	overall	 sequence	 identity.	The	residues	1-164	 comprise	the	G-
domain	that	contains	the	nucleotide	binding	domains,	the	effector	binding	domain,	and	the	switch	
regions.	The	nucleotide	binding	domains	(blue)	comprise	the	five	conserved	GTP-binding	motifs.	The	
effector-binding	 domain	 (purple)	 (residues	 32-40)	 is	 involved	 in	 effector	 binding	 specificity.	 The	
switch	 I	 (residues	 30-38)	 and	 II	 (residues	 60-76)	 regions	 change	 conformation	 with	 GDP/GTP	
binding.	 The	 last	 25	 amino	 acids	 comprise	 the	 hypervariable	 region	 (HVR)	 that	 is	 essential	 for	
membrane	binding.	The	key	residues	that	are	mutated	in	cancers	are	identical	among	the	three	Ras	
isoforms	and	are	highlighted	in	red.			
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The KRAS gene encodes for two gene products that are generated by alternative 
splicing. These splice variants differ by the use of alternative fourth exons and are 
designated K-ras4A and 4B. The alternative fourth exons encode the C-terminal 
regions responsible for membrane targeting. K-ras4A can be palmitoylated and K-
ras4B lacks the palmitoylation site. Recent data suggest that K-ras4A is expressed in 
several cancers including colorectal cancers (Tsai et al., 2015). However, K-ras4B is 
the ubiquitously expressed splice variant, and unless otherwise mentioned K-ras4B 
will hereafter be denoted as K-ras.  
 
1.3 Ras	activation	is	regulated	by	GEFs	and	GAPs	
Ras proteins are activated by receptor tyrosine kinases (RTKs), G-protein coupled 
receptors or steroid hormones in response to various extracellular stimuli required 
for cell proliferation, growth, tissue development or repair. These cellular functions 
are tightly controlled via Ras proteins in normal cells and the deregulation of these 
key functions is a hallmark of cancer (Hanahan and Weinberg, 2011). In non-
malignant cells, growth factor binding to the extracellular domain of the RTK 
activates the receptor, which initiates the recruitment of adaptor proteins, like Grb2 
or Shc. This in turn leads to the recruitment of GEFs to the plasma membrane. Ras 
can be activated by one of the eight known GEFs, including the two SOS (Son of 
Sevenless) isoforms, two specific guanyl nucleotide releasing factors (RASGRF) and 
four RAS‐specific guanine nucleotide-releasing proteins (RASGRP) (Vigil et al., 
2010). These GEFs contain the CDC25 homology catalytic domain, which stimulates 
GDP release, and the N-terminal Ras exchange motif. SOS is one of the best-
characterized GEFs; first identified to regulate Drosophila melanogaster eye 
development and later identified in humans (Rogge et al., 1991). The Grb2-SOS 
complex translocates via the SH2-domain close to the plasma membrane associated 
RTK and brings SOS in the vicinity of Ras. The Ras-SOS-binding stimulates the 
release of the bound nucleotide from Ras. Because the cytosolic GTP concentrations 
are ten-fold higher than GDP, GTP is rapidly exchanged for the previously utilized 
GDP, thus promoting the formation of active GTP-bound Ras (Vetter and 
Wittinghofer, 2001). This active Ras can bind with high affinity to the downstream 
effectors. The active GTP-bound Ras needs to be deactivated. As Ras has a very weak 
intrinsic GTPase activity, the deactivation is accelerated by the GAPs that can 
increase the rate of GTP hydrolysis by a factor of 105. Thus, GAPs, by acting as 
negative regulators of Ras, limit Ras signaling. In 1987, Trahey and McCormick 
characterized the first Ras-GAP, p120RasGAP (Trahey and McCormick, 1987). It 
was shown to bind Ras and increase the rate of GTP hydrolysis by 300 fold. This was 
followed by the identification of neurofibromin (NF1) as a RasGAP, from patients 
with type I neurofibromatosis, an inherited condition of benign brain tumors 
(Martin et al., 1990). Currently, there are seven known mammalian Ras-specific 
GAPs and they function through binding to the catalytic site of Ras and increasing 
the hydrolysis of Ras-GTP by inserting an ‘Arg finger’ into the active site (Ahmadian 
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et al., 1997; Vigil et al., 2010). This favors the nucleophilic attack of water on GTP 
and this catalysis is mediated by the conserved glutamine 61, as the GAP stabilises 
the switch II domain. However, oncogenic mutations on Ras, such as the mutations 
on Glycine 12, 13 and Glutamine 61 render Ras insensitive to GAP hydrolysis and 
thereby persistently lock Ras into a GTP-bound active state (Bos et al., 2007). Ras 
GEFs are deregulated in cancers through infrequent somatic mutations and 
increased gene expression leading to aberrant GEF activation. Though somatic 
mutations are rare, germline gain-of-function mutations in Ras GEF SOS are found 
in almost 13% of patients with Noonan syndrome, which is also associated to an 
increased risk to cancer (Roberts et al., 2006). However, these mutations are thought 
to be weakly activating and not potent enough to lead to cancer formation (Swanson 
et al., 2008). Ras GAPs stimulate the intrinsic GTPase activity and in general act as 
tumor suppressors. Ras GAP neurofibromin encoded by tumor suppressor NF1 is 
found to have both germline and somatic mutations. Loss-of-function germline 
mutations in NF1 are found in neurofibromatosis type 1 patients that have an 
increased risk of developing cancers of the nervous system (Vigil et al., 2010).  
 
1.4 Ras	signal	transduction	
Active Ras transmits the signal downstream through interacting with proximal Ras 
effectors. There are more than ten reported Ras effectors that have a strong affinity 
for GTP-Ras, initiating downstream signaling cascades (Figure 4). The majority of 
the Ras effectors share the same structural feature known as the Ras-binding domain 
(RBD) that promotes interaction of the effectors with GTP-Ras. Although there are 
no obvious primary sequence similarity in the RBDs and RA (Ras-association) 
domains of the different effectors, they all exhibit the same topology of a ubiquitin 
superfold (Herrmann, 2003). This common structural fold of these otherwise diverse 
primary sequences accounts for the similar mode of interaction of different effectors 
with Ras (Repasky et al., 2004). These different Ras effectors determine the biological 
effects of Ras downstream signaling. The best-studied Ras effector pathways are the 
Raf and PI3K pathways.  
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The Raf-Mek-Erk pathway is a major part of the mitogen activated protein kinase 
(MAPK) signaling cascade. There are three Raf isoforms: A-Raf, B-Raf and C-Raf 
(Raf-1), and these Raf isoforms share sequence and domain identity. At the N-
terminus they have an RBD followed by the cysteine-rich domain (CRD), and at the 
C-terminus a serine/threonine kinase domain. C-Raf serine/threonine kinase is the 
first and the best characterized Ras effector, identified originally from the retrovirus 
(3611-MSV) that caused rapidly accelerated fibrosarcomas (Lavoie and Therrien, 
2015). Active Ras directly interacts with Raf through the RBD and relieves Raf auto-
inhibition and initiates plasma membrane recruitment of Raf. This leads to 
additional phosphorylations that activate the catalytic region (Dickson et al., 1992; 
Koide et al., 1993; Lavoie and Therrien, 2015). Active Rafs proceed to phosphorylate 
and activate MAPK kinases/extracellular signal-regulated kinases (Mek1/2) 
(Kyriakis et al., 1992). Activated Mek phosphorylates and activates extracellular 
signal-regulated kinases (Erk1/2) (Gallego, 1992). Active Erk can phosphorylate 
cytosolic proteins, such as p90 S6 kinase, or it can translocate to the nucleus and 
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Figure	 4.	 Simplified	 representation	 of	 selected	 Ras	 signaling	 pathways.	 In	 this	 highly	 simplified	
depiction	of	 the	Ras	 signal	 transduction	pathway,	 growth	 factors	 activate	 receptor	 tyrosine	 kinases,	
which	 through	 a	 series	 of	 phosphorylations	 activate	 adaptor	 proteins	 and	 exchange	 factors	 that	
activate	 Ras.	 Active	 Ras	 binds	 and	 activates	 among	 others,	 the	 Raf/Mek/Erk,	 PI3K/PDK1/Akt	 and	
RalGEF/Ral/TBK1	pathways.	Ras	binds	and	recruits	Raf	to	the	plasma	membrane,	Raf	phosphorylates	
Mek1/2	 and	Mek	 in	 turn	activates	Erk.	 Consequently,	Erk	activates	 a	group	of	 effector	proteins	 and	
transcription	 factors	 that	 are	 involved	 in	 cell	 cycle	 regulation	 and	 proliferation.	 Furthermore,	 Ras	
activates	 PI3K	 that	 via	 PIP3	 activates	 PDK1,	 which	 in	 turn	 phosphorylates	 and	 activates	 Akt	 that	
controls	cell	survival	and	growth	via	a	number	of	key	proteins.	Ras	also	activates	RalGEFs	that	in	turn	
activate	RalB,	which	activates	TANK-binding	kinase1	(TBK1).	
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activate transcription factors such as Elk-1, c-Fos and c-Jun, which can regulate cell 
cycle or proliferation (Figure 4).  
Phosphoinositide 3-kinase (PI3K) is the next best characterized Ras effector 
(Rodriguez-Viciana et al., 1994). There are three classes of PI3Ks, of which the class I 
PI3Ks are the best described. PI3Ks are heterodimeric lipid kinases consisting of one 
of three catalytic subunits (p110α, β, and δ) and one regulatory subunit (p85) (Esther 
Castellano, 2011; Simons and Ikonen, 1997; Simons and Sampaio, 2011). PI3Ks 
convert phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol 
(3,4,5) trisphosphate (PIP3). PIP3 in turn activates PDK1 that phosphorylates the 
kinase Akt. Depending on the cellular context, Akt plays a role in an array of 
signaling pathways including cell growth, survival and migration (Figure 4) (Wong 
et al., 2010; Yuan and Cantley, 2008). Akt-mediated signaling through the tuberous 
sclerosis complex (TSC) leads to activation of the mammalian target of rapamycin 
(mTOR) complex that primarily regulates protein synthesis. These Ras effector 
pathways have gathered attention as some effector components of these pathways 
are frequently mutated in cancers and thus can drive cancer formation. 
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2 Post-translational	modifications	of	Ras	GTPases	
R e v i e w 	 o f 	 t h e 	 L i t e r a t u r e 	 – 	 P o s t - t r a n s l a t i o n a l 	 m o d i f i c a t i o n s 	 o f 	 R a s 	
The wide number of biological functions of the Ras superfamily of small GTPases 
are dependent on signaling specificity. Together with the activity as molecular 
switches, signaling specificity of small GTPases is achieved through post-
translational modifications. Nearly all members of the Ras, Rab and Rho superfamily 
small GTPases undergo distinct post-translational modifications in the C-terminus. 
These modifications modulate the subcellular localization, as well as interactions 
with negative and positive regulators, downstream effectors and chaperones.  
 
2.1 Ras	synthesis,	processing	and	trafficking	to	the	plasma	
membrane		
 
Ras proteins are synthesized in the cytosol and are subsequently targeted to the 
cellular membranes by series of post-translational modifications in the HVR (Figure 
5).  
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Figure	 5.	 The	 Ras	 hypervariable	 membrane	 targeting	 region.	 The	C-terminal	 hypervariable	 region	
(HVR)	of	the	four	Ras	isoforms	is	shown.	This	region	of	24-25	amino	acids	contains	all	the	membrane	
targeting	 information	 required	 for	 proper	 membrane	 targeting	 of	 the	 specific	 Ras	 isoforms.	 It	
comprises	 the	C-terminal	 CAAX	box	 (pink)	 that	dictates	 the	prenylation	and	post-prenyl	processing.	
Followed	 by	 the	 ‘second	 signals’	 immediately	 upstream	 of	 the	 CAAX	 box,	 such	 as	 palmitoylated	
cysteine(s)	(in	blue),	polybasic	regions	(in	red)	or	serine	phosphorylation	sites	(green).	For	H-,	N-	and	
K-ras4A,	 the	 second	 signal	 is	 the	 palmitoylation	 on	 the	 cysteines	 (blue)	 or	 clusters	 of	 polybasic	
regions.	 In	 K-ras4B	 the	 second	 signal	 is	 provided	 by	 a	 stretch	 of	 polybasic	 lysines	 (red).	 S	 (green)	
marks	the	phosphorylated	Serine	181	of	K-ras4B.	P	(brown),	the	Proline	179	involved	in	the	cis-trans	
isomerization	that	regulates	H-ras	depalmitoylation.	
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For the canonical Ras isoforms, the first step in post translational modifications is 
the irreversible addition of the 15-carbon farnesyl isoprenoid catalyzed by the 
enzyme farnesyl transferase (FTase) to the cysteine residue on the CAAX box (C 
denotes cysteine, A aliphatic amino acid, and X is any amino acid) (Figure 6) (Casey 
et al., 1989; Hancock et al., 1989). Alternatively, in the presence of FTase inhibitors, 
K-ras and N-ras become prenylated by the 20-carbon geranylgeranyl chain through 
the geranylgeranyl transferase I (GGTase I) (Whyte et al., 1997). The isoprenoids 
offer weak but sufficient membrane affinity for the prenylated proteins and serve as 
a foundation to promote the next processing steps.  Prenylated Ras is targeted to the 
endoplasmic reticulum (ER) where the ‘AAX’ amino acids are proteolytically cleaved 
by the ER-resident metalloprotease RCE1 (Ras-converting enzyme 1). This is 
followed by the carboxy methylation of the farnesylated cysteine by the 
isoprenylcysteine carboxymethyltransferase (ICMT) in the ER (Figure 6) (Gutierrez 
et al., 1989).  
 
These CAAX-processed proteins require at least one ‘second signal’ to enhance their 
membrane interactions and trafficking to the plasma membrane (Hancock et al., 
1990). There are two types of second signals, in the case of H-ras, N-ras and K-ras4A 
it is the Cys residues that get palmitoylated and for K-ras4B the second signal is the 
stretch of polybasic lysines (polybasic region) upstream of the CAAX motif. The 
covalent addition of acyl chain of a fatty acid to a protein is termed acylation and the 
addition of a 14-carbon myristoyl chain (myristoylation) or a 16-carbon palmitoyl 
chain (palmitoylation) to a protein is most common (Resh, 2013). Myristoylation 
occurs as an irreversible cotranslational modification usually at the N-termini 
glycine of the proteins (Magee, 1990). Palmitoylation is a reversible post-
translational modification that in the case of Ras proteins is catalyzed by protein acyl 
transferases (PATs) present in the cytoplasmic face of the Golgi. DHHC9 and 
GCP16 together create a PAT that selectively palmitoylates H- and N-ras (Figure 6) 
(Swarthout et al., 2005). H-ras is palmitoylated on 2 cysteines (Cys181 and Cys184), 
K-ras4A and N-ras on cysteine (Cys180 in K-Ras 4A and Cys181 in N-ras) (Laude 
and Prior, 2008). This palmitoylation together with farnesylation creates a 100-fold 
higher affinity of Ras to the membranes (Shahinian and Silvius, 1995).  
 
In contrast, K-ras4B is not palmitoylated, instead it has a polybasic region (PBR) that 
together with the farnesyl group provide electrostatic interactions with the 
negatively charged phospholipids at the inner leaflet of the plasma membrane 
(Hancock et al., 1989; 1990). Neither the farnesylation alone, nor the PBR can 
provide stable membrane association for K-ras4B, but both these interactions 
together provide enough affinity.  K-ras4B does not go to the Golgi instead traffics 
more directly to the plasma membrane. Recent data show that K-ras4A is unique 
with a hybrid membrane targeting sequence that has a palmitoylated cysteine 
flanked by two short polybasic regions (Tsai et al., 2015). It is also shown that either 
of these two motifs is enough to deliver K-ras4A to the plasma membrane. 
Furthermore, palmitoylated K-ras4A lacks Golgi enrichment, suggesting that a 
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plasma membrane-associated PAT is likely involved in the palmitoylation rather 
than DHHC9/GCP16 (Tsai et al., 2015).  
 
 
2.2 Ras	spatial	organization	and	regulation	
The regulation of Ras membrane-association and trafficking is rather complex and 
not yet fully understood (Figure 6). The association of Ras with multiple subcellular 
membranes is dynamic and it is facilitated by the reversible interactions of the 
polybasic domains and the palmitoyl groups. This is achieved through a dynamic 
Ras palmitoylation and depalmitoylation cycle consisting of palmitoylation at the 
Golgi, delivery to the plasma membrane by the secretory pathway, followed by 
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Figure	 6.	 Ras	 post-translational	 processing	 and	 trafficking.	 Ras	 proteins	 are	 synthesized	 on	 the	
cytosol	 and	 quickly	 farnesylated	 (green,	 lipid	 anchor)	 by	 farnesyl	 transferase	 (FTase)	 at	 the	 C-
terminal	cysteine	of	the	CAAX	motif	and	are	transported	to	the	endoplasmic	reticulum	(ER).	In	 the	
ER,	Ras	encounters	the	Ras-converting	enzyme	(RCE1),	which	cleaves	the	terminal	AAX	residues,	as	
well	 as	 isoprenylcysteine	 carboxymethyltransferase	 (ICMT1),	 which	 carboxymethylates	 the	 C-
terminal	 farnesylated	 cysteine.	 K-ras4B,	 which	 is	 not	palmitoylated,	 traffics	 directly	 to	 the	plasma	
membrane	and	the	 farnesyl	motif	 together	with	electrostatic	interactions	from	 its	polybasic	region	
(PBR)	provide	stable	plasma	membrane	binding.	H-ras	and	N-ras	undergo	reversible	palmitoylation	
by	golgi-resident	protein	acyltransferases	 (PATs)	 that	 add	palmitoyl	groups	 (red,	palmitate)	on	the	
cysteines,	which	enables	stable	binding	to	the	plasma	membrane.	Deacylation	by	the	acyl¬protein	
thioesterases	(APT1/2)	release	Ras	from	the	plasma	membrane	to	be	reacylated	back	to	the	plasma	
membrane.	 The	 prenyl-binding	 protein	 PDEδ	 controls	 association	 of	 all	 Ras	 isoforms	 with	
membranes	by	binding	 to	 the	 farnesyl	moiety	 and	 solubilizing	non-palmitoylated	Ras,	 so	 that	Ras	
can	be	restored	to	the	plasma	membrane.	(Figure	modified	from	Ahearn	et	al.,	2011a)	
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ubiquitous depalmitoylation and return to the Golgi where they can interact with 
PATs for palmitoylation (Figure 6). Recent work has demonstrated that acyl protein 
thioesterases (APT1/2) are responsible for H- and N-ras depalmitoylation. APT1 
cleaves the thioester bond and removes the S-palmitoylation leaving the Ras with the 
farnesyl moiety (Dekker et al., 2010). This depalmitoylation solubilizes the Ras to the 
cytosol, leaving it to be re-palmitoylated in the Golgi and trafficked back to the 
plasma membrane. This makes up a unidirectional cycle between the plasma 
membrane and Golgi. This cycle is critical for ensuring the proper distribution of 
palmitoylated Ras to the plasma membrane and the Golgi.  
 
This is further enhanced by the prenyl-binding protein PDE6δ (phosphodiesterase 
of retinal rod subunit δ) that acts as a solubilizing factor that modulates Ras proteins 
by sustaining their dynamic distribution in cellular membranes. PDE6δ sustains 
correct intracellular organization of farnesylated Ras proteins, Rheb and other small 
G proteins (Chandra et al., 2012). Shuttling by PDEδ is regulated by the allosteric 
interaction with ADP ribosylation factor-like 2/3 (Arl2/3). In fact, the binding of the 
GTP-bound active Arl2 to PDEδ allosterically expels farnesylated Ras from the 
binding pocket of PDEδ (Ismail et al., 2011). This expulsion results in enrichment of 
farnesylated Ras on perinuclear membranes. From these membranes, K-ras with its 
polybasic region is trapped by negatively charged recycling endosomes (Schmick et 
al., 2014) and depalmitoylated H/N-ras are re-acylated in the Golgi (Rocks et al., 
2010). From both these compartments – recycling endosomes and the Golgi – Ras is 
trafficked back to the plasma membrane, where it again participates in signal 
transduction. In addition, depalmitoylation of H-ras was recently shown to be 
stimulated by the peptidyl-prolyl isomerase activity of 12 kDa FK506-binding 
protein (FKBP12) (Ahearn et al., 2011). FKBP12 catalyzes the cis-trans isomerization 
of Gly-Pro at 178-179 of H-ras and accelerates depalmitoylation. Inhibiting or 
silencing FKBP12 inhibits H-ras depalmitoylation (Ahearn et al., 2011), implicating 
peptidyl-prolyl isomerization in Ras organization and regulation. 
 
There are also other modifications that can regulate Ras trafficking and signaling. 
For instance, protein kinase C (PKC)-dependent phosphorylation of Serine 181 in 
K-ras4B – a process mutually exclusive with calmodulin binding to K-ras4B - 
interferes with the electrostatic interaction of the HVR with the plasma membrane 
(Villalonga et al., 2001; 2002). This changes the localization of K-ras4B from the 
plasma membrane to the cytosol and mitochondria where K-ras4B triggers apoptosis 
via Bcl-XL (Bivona et al., 2006), thereby converting K-ras4B from a growth-
promoting to a growth-suppressing protein (Sung et al., 2013). However, there have 
also been reports suggesting that phosphorylation of K-ras4B is necessary for its 
oncogenic properties and tumor growth (Alvarez-Moya et al., 2010; Barceló et al., 
2014). Taken together, although the different Ras isoforms share a high degree of 
sequence identity the mature protein products display distinct patterns of 
intracellular processing, post-translational modification, and subcellular location, 
largely depending on the differences in the HVR. 
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3 Nanoclustering	
R e v i e w 	 o f 	 t h e 	 L i t e r a t u r e 	 - 	 N a n o c l u s t e r i n g 	
The plasma membrane was for long thought to act just as a permeable lipid barrier 
separating the cytosol and the extracellular environment. Now it is clear that the 
plasma membrane is a complex, heterogeneous and dynamic organelle comprised of 
a large array of subdomains that are regulated both spatially and temporally. These 
lipid domains are formed through lipid-lipid, lipid-protein, protein-protein and 
protein-cytoskeleton interactions.  
 
3.1 Lipid	rafts	to	signaling	protein	nanoclusters	
In 1972 the famous Singer-Nicolson ‘fluid-mosaic’ model of the plasma membrane 
integrated transmembrane proteins into a bilayer lipid matrix, where membrane 
proteins could diffuse freely among homogenous lipids as independent components 
(Singer and Nicolson, 1972). Already by 1974 experimental evidence suggested that 
the fluid-mosaic model was probably inaccurate and that lipids were proposed to 
exist as ‘clusters of lipids’ that appeared in a ‘more ordered-state’ surrounded by free 
lipids (Lee et al., 1974; Wunderlich et al., 1975).  In 1982 Karnovsky et al. first 
formalized the idea of lipid domains (Karnovsky et al., 1982), followed by the classic 
report from Brown and Rose in the early 1990s, showing the selective partitioning of 
glycophosphatidylinositol-anchored proteins (GPI-APs) to cholesterol and 
sphingolipid enriched detergent-resistant fractions (Brown and Rose, 1992). This 
was followed by studies from Simons et al. in the mid-1990s suggesting the 
functional significance of lipid raft membrane microdomains would be to act as 
signaling platforms (Simons and Ikonen, 1997; Simons and Sampaio, 2011). 
According to these early descriptions, lipid rafts were viewed as stable pre-existing, 
100-500 nm wide, rigid, cholesterol-rich liquid-ordered membrane domains into 
which proteins with appropriate lipid anchors or transmembrane domains 
partitioned preferentially. Indeed, experiments with artificial bilayers showed 
existence of such domains, thereby supportive of their existence also in live cell 
plasma membranes. However, such rafts could not be detected in plasma 
membranes, leading to the questioning of their very existence in cells. This along 
with difficulties to visualize rafts in living cells and ambiguities of the approaches 
used made this model very contentious. More recent and alternative models view 
rafts as transient, dynamic, nanoscale cholesterol-dependent domains encompassing 
specific lipids and proteins that influence the formation and stability of the domains. 
 
3.2 Ras	nanoscale	organization	on	the	plasma	membrane	
Already in the wake of the raft-model, the application of fluorescence-based 
methods such as fluorescence resonance energy transfer (FRET) and fluorescence 
polarization anisotropy (FPA), lead to the identification of transient, nanoscale 
cholesterol-dependent clusters of GPI-anchored proteins (Goswami et al., 2008; 
Sharma et al., 2004; Varma and Mayor, 1998). This provided compelling evidence 
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for the existence of nanoscale assemblies for previously identified raft associated 
proteins including Ras, Src-kinases and heterotrimeric G-proteins. 
 
The first tentative evidence for raft association of Ras was from membrane 
fractionation and biochemical experiments (Prior et al., 2001; Roy et al., 1999). This 
was followed by the direct visualization of the distribution of GFP tagged Ras on 
intact apical plasma membranes sheets using electron microscopy (EM) combined 
with spatial mapping (Prior et al., 2003). This EM spatial analysis showed that ~44 % 
of the Ras proteins on the plasma membrane are distributed in immobile 
nanodomains called nanoclusters, while the rest exist as freely diffusing monomers 
(Plowman et al., 2005; Prior et al., 2003). Moreover, these Ras nanoclusters and free 
monomers are also found to be freely diffusing and not confined to any membrane 
ultrastructure. Each of these nanoclusters is 12-20 nm in diameter and contains 6-7 
Ras proteins. These experiments provided the definitive evidence for existence of 
Ras nanoclusters (Figure 7). Single particle tracking (SPT) experiments using GFP-
Ras in live cells estimated the lifetime of Ras nanoclusters to be ~0.1 to 1 s, 
suggesting a dynamic turnover of Ras nanoclusters (Murakoshi et al., 2004; 
Plowman et al., 2005) that are constantly forming and disassembling.  
 
 
With the combination of quantitative imaging techniques such as EM-mapping, 
SPT, FLIM-FRET and FRAP it is now clear that the Ras isoforms: H, N and K, all 
occupy and operate as spatially distinct, non-overlapping nanoclusters (Figure 7). 
There is further lateral segregation for each Ras isoform based on the activation 
Figure	7.	Ras	nanoclusters.	Top,	Ras	proteins	form	isoform-	and	guanine	nucleotide-specific	spatially	
segregated	 and	 functionally	distinct	 nanoclusters	 that	serve	 as	 signaling	platforms	of	 downstream	
effector	proteins.	
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state, such that Ras-GTP and Ras-GDP nanoclusters are distinct and non-
overlapping for each isoform.  This highly dynamic spatiotemporal system of Ras 
nanoclustering is very similar to the clustering of GPI-APs (Sharma et al., 2004). 
Similar to Ras, GPI-APs also exist as freely diffusing monomers and transient 
immobile cholesterol-sensitive nanoclusters (Sharma et al., 2004). Computational 
modeling and signaling experiments have shown for both GPI-APs and Ras that the 
fraction of proteins in nanoclusters, i.e. the clustered fraction, is constant over a 
multi-log range of plasma membrane expression levels. This means that the 
clustered fraction is insensitive to the expression levels, suggesting that the system is 
actively held in a non-equilibrium state. For GPIs, this is regulated by the cortical 
actin cytoskeleton, but in the case of Ras, the spatiotemporal dynamics is a 
combination of the plasma membrane interactions of the lipid anchors, the HVR 
and G-domain and the recently characterized lipid components of the plasma 
membrane (Zhou and Hancock, 2015). Furthermore, the different Ras isoforms with 
distinct nanocluster composition differentially use these components. 
 
3.3 Ras	nanocluster	composition	
3.3.1 Cholesterol	
Cholesterol mediates the lateral segregation of Ras, which is essential for proper 
effector recruitment and downstream signaling (Prior et al., 2003; Zhou et al., 2010). 
The first evidence of difference in lipid composition of Ras nanoclusters was from 
cholesterol depletion experiments with methyl β-cyclodextrin (MβCD) (Prior et al., 
2003). These experiments provided evidence for time-dependent loss of GFP-tH 
clustering in MβCD treated cells, however this treatment had no effects on GDP or 
GTP bound H-ras. It is now clear that H-ras-GDP forms cholesterol-dependent 
clusters and H-ras-GTP forms cholesterol-independent clusters (Prior et al., 2003). 
EM and FLIM-FRET measurements show that MβCD mediated cholesterol 
depletion disrupts the lateral segregation of H-ras-GTP and H-ras-GDP 
nanoclusters leading to extensive mixing of GTP and GDP-bound H-ras. These 
heterotypic clusters significantly compromise H-ras mediated signal transduction 
(Ariotti et al., 2014; Roy et al., 1999). In contrast to H-ras, GTP bound N-ras is 
cholesterol dependent, and GDP bound N-ras is cholesterol independent. N-ras-
GDP nanoclusters are insensitive to cholesterol depletion while N-ras-GTP clusters 
are highly sensitive to MβCD treatment (Roy et al., 2005). K-ras-GTP and GDP 
nanoclusters, however, are both cholesterol-independent structures (Plowman et al., 
2005). Taken together, these data clearly show that cholesterol operates distinctly in 
different Ras nanoclusters.  
 
3.3.2 Acidic	Lipids	
Apart from cholesterol, the lipid composition of the various Ras nanoclusters was 
revealed in a recent study (Zhou et al., 2014). In this study, systematic EM mapping 
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of the lipid content associated with different Ras isoforms was performed using 
fluorescently tagged lipid-binding probes, such as pleckstrin homology (PH) and C2 
domains. Phosphatidic acid (PA), labeled with GFP-Spo20, co-clustered more with 
K-ras-GTP and H-ras-GTP than H-ras-GDP nanoclusters. Whereas 
phosphatidylinositol 4,5-biphosphate (PIP2), labeled with GFP-PH-PLCδ, and 
phosphatidylinositol 3-phosphate (PI3P), labeled with GFP-PH-FYVE, were found 
to be enriched in clusters with H-ras-GDP. On the other hand, phosphatidylinositol 
4-phosphate (PI4P) preferentially co-clusters with H-ras-GDP and H-ras-GTP 
nanoclusters but not K-ras nanoclusters. Particularly phosphatidylserine (PS), 
labeled with GFP-LactC2, co-clustered with all Ras nanodomains tested.  
Nevertheless, PS is also important for the structural integrity of the nanoclusters, as 
discussed below.  These results clearly indicate that nanoclusters of different Ras 
isoforms are composed of distinct lipid compositions (Zhou et al., 2014). This is 
consistent with the observations that different Ras effectors have lipid substrate 
preferences, like H-ras that efficiently activates PI3Ks, which bind PIP2 via the p110 
subunit. K-ras on the other hand extensively co-clusters with PA, and activates Raf 
that has a PA-binding domain. Thus the lipid composition of each Ras nanocluster 
also determines the effector recruitment and signaling downstream. 
 
In particular, EM and FLIM-FRET experiments show that PS is required for the 
structural stability of K-ras-GTP nanoclusters, but not H-ras-GDP or -GTP 
nanoclusters (Zhou et al., 2014). K-ras interacts with PS through electrostatic 
interactions with the HVR while H-ras mostly interacts with PS via the palmitate 
anchors (Hancock, 2003). However, the PS-H-ras interaction is less specific and less 
sensitive to PS level changes (Zhou et al., 2014). Moreover, PS depletion has been 
shown to disrupt K-ras nanoclustering and mislocalise K-ras, thus abrogating K-ras 
signaling (Cho et al., 2012b). Analogous to cholesterol, distribution of PS has 
significant effects on the lateral segregation of Ras. Proper lateral segregation of K- 
and H-ras-GTP occurs over a narrow optimal range of plasma membrane PS levels. 
Like cholesterol, PS levels beyond this optimal range lead to mixing of K-ras and H-
ras and these heterotypic clusters compromise Ras signaling (Zhou et al., 2014).  
 
3.3.3 Nanocluster	Scaffolds	
In addition to cholesterol and lipids, protein scaffolds are also involved in regulating 
Ras nanoclustering. Galectins are a family of 15 β-galactoside-binding lectins that 
share a consensus amino acid sequence and members of this family are shown to act 
as Ras nanocluster scaffolds. Galectins have been implicated in a wide range of 
biological functions such as homeostasis, apoptosis, and vascular embryogenesis and 
in pathological conditions such as inflammation, diabetes, atherosclerosis and 
cancer (Astorgues-Xerri et al., 2015). Several lines of evidence show galectins to have 
extracellular and intracellular functions (Liu et al., 2002). Galectin-1 (Gal-1), a 
member of the galectins, was first shown to interact with H-rasG12V and increase 
Ras activity and support cell transformation (Paz et al., 2001). Now we know that 
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Gal-1 is an integral component of the H-ras nanoclusters and Gal-1 overexpression 
enhances H-rasG12V nanoclustering (Belanis et al., 2008). Moreover, H-ras 
activation increases Gal-1 co-localization with H-ras on the plasma membrane, 
suggesting that Gal-1 levels can modulate H-ras signaling (Rotblat et al., 2010). 
 
However, Galectin-3 (Gal-3), another member of the β-galactosidase binding lectins, 
was shown to be a specific binding partner of activated K-ras (Shalom-Feuerstein et 
al., 2008). K-ras and Gal-3 interaction is GTP dependent and Gal-3 is recruited to 
the plasma membrane by active K-ras. This K-ras-GTP/Gal-3 association promotes 
PI3K and C-Raf activation but reduces EGF induced ppErk activation. Moreover, 
ectopic Gal-3 expression enhances K-ras-GTP nanoclustering, while by suppressing 
Gal-3 this nanoclustering can be reduced, suggesting that cytosolic Gal-3 levels also 
are able to modulate K-ras-GTP clustering (Shalom-Feuerstein et al., 2008). This 
makes Gal-3 an integral component of the K-ras nanoclusters. 
 
Proteins such as nucleolin (NCL) and nucleophosmin (NPM, also known as B23) 
have been identified to modulate K-ras nanoclustering. NCL and NPM are 
phosphoproteins that are ubiquitously expressed in the nucleus and cytoplasm. NCL 
and NPM play key roles in ribosome biogenesis, cell proliferation, cell 
transformation and they are overexpressed in many cancers. Interestingly, these 
proteins were found to specifically interact with K-ras, but not H-ras on the plasma 
membrane (Inder et al., 2009). Unlike Gal-1 and Gal-3, this interaction is 
independent of the activation state of K-ras. NPM and NCL both increase – through 
distinct mechanisms – K-ras plasma membrane levels. Indeed, NPM was found to 
specifically interact with K-ras on the plasma membrane and stabilize both K-ras-
GDP and K-ras-GTP nanoclusters (Inder et al., 2009). This increased clustering of 
K-ras-GTP leads to increased MAPK signaling output. In contrast, NCL is not a 
recognized nanocluster scaffold, rather it is proposed to act as a chaperone that 
brings K-ras to the plasma membrane, as NCL overexpression does not affect K-ras 
nanoclustering. Therefore, NPM and NCL modulate K-ras nanoclustering and 
signaling through distinct mechanisms.  
 
3.3.3.1 Caveolin	and	Caveolae	
Caveolae affect signaling by altering the organization of the plasma membrane. 
Caveolae are morphologically identifiable 60-80 nm wide cup-shaped plasma 
membrane pits found abundantly in many mammalian cell types (Parton and del 
Pozo, 2013). There are remarkable cell type-specific and quantitative differences in 
caveolae densities between cells. Caveolae play an important role in endocytosis, 
vesicle transport, mechanosensing, plasma membrane organization and signaling 
(Ariotti and Parton, 2013). Caveolae are considered as a subset of lipid rafts, with 
enrichment of cholesterol, glycosphingolipids and lipid-anchored proteins. The 
signature components of caveolae are the caveolins and cavins, which are key for 
caveolae formation. Three mammalian caveolins have been well characterized: Cav1, 
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Cav2 and Cav3 (Ariotti and Parton, 2013). Cav1 and Cav2 are mostly co-expressed 
ubiquitously in cells, except for skeletal muscles, which have high Cav3 expression. 
Cavins are cytoplasmic proteins that are recruited to the caveolae to work together 
with caveolins in caveola-formation and regulation. Cavin 1 (also known as 
Polymerase I and transcript release factor, PTRF) was originally identified as a 
protein involved in dissociation of transcription complexes in vitro (Jansa and 
Grummt, 1999). Absence of PTRF leads to loss of caveolae in cultured cells, and 
expression of PTRF induces formation of caveolae in various cultured cells and in 
zebrafish embryos (Hill et al., 2008).  
 
The role of caveolae in cancer development and progression has been subject of 
controversy. Initial studies showed that loss of Cav-1 was sufficient to induce 
anchorage-independent growth and tumor formation (Galbiati et al., 2000). 
Expression of the oncogenes K-ras, H-ras and Src reduced Cav-1 expression in 
NIH3T3 cells and re-expression of Cav-1 in transformed murine fibroblasts down-
regulated signaling via the Ras-Raf-Erk pathway (Williams and Lisanti, 2005). 
Consistent with these observations, Cav-1 is down-regulated in several cancers, 
including breast and ovarian cancer. However, this is not the case with metastatic 
prostate cancers that have increased Cav-1 expression (Nassar et al., 2013a). Thus, 
caveolae may have both oncogenic and tumor-suppressive properties but the factors 
that determine these differential effects are not well understood.  
 
EM immunogold labeling experiments have shown PS to be enriched in the caveolae 
(Ariotti et al., 2014). Although the mechanism is unclear, caveolae specifically 
regulate PS distribution and interestingly all members of the cavin family bind PS in 
vitro. As mentioned earlier, PS plays an important role in K-ras nanoclustering and 
it was recently shown that loss of caveolae perturbs Ras organization in an isoform-
specific manner (Ariotti et al., 2014). Loss of Cav-1 or PTRF alters cellular lipid 
composition and PS distribution in the plasma membrane, thus leading to increased 
K-ras nanoclustering and MAPK signaling. In contrast, loss of caveolae negatively 
affects the GTP-dependent lateral segregation of H-rasG12V nanoclusters, possibly 
due to a role of caveolae in regulating plasma membrane cholesterol. However, in 
cells expressing both active H- and K-ras, loss of caveolae leads to formation of 
heterotypic clusters (Zhou et al., 2014). These studies suggest that caveolae provide a 
scaffold that function to sequester specific lipids and thereby control Ras signaling.  
 
3.4 Ras	nanocluster	formation	
3.4.1 Lipid	anchors	
Lipid modifications of Ras are required for proper plasma membrane targeting. The 
minimal membrane anchors of H-ras (tH) and K-ras (tK) constitute the C-terminal 
CAAX motif in addition to a ‘second signal’. The ‘second signals’ are required for 
proper plasma membrane localization and they play distinct roles in Ras spatial 
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regulation and nanoclustering. For instance, EM-mapping data show that dual-
palmitoylated H-ras-GTP localizes to cholesterol-independent domains but the 
mono-palmitoylated mutant H-RasG12V C184S localizes to cholesterol-dependent 
clusters (Roy et al., 2005). These data together with others suggest that the 
palmitoylation of Cys184 is essential for proper H-ras-GTP nanocluster formation. 
In contrast, the polybasic domain together with the farnesyl lipid moiety determines 
K-ras plasma membrane localization and nanoclustering. Indeed, tK localizes to 
cholesterol-independent nanoclusters, as the highly polar polybasic region of K-ras 
prefers the fluid, cholesterol-poor lipid domains and also pull the negatively charged 
lipids (Zhou and Hancock, 2014). This indicates the presence of a K-ras induced 
lipid sorting that leads to segregation of the phospholipids. 
 
3.4.2 HVR	and	G-domain	conformation	orientation		
In addition to Ras membrane anchors that are critical for membrane binding, the 
orientation of the G-domain with respect to the membrane is now considered a 
novel codec for Ras membrane organization and isoform-specific signaling 
(Abankwa and Vogel, 2007; Abankwa et al., 2008). The GTP-dependent lateral 
segregation of Ras is ascribed to the nucleotide-dependent changes in the G-domain 
conformational orientation. Molecular dynamics simulations of lipid modified full-
length H-ras on a model membrane show GDP/GTP dependent interactions with 
the bilayer through distinct residues in the catalytic domain. In GTP-H-ras, basic 
residues R128 and R135 on helix α4 interact with membrane lipids, whereas basic 
residues R169 and K170 of the HVR stabilize GDP-H-ras. These charged residues in 
α4 and the proximal HVR that engage in mutually exclusive interactions with the 
membrane are called the ‘switched elements’. GTP binding leads to structural 
rearrangements in the switch I and II; and also in the switch III region, which is a 
network of salt bridges involving β2-β3-loop and helix α5. GTP-induced structural 
changes in switch III (D47 and E49 in the β2–β3 loop, R161 and R164 in helix-α5) 
leads to the release of R169 and K170 in the HVR from membrane binding, leading 
to a ~100° rotation of the H-ras G-domain (Abankwa et al., 2008; 2007). At the same 
time, R128 and R135 in helix-α4 now interact with membrane lipids and stabilize the 
new orientation. The proper orientation of the G-domain was recently shown to be 
essential also for scaffold interactions (Guzmán et al., 2014b). The switch III region 
is found to be partly conserved in several Ras isoforms (Abankwa et al., 2008; 2010). 
Recent work from our laboratory identified that rare cancer associated mutations in 
the switch III region increase Ras activity by increasing nanocluster formation. 
These mutations do not alter the biochemical functions of Ras in solution, rather the 
increase in nanoclustering leads to increased downstream effector recruitment and 
tumorigenicity (Solman et al., 2015). These studies suggest that the isoform-specific 
lateral segregation of the Ras isoforms is attributed to the difference in lipid anchors 
and conformations, and to the different G-domain conformations of the Ras 
isoforms. 
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3.5 Ras	dimerization	
Thus far we have considered Ras-proteins as a freely diffusing monomer or as 
transient nanoclusters, but recently the idea that Ras exists partially as a homo-dimer 
has gained interest. It was proposed over a decade ago that membrane anchored Ras 
dimerization could mediate C-Raf activation (Inouye et al., 2000). This notion has 
gathered more attention recently. Molecular simulations show that lipidated N-ras 
adopts a perpendicular orientation that is stabilized only by dimer formation. The 
residues involved in this N-ras dimer interface are located to the G-domain. 
Interestingly, Lin et al., reported H-ras to form dimers through protein-protein 
interactions (Lin et al., 2014). Using a combination of quantitative biophysical 
techniques, they mapped the dimerization interface to the switch II region (residues 
60-76). Nussinov and colleagues recently showed that the catalytic domain of K-ras-
GTP could form stable homo-dimers with two distinct dimer interfaces, one with 
switch I and effector binding regions and another with the helical interfaces that may 
promote Raf activation (Muratcioglu et al., 2015). By utilizing super resolution 
imaging techniques, Chu’s Lab showed that endogeneous levels of K-ras-GTP forms 
dimers and activates signaling (Nan et al., 2015). Indeed, active Ras has been shown 
to drive formation of C-Raf dimers, trimers and tetramers (Nan et al., 2013). These 
studies suggest that Ras dimerization can mediate and assist Raf dimerization and 
signaling. Therefore, it now seems likely that Ras dimers could act as intermediate 
building blocks for forming higher order nanoclusters. 
 
3.6 Nanocluster	and	signaling	
Active Ras nanoclusters act as signaling sites for recruitment of downstream 
effectors such as Raf and PI3K to the plasma membrane. The activation of these 
distinct effector pathways is confined to Ras-GTP nanoclusters. Furthermore, direct 
relationship between the G-domain orientation and effector binding further 
supports the link between Ras nanoclustering, activation and effector recruitment 
(Abankwa et al., 2008; 2010). However, there are marked quantitative differences in 
the ability of K- and H-ras to activate C-Raf and PI3K (Yan et al., 1998). As 
mentioned earlier, Ras effectors also have distinct lipid binding domains. For 
example, C-Raf has PS- and PA-binding domains and binding to these domains is 
critical for its activation (Ghosh et al., 2003; McPherson et al., 1999). This is further 
supported by experiments that show C-Raf-RBD with the PS-binding domain (CRD 
- cysteine-rich domain) has significantly enhanced binding specificity to K-ras-GTP 
nanoclusters, compared to just the C-Raf-RBD (Abankwa et al., 2010). The recent 
mapping of lipids in K- and H-ras nanoclusters further supports this notion, as K-
rasG12V nanoclusters have high content of the key cofactor PA, as compared to H-
rasG12V nanoclusters (Zhou et al., 2014). Therefore, isoform specific signaling 
stems from Ras nanoclusters acting as signaling platforms, where all the key 
components such as lipids and cofactors are assembled to promote recruitment and 
activation of specific effectors.   
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Spatiotemporal dynamics of Ras nanoclustering are essential for high fidelity 
signaling (Kholodenko et al., 2010).  According to Hancock and colleagues, the non-
equilibrium kinetics constantly maintains the fraction of Ras found in nanoclusters 
(Tian et al., 2010). As a result, this clustered fraction gives a linear relationship 
between levels of Ras-GTP and the number of Ras-GTP nanoclusters on the plasma 
membrane (Tian et al., 2007). Each of this Ras-GTP nanocluster responds maximally 
to low input signals, enabling the nanoclusters to operate at a low threshold. Thus, 
they function as a digital nanoswitch that could deliver a fixed quantum of activated 
Erk output into the cytosol. (Harding and Hancock, 2008). This makes the total Erk 
system output from the plasma membrane to be analog, as the amount of 
nanoswitches generated is a linear function of the EGF input. This spatiotemporal 
dynamics of Ras allows for the plasma membrane to be an analog-digital-analog 
(ADA) converter, which digitizes the analog EGF input signal by forming an 
appropriate number of Ras nanoclusters, thus regenerating the analog signal into a 
corresponding level of ppErk output into the cytosol with high-fidelity (Harding and 
Hancock, 2008; Kholodenko et al., 2010; Tian et al., 2007; Zhou and Hancock, 2015). 
An important feature of this system is that the output signal response is determined 
by the clustered fraction. As described earlier, the nanoclusters are regulated by 
multiple factors, such as lipid anchors, lipid content of the plasma membrane, actin 
cytoskeleton and scaffolding proteins (Zhou and Hancock, 2015).  
 
Importantly, computation and experimental evidence shows that loss or reduction of 
nanoclusters result in a reduction in the ppErk response to EGF. This holds true 
even if the levels of Ras-GTP on the membrane are unchanged, as in the case of 
oncogenic Ras. Although oncogenic Ras mutant cells have high Ras-GTP levels, 
reducing the clustered fraction abrogates the Ras signal output (Zhou et al., 2014). 
This suggests that Ras nanoclusters could be important pharmacological targets, and 
targeting these nanoclusters would be a novel and viable therapeutic approach to 
blocking oncogenic Ras signaling in cancers and diseases. 
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4 Molecular	and	cellular	effects	of	Ras	signaling	
R e v i e w 	 o f 	 t h e 	 L i t e r a t u r e 	 – 	 E f f e c t s 	 o f 	 R a s 	 S i g n a l i n g 	
4.1 Ras	isoforms	play	critical	role	in	development	
Despite the high sequence similarities, the Ras isoforms differ significantly in 
functions in distinct tissues. It was already reported in the late 1980s through 
expression analysis of adult mouse tissues that H-ras is highly expressed in skin, 
brain and muscle, while K-ras is mostly found in lungs, colon and thymus and N-ras 
in thymus and testis (Leon et al., 1987). Ras isoforms are differentially expressed also 
during mouse development (Muller et al., 1983). These early studies clearly 
suggested that the Ras proteins have distinct cell- and tissue-specific functions. 
Knock-out studies in mice revealed the importance of K-ras4B in embryonal 
development. The K-ras4B knockouts are embryonic lethal where the embryos die 
within 2 weeks of gestation with liver defects and anemia (Esteban et al., 2001; Koera 
et al., 1997). In contrast, mice without H-ras, N-ras, both H- and N-ras, or K-ras4A 
were viable and do not show any obvious phenotype (Johnson et al., 1997; Umanoff 
et al., 1995). The importance of Ras signaling during embryo development is further 
highlighted when microinjection of a dominant negative H-ras17N mutant into the 
two-cell stage embryos resulted in embryonic lethality, suggesting that Ras signaling 
is required for progressing through two-cell stage (Yamauchi et al., 1994). Although 
substituting H-ras for K-ras supports normal embryonic development in mice, the 
adult mice nevertheless develop with cardiovascular pathology suggesting functional 
differences (Potenza et al., 2005). The importance of Ras in development is further 
highlighted in the so-called Rasopathies – a class of developmental disorders caused 
by germline mutations in the Ras/MAPK pathway (Rauen, 2013). In Costello and 
Noonan syndromes, germline mutations in the HRAS and KRAS genes, respectively, 
give rise to distinct phenotypic features. The phenotypic features include facial 
abnormalities, heart defects, impaired growth and development, and especially for 
the patients with Noonan syndrome, a predisposition to specific cancers (Castellano 
and Santos, 2011). Taken together, this data show that Ras is important for the 
development and that the distinct Ras isoforms have both specific and overlapping 
functions during development. 
 
4.2 Ras	mutations	in	cancer		
The frequency and distribution of Ras mutations in human cancers are variable 
(Table 1). According to the recent data in the COSMIC v73 (Catalogue of Somatic 
Mutations in Cancer) database, the three Ras genes are mutated in almost 27% of all 
analyzed cancers (http://cancer.sanger.ac.uk/cosmic). These Ras mutations occur in 
the following preferential frequency: K-ras (19%, in 32,021 of 165,870 samples), N-
ras (5.0%, in 4,278 of 85,415 samples) and H-ras (2.6%, in 1426 of 54, 418 samples). 
It is also worth mentioning that the frequency of these mutations change according 
to the database used, the dataset used for analysis, and the type of cancers 
represented in the database.  
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However, it is clear that more than 99% of these Ras mutations identified in cancer 
occur in the hot-spot residues G12, G13 and Q61 (Figure 3). The G12 and Q61 
mutations lead to impaired GAP-stimulated GTP hydrolysis, resulting in 
constitutively active Ras. The G12 and G13 mutations are common in K-ras and H-
ras, whereas the Q61 mutation occurs predominantly in N-ras. These are the three 
most common activating Ras mutations that result in aberrant downstream 
signaling. The functional differences between the different Ras isoforms mentioned 
before are also reflected in the frequency of their mutations. More than 85% of the 
Ras cancer mutations occur in K-ras (Cox and Der, 2010; Prior et al., 2012). The 
highest frequencies of K-ras mutations are found in pancreatic ductal 
adenocarcinoma (PDAC) around 95%, colorectal cancer (CRC) around 50%, and 
lung adenocarcinomas around 30%, whereas N-ras is highly mutated in melanoma 
and myelogenous leukemia. Even though rare overall, H-ras is predominantly 
mutated in thyroid, bladder and head and neck cancers.  
 
Table	1.	Frequency	of	Ras	mutations	in	selected	human	cancers	
Primary	Tissue	 KRAS	(%)	 HRAS	(%)	 NRAS	(%)	 Total	(%)	
Pancreas	 60.30	 0.00	 1.64	 61.95	
Colon	 35.31	 0.81	 4.25	 40.36	
Skin	 2.29	 10.74	 16.26	 29.30	
Biliary	tract	 26.29	 0.00	 2.12	 28.40	
Endometrium	 16.86	 1.21	 4.41	 22.48	
Small	intestine	 21.10	 0.00	 0.00	 21.10	
Lung	 17.51	 0.84	 0.75	 19.09	
Cervix	 7.71	 8.88	 1.54	 18.13	
Haematopoietic	and	
lymphoid	tissue	 5.75	 0.36	 11.23	 17.34	
Ovary	 13.89	 0.40	 1.96	 16.25	
Urinary	tract	 4.83	 10.06	 1.23	 16.13	
Prostate	 8.29	 5.53	 1.47	 15.28	
Upper	aerodigestive	tract	 3.01	 9.17	 2.93	 15.11	
Salivary	Gland	 3.18	 10.83	 1.06	 15.07	
(Data shown in the table are compiled from the COSMIC v73. Cancers with total 
Ras mutation frequencies above 15% are listed). 
 
In many of these cancers, Ras mutations are considered to be one of the early events 
leading to cancer development and progression. One study with active K-ras in 
mouse models found that activation of K-ras but not N-ras promoted colon cancers 
(Haigis et al., 2008). Interestingly, they also reported that K-ras activation alone 
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leads to hyperplasia in the colon and not neoplasia. However, K-ras together with 
loss of tumor suppressor functions, like APC, lead to enhanced cancer progression. 
In many cases of CRC, loss of APC is the initiating event followed by a K-ras 
mutation (Kinzler and Vogelstein, 1996). Furthermore, the well-understood 
molecular events of PDAC implicate mutational activation of K-ras as a general early 
event followed by the loss of tumor suppressors CDKN2A and p53 (Eser et al., 
2014). This early role of Ras supports its role in cancer initiation and progression. 
Furthermore, depletion of Ras in cancer cells or suppression of Ras expression in Ras 
driven mouse models lead to impaired cell growth and tumor recession (Chin et al., 
1999; Singh et al., 2009; Ying et al., 2012). These studies suggest that Ras activity is 
not only needed for tumor initiation and progression, but it is as an essential 
component of tumor maintenance and they further validate Ras a relevant 
therapeutic target in human cancers. 
 
One of the puzzling issues for Ras biologists has been the preferential mutation and 
activation of different Ras isoforms in different cancer tissue types (Table 1).  More 
specifically, the preponderance of K-ras mutations in human cancers compared to 
H- and N-ras, in spite of the fact that all these isoforms have potent transforming 
properties in model systems and are expressed widely in adult tissues and tumors. 
Even though direct experimental evidence is still lacking, some observations account 
for this. First support for the idea that K-ras has distinct functions came from the 
role of K-ras in development (as discussed earlier). These studies indicated that it is 
the genomic locus and the differential expression of K-ras that are critical for 
development (Potenza et al., 2005). Balmain and colleagues further extended this 
idea to show that the H-ras knock-in mice with H-ras in the K-ras locus are highly 
susceptible to urethane-induced lung tumors (To et al., 2008). This argues that the 
Ras locus and tissue specific expression are essential and not the proteins themselves. 
Consequently, the tissue specific expression of different Ras isoforms has been 
thought to account for the association of specific Ras isoform mutations in distinct 
tissues. An elegant study from Barbacid and colleagues demonstrated the 
importance of this cellular context of Ras signaling (Guerra et al., 2014). They 
employed a mouse model with whole body expression of active K-ras12V to 
understand the tumor induction capacity of endogenous K-ras. Surprisingly, 
mutated K-ras in these mice failed to induce uncontrolled cell proliferation and had 
no effect on most tissues. Interestingly, only the lung alveolar cells underwent K-ras 
mediated transformation and formed lung adenocarcinomas. This study suggested 
that K-ras driven tumor formation is highly dependent on the cellular context.  
Following this Jacks and colleagues reported the potential role of K-ras in self-
renewal, when they demonstrated that the conditional expression of K-rasG12D 
could lead to expansion of bronchioalveolar stem cells (BASCs) stem cells in vivo 
(Kim et al., 2005). This suggested that some Ras mutated cancers could develop from 
stem cells or progenitor cells.  
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4.3 Some	Ras	isoforms	can	confer	stem	cell	properties		
Stem cells are characterized by their cardinal property to self-renew. Self-renewal is 
the process whereby, upon cell division, a stem cell can give rise to one or two 
daughter cells that retain the capacity to self-renew, ensuring the maintenance of the 
stem cell population. In normal adult tissues, these stem cells differentiate to 
produce the differentiated tissues. In the context of cancer, it was already suggested 
in the 1980s that cancer cells are differentiated cells generated from tumor ‘stem’ 
cells. Today, we understand some of the molecular mechanisms behind stem cell 
properties, whether normal or in cancerous cells. It is noteworthy that early studies 
to understand Ras function in embryonic stem cells (ESCs) reported the 
identification of mouse embryonic-Ras (E-ras) (Takahashi et al., 2003). E-ras was 
found to share 40% homology to other Ras proteins with amino acid substitutions in 
the residues corresponding to GTPase activity implying a constitutive active E-ras. 
In mouse, E-ras was expressed specifically in ESCs and not in differentiated cells. 
Interestingly, the human orthologue of E-ras (Hrasp), is also reported to be 
constitutively active (Takahashi et al., 2003). Though the importance of E-ras in 
human cancers is largely unclear, its expression and epigenetic regulation has been 
reported in gastric cancer cells (Yashiro et al., 2009). 
  
More recently, one reason for the high frequency of K-ras mutations has been 
attributed to its role in stem-like or progenitor cells. While trying to understand the 
preponderance of K-ras mutations in cancers of endoderm-derived tissues such as 
pancreas, colon and lung, Settleman and colleagues provided the first functional 
evidence that out of K-, H- and N-ras, only K-ras can endow stem cell-like 
properties on certain cell types (Quinlan et al., 2008). Using the well-established 
retinoic acid (RA)-induced stem cell differentiation model of F9 cells, they identified 
that active K-ras promotes the expansion of the F9 stem cells, expression of stem cell 
markers and blocking of RA induced differentiation. In contrast, H-ras leads to RA-
induced differentiation, while N-ras is inert in this system. Interestingly, the ability 
of K-ras to confer stem cell properties was not limited to its subcellular localization, 
as cells expressing the K-rasG12V chimera substituted with the H-ras c-terminal tail 
do not differentiate and continue to express stem cell markers. Analysis of the 
effector pathways revealed that K-ras employs distinct PI3K, Raf and also RalGDS 
signaling pathways for stem cell proliferation and maintenance. These data have 
been consistent with the reported role of K-rasG12D in the expansion and 
maintenance of colonic epithelial stem cells in vivo (Haigis et al., 2008). Moreover, 
K-ras, but not H- and N-ras, is shown to directly bind calmodulin (Villalonga et al., 
2001). K-ras and calmodulin interaction is inhibited by the calmodulin kinase II 
calmodulin-binding domain. This calmodulin binding has been shown to be 
mutually exclusive with the K-ras phosphorylation at S181 (Bivona et al., 2006; 
Naujokat and Steinhart, 2012; Villalonga et al., 2002). Recent evidence emerging 
from Frank McCormick’s laboratory suggests that K-ras and not H-ras with these 
unique properties can impart stem-cell like characteristics to cancer cells (Wang et 
al., 2014; 2015).  
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Apart from K-ras, there is also evidence suggesting that N-ras plays a critical role in 
hematopoietic stem cells (HSCs) (Li et al., 2013). The mutational activation of N-ras 
results in enhanced proliferation and self-renewal of HSCs in mice. Furthermore, in 
these HSCs N-ras activates both the Mek-Erk and STAT signaling cascades. 
Interestingly, N-ras promotes a bimodal response in HSCs, by driving self-renewal 
in one subset of HSCs and increasing cell division in the other subset of cells. 
However, it is not known whether this bimodal effect also applies to other Ras 
isoforms. Nevertheless, there is evidence showing that activation of K-rasG12D in 
HSCs also initiates acute leukemia in mice, leading to the emergence of distinct self-
renewable cell populations that acquire cooperating mutations as the cancer 
progresses (Sabnis et al., 2009). Thus it is speculated that some cancer cells within 
Ras mutated tumors would possess inherent self-renewal capacity and survival 
advantage. 
 
4.4 Cancer	stem	cells	(CSCs)		
R e v i e w 	 o f 	 t h e 	 L i t e r a t u r e 	 – 	 C a n c e r 	 S t e m 	 C e l l s 	
Cells that make up a tumor exhibit significant heterogeneity in terms of morphology, 
genetic lesions and functionally. This heterogeneity is also seen in cancers derived 
from a single cell, as some cancer cells harbor the dynamic ability of co-opting self-
renewal mechanisms and can transit from a differentiated to non-differentiated 
states and vice versa. This may be modulated by specific micro environmental 
signals and cellular interactions arising in the tumor. Understanding the basis for 
tumor heterogeneity has interested cancer researchers for decades. Two mutually 
exclusive explanations or theories were put forward to explain tumor heterogeneity 
(Figure 8a). According to the clonal evolution theory of cancer, when a mutant 
cancer cell divides and gives rise to a number of descendants, a few of these 
descendants may acquire a new mutation or epigenetic change that can give them a 
selective advantage over other tumor cells. This is called clonal expansion. This clone 
of cells can now expand and dominate the cancer. By acquiring new mutations these 
cells can further evolve to make the next clone of cancer cells. According to this 
theory, all the cancer cells from the dominant clone will have similar tumorigenic 
potential (Greaves and Maley, 2012). 
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According to the cancer stem cell model, only a small fraction or population of 
cancer cells within a tumor have the extensive replicative potential or self-renewal 
capacity, and can give rise to the tumor (Figure 8b). The cancer stem cell hypothesis 
was first developed through transplantation experiments with leukemia cells that 
suggested that only a fraction of cells from the tumor could give rise to new tumors 
in mice. These small population of cells comprised of self-renewing, tumorigenic 
cells were termed the cancer stem cells (CSCs) (Dick, 2008). The proof for CSCs in 
solid tumors was established from the seminal work showing that only 2% of the 
neoplastic cells taken directly from breast cancers are capable of forming new 
tumors (Al-Hajj et al., 2003). This work also described that cells with a 
CD44high/CD24low phenotype are highly enriched for CSCs, and as little as 100 of 
these putative-CSCs could recapitulate the tumor (Al-Hajj et al., 2003). This was 
followed by work from others showing identification of CSCs in many tissues (Kreso 
and Dick, 2014).  
 
Although there has been no consensus over CSCs and their properties, it is now 
accepted by definition that these cells must have the capacity to self-renew. However, 
in some cancers it is impossible to distinguish between CSCs and non-CSCs. Recent 
studies support the possibility that tumor heterogeneity is a complex process and 
that clonal evolution and CSC models may not be mutually exclusive. A unified 
model of clonal evolution and cancer stem cells suggests that a CSC may acquire a 
mutation and give rise to sub clones with self-renewal capabilities. These clones may 
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Figure	 8.	 Schematic	 representation	 of	 clonal	 evolution	 and	 cancer	 stem	 cell	 models	 of	 tumor	
growth.		a)	 In	 the	clonal	evolution	model	of	 tumor	growth,	all	 tumor	cells	are	equally	 tumorigenic	
and	 can	 stochastically	 self-renew	 or	differentiate,	 leading	 to	 tumor	 heterogeneity.	 Acquiring	new	
mutations	 generates	 clones	diversity	 that	 further	 increases	 tumor	heterogeneity.	 b)	 In	 the	 cancer	
stem	cell	 (CSC)	model,	only	a	small	 subset	of	 tumor	cells	have	self-renewal	capacity	and	they	give	
rise	to	progenitors	cells	that	eventually	differentiate	to	 form	the	bulk	of	the	tumor.	Acquiring	new	
mutations	leads	to	further	clonal	diversity.	
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over time accumulate distinct mutations and evolve in parallel and give rise to 
progenitors without self-renewal capabilities (Kreso and Dick, 2014). It is also 
suggested that some cancer cells can transit from non-CSC and CSC-states resulting 
in higher cancer cell plasticity, which seems to be governed by transcription factors 
(Chaffer et al., 2011; 2013; Mani et al., 2008; Morel et al., 2008). The initial evidence 
for this came from the Weinberg and Puisieux groups showing that induction of 
epithelial-mesenchymal transition (EMT) may play a role in the conversion of non-
CSC cells to CSC-like cells. EMT is a transdifferentiation process during 
embryogenesis where epithelial cells transdifferentiate to mesenchymal cells. During 
this conversion, epithelial cells transiently lose their cell-cell junctions, apico-basal 
polarity, reorganize the cytoskeleton and alter their gene expression and signaling 
(Polyak and Weinberg, 2009). These EMT processes are activated during cancer and 
wound healing, and recent evidence links EMT to self-renewal and CSC-state. Using 
a breast cancer model, Puisieux and colleagues reported that overexpression of 
oncogenic Ras and activation of MAPK can drive EMT and lead to enrichment of 
breast epithelial cells with stem-like properties (Morel et al., 2008). In a correlative 
study, Weinberg and colleagues showed that overexpression of transcription factors 
Twist or Snail in immortalized breast epithelial cells induced EMT and these cells 
acquired a CD44high/CD24low phenotype of breast CSCs (Mani et al., 2008). Recent 
studies from Weinberg and group also show that CSC hierarchy is not valid for all 
cancers, as they found a subpopulation of breast non-CSCs that can dynamically 
transition from non-CSC to CSC-states, mediated by the transcription factor Zeb1 
(Chaffer et al., 2011).  
 
 
 
 
 
 
 
 
 
	
Figure	9.	Mechanisms	and	pathways	that	contribute	to	the	resistance	of	CSCs	to	conventional	drugs	
and	 radiation	 therapy.	 	 The	 Wnt/β-catenin,	 Hedgehog	 and	 Notch,	 and	 NF-κB	 pathways	 are	 all	
involved	 in	progenitor	 cell	expansion.	The	Akt	and	ATR/CHK1	pathways	promote	survival	e.g.	by	an	
amplified	 checkpoint	 activation	 and	 efficient	 DNA	 repair.	 	 The	 ATP-binding	 cassette	 (ABC)	 drug	
transporter,	 aldehyde	 dehydrogenase	 (ALDH)	 and	 CD133/prominin-1	 all	 contribute	 to	 drug	 or	
radioresistance.	CSCs	are	also	resistant	against	apoptosis	and	have	defective	apoptotic	signalling,	and	
e.g.	autocrine	production	of	interleukin-4	(IL-4)	has	been	shown	to	protect	against	apoptosis	in	CSCs.	
The	 PI3K/Akt/mTOR	 pathway	 has	 been	 shown	 to	 be	 involved	 in	 both	 cell	 survival,	 progenitor	 cell	
renewal,	drug	resistance	and	EMT.	Other	mechanisms	that	contribute	to	resistance	include	transient	
dormacy,	changes	 in	cell	metabolism	to	a	preference	for	hypoxia,	evasion	from	the	 immune	system	
and	protection	by	the	microenvironment	(reviewed	in	Pattabiraman	and	Weinberg,	2014).	
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Notwithstanding these issues, it is now widely accepted that the CSC properties are 
defined by a collection of genetic, epigenetic and tumor microenvironment factors 
that confer self-renewal properties to a cell. This is collectively referred to as 
‘stemness’. There is now strong evidence to support the link between stemness of 
CSCs and tumor therapy resistance, progression and tumor recurrence (reviewed in 
(Kreso and Dick, 2014). Several mechanisms and pathways have been shown to 
contribute to the resistance of CSCs (Figure 9). The clinical relevance of CSCs and 
stemness in patients is highlighted by studies showing that cancers with stem cell-
like gene expression signature are associated with relapse and patient outcome in 
human breast, gliobastoma, leukemia and ovarian cancers (Cabrera et al., 2015; 
Eppert et al., 2011; Wicha, 2012). These studies indicate that targeting the CSCs and 
their stemness features might be the most viable therapeutic strategy against CSCs 
and targeting CSCs might lead to a more effective clinical response (Figure 10). 
 
  
4.4.1 Compounds	and	drugs	targeting	CSCs	
The understanding of the molecular pathways involved in breast CSCs was first 
successfully used in a high throughput chemical screen of small molecules when the 
CSC inhibitor salinomycin was identified by utilizing the differences in the 
CD44/CD24 ratio between CSCs and non-CSCs (Gupta et al., 2009). Subsequently, 
similar high-throughput screens have been used to identify CSC inhibitors of AML 
CSCs (Sachlos et al., 2012), breast CSCs (Carmody et al., 2012), ovarian CSCs 
(Mezencev et al., 2012) and glioblastoma CSCs (Visnyei et al., 2011). This has lead to 
the identification and characterization of several drugs that target CSCs (Naujokat 
and Laufer, 2013; Sachlos et al., 2012). Table 2 shows the various sources of CSC 
Figure	10.	Therapeutic	relevance	of	targeting	CSCs.	Top:	Tumor	contains	a	mix	of	CSCs,	progenitor	
and	differentiated	cancer	cells,	and	these	cells	contribute	to	the	heterogeneity.	Conventional	cancer	
therapy	kills	mostly	progenitor-like	and	highly	proliferative	cells	 leading	to	a	 transient	reduction	 in	
tumor	burden.	While	the	therapy-resistant,	relatively	dormant	CSCs	survive	and	seed	a	new	tumors	
leading	 to	 relapse.	 Bottom:	CSC	 drugs	 and	 therapies	 in	 combination	with	 conventional	 therapies	
would	kill	or	differentiate	the	CSCs	and	also	kill	the	proliferative	cells.	The	reduction	in	CSCs	leads	to	
a	reduction	in	tumor	recurrence	and	relapse.	
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drugs and their targets in different cancer types and their current status in clinical 
trials (www.clinicaltrials.gov). In many of these trials the CSC drugs are used in 
combination with conventional drugs. Many of these clinical CSC drug candidates 
target pathways that are altered in CSCs (Figure 9). The following section briefly 
summarizes the activity of some of these compounds, such as the microbial 
derivatives e.g. salinomycin, plant-derivatives e.g. resveratrol, curcumin, and 
classical drugs e.g. metformin, tranilast and thioridazine (Naujokat and Laufer, 
2013).  
 
Table	 2.	 Compounds	 and	 drugs	 that	 target	 CSCs	 and	 their	 molecular	 targets.	 The	 clinical	 trial	
identifiers	 are	 from	 www.clinicaltrials.gov	 (13.12.2015).	 In	 case	 there	 were	 several	 trials	 only	 one	
number	is	given.		
Compound	Name	 Molecular	
Targets/Targeted	
Pathways	
Cancer	Type	 Clinical	
Trials	
Clinical	Trial	
Identifier/	
Reference	
Antibiotics	
Salinomycin	
(ionophore	
antiobiotic)	
Wnt	pathway,	etc	 Vulvar	carcinoma	 No	clinical	
trials,	case	
reports	
only	
Naujokat	and	
Steinhart	et	al.,	
2012	
IPI-926	
(Cyclopamine	
derivative)	
Hedgehog	pathway	
inhibitor	
Head	and	neck,	advanced	
solid	tumors	
I-II	 NCT01383538	
Resveratrol	 Wnt	and	hedgehog	
pathways,	p53	
Medulloblastoma,	
glioblastoma,	breast,	
pancreatic,	colon	
I	 NCT00256334	
Sulforaphane	
(naturaal	
isothiocyanate)	
NF-κB,	hedgehog,	
EMT	and	Wnt/β-
catenin	pathways	
Pancreatic,	breast,	
prostate,	chronic	myeloid	
leukemia	
II	 NCT01228084	
Mithramycin	 RNA	synthesis	
inhibitor	
Breast,	lung,	esophageal,	
mesothelioma,	
gastrointestinal	neoplasm,	
solid	tumors,	Ewing	
sarcoma	
I,	II	 NCT01624090	
Small	molecular	inhibitors	
BMS-833923	
(XL139)	
Hedgehog	pathway	
inhibitor,	Gli	
inhibition,	Smo	
antagonist	
Leukemia,	lung,	stomach	
and	esophaegal	neoplasms	
I,	II	 NCT01357655	
GDC-0449	
(Vismodegib)	
Hedgehog	
pathway,	Smo	
antagonist	
Pancreas,	
medulloblastoma,	solid	
tumors	
II	 NCT00607724	
LDE225	
(Sonidegib)	
Hedgehog	pathway	
inhibitor,	Gli	
inhibition,	Smo	
antagonist	
Ovarian,	prostate,	
hematologic	
I,	II	 NCT02195973	
PF-04449913	
(Glasdegib)	
Hedgehog	pathway	
inhibitor,	Gli	
inhibition,	Smo	
antagonist	
Leukemia,	myelofibrosis	 I,	II	 NCT02226172	
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Compound	Name	 Molecular	
Targets/Targeted	
Pathways	
Cancer	Type	 Clinical	
Trials	
Clinical	Trial	
Identifier/	
Reference	
LEQ506		 Hedgehog	pathway	
inhibitor	
Solid	tumors	 I	 NCT01106508	
RO4929097	 γ-secretase	
inhibitor	(Notch	
pathway)	
Pancreatic,	breast,	lung,	
glioma,	colon,	prostate,	
solid	tumors,	melanoma,	
ovarian	
I	 NCT01122901	
MK-0752	 γ-secretase	
inhibitor	(Notch	
pathway)	
Breast,	pancreatic,	
refractory	CNS	cancer	
I-II	 NCT00645333	
Reparixin/	
Repertaxin	
Chemokine	
receptor	1/2	
inhibitor	(IL-8	
pathway)	
Breast	 II	 NCT02370238	
SL-401		 IL-3	receptor	 Leukemia	 I,	II	 NCT02113982	
PF-04691502	 Dual	PI3K/mTOR	
inhibitor	
Breast,	endometrial	 I,	II	 NCT00927823	
VS-5584	 PI3K/mTOR	kinase	
inhibitor	
Non-hematologic	cancers,	
lymphoma	
I	 NCT01991938	
VS-4718	 FAK	inhibitor	 Metastatic	non-
hematologic	cancers	
I	 NCT01849744	
VS-6063	
(Defactinib)	
FAK	inhibitor	 K-ras	mutant	non-small	cell	
lung	cancer,	mesothelioma,	
ovarian	cancer,	non-
hematologic	cancers	
I,	II	 NCT01951690	
GO-203-2c		 MUC1-C	 Leukemia,	solid	tumors	 I,	II	 NCT02204085	
BBI608	
(Napabucasin)	
STAT3	and	β-
catenin	inhibitor	
Glioblastoma,	colorectal,	
hepatocellular	carcinoma,	
advanced	malignancies	
I-III	 NCT01325441	
BBI503	 Multiple	stemness	
kinases	inhibitor	
Hepatocellular	carcinoma,	
colorectal	cancer,	
advanced	solid	tumors	
I,	II	 NCT01781455	
GW572016	
(Lapatinib)	
Tyrosine	kinase	
inhibitor,	EGFR	and	
ErbB2	pathway	
inhibition	
Breast,	colorectal,	gastric,	
head	and	neck,	lung	
II,	III,	FDA	
approved	
for	use	in	
breast	
cancer	
NCT00486954	
AZD3965	 Mitochondrial	
monocarboxylate	
transporter	1	
inhibitor	
Prostate,	gastric,	solid	
tumors	
I	 NCT01791595	
Antibodies	
CSL362	 CD123	 Leukemia	 I	 NCT01632852	
IIPOP	
(Catumaxomab)	
EpCam	and	CD3	 Ovarian,	gastric	 II	 NCT01784900	
MT110	 EpCam	and	CD3	 Lung,	gastric,	colorectal,	
breast	
I	 NCT00635596	
OMP-21M18	
(Demcizumab)	
DLL4	(Notch	
pathway)	
Pancreatic,	non-small	cell	
lung	cancer	
I,	II	 NCT01189968	
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Compound	Name	 Molecular	
Targets/Targeted	
Pathways	
Cancer	Type	 Clinical	
Trials	
Clinical	Trial	
Identifier/	
Reference	
OMP-305B83		 DLL4	and	the	VEGF	
receptor		
Solid	tumors	 I	 NCT02298387	
OMP-52	M51		 Notch1	receptor	 Lymphoid,	solid	tumor	 I	 NCT01703572	
OMP-59R5	
(Tarextumab)	
Notch2/3	 Pancreatic,	small	cell	lung	
cancer	
I,	II	 NCT01647828	
OMP-18R5	
(Vantictumab)	
Frizzled	7	receptor	
(Notch	pathway)	
Pancreatic,	breast,	non-
small	cell	lung	cancer,	solid	
tumors	
I	 NCT01957007	
OMP-54	F28		 Wnt	ligands	 Liver,	ovarian,	pancreatic,	
solid	tumors	
I	 NCT02069145	
OMP-131R10		 RSPO3	(RSPO-LGR5	
pathway,	Wnt	
signaling)	
Colorectal	cancer	 I	 NCT02482441	
Trastuzumab	 HER2/neu	receptor	 Breast,	HER2-positive	
carcinomas	
I,	II,	FDA	
approved	
for	breast	
NCT02120911	
Classical	drugs	
Metformin	(anti-
diabetic	drug)	
Activates	AMPK,	
suppresses	mTOR		
Breast	cancer,	prostate	
cancer,	gynaecological	
cancers,	solid	tumors	
I-III	 NCT01579812	
Thioridazine	(anti-
psychotic	drug)	
Activates	AMPK	 Leukemia	 I	 NCT02096289	
Lovastatin	
(hypolipidemic	
agent)	
HMGCoA	
reductase	
inhibition	
Leukemia	 I,	II	 NCT00583102	
Others	
Fursultiamine	
(derivative	of	
thiamine)	
Inhibits	expression	
of	Oct4,	Nanog,	
Sry,	ABC	
Esophageal	squamous	cell	
carcinoma	
II	 NCT02423811	
2-
Methoxyestradiol	
(Panzem,	
metabolite	of	
estradiol)	
HIF	inhibitor,	
microtubule	
inhibitor	
Leukemia,	glioblastoma,	
ovarian,	breast,	myeloma	
I,	II	 NCT00400348,	
Hartwell	et	al.,	
2013	
NVP-BEZ235	
(Imidazoquinoline	
derivative)	
Dual	PI3K/mTOR	
inhibitor	
Breast,	renal,	prostate,	
solid	tumors	
I,	II	 NCT00620594	
Curcumin,	analogs	
GO-Y030,	
difluorinated-
curcumin	(CDF)	
Amplifying	E-
cadherin/β-catenin	
negative	feedback		
Pancreatic,	rectal,	breast	 I,	II	 NCT00745134	
 
 
4.4.1.1 Microbial-derived	compounds	
Salinomycin is a polyether antibiotic isolated from Streptomyces albus, which has 
been used for more than 30 years to treat coccidiosis in poultry (Callaway et al., 
2003). It is a very selective potassium ionophore that acts in cytoplasmic and 
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mitochondrial membranes, promoting efflux of K+ ions and interfering with their 
transmembrane potential (Naujokat et al., 2010). Weinberg and colleagues 
demonstrated that salinomycin was 100-fold more potent than standard 
chemotherapeutics against breast CSCs (Gupta et al., 2009). Pre-treatment of these 
cells with salinomycin resulted in a more than 100-fold reduction in tumor-seeding 
capacity. Moreover, gene expression analysis showed that salinomycin down-
regulated genes involved in expansion of mammary stem cells, formation of 
mammospheres and genes inversely correlating with overall survival of breast cancer 
patients. In addition, treatment of mice bearing breast CSC-derived tumors with 
salinomycin reduced the tumor mass and metastasis as well as the number of tumor 
CSCs and induced their differentiation (Gupta et al., 2009). A follow-up study 
reported that salinomycin induced apoptosis in multiple cancer cell types but not in 
normal cells. Furthermore, salinomycin activates a distinct apoptotic pathway 
independent of p53, cell cycle arrest and caspase activation (Fuchs et al., 2009). A 
subsequent study demonstrated that salinomycin treatment overcame ABC-
transporter mediated drug resistance and induced apoptosis of AML stem cells 
(Fuchs et al., 2010). A series of studies have shown salinomycin to target CSCs in 
different cancers including gastric, lung, colorectal, and prostate cancer (reviewed in 
(Naujokat and Steinhart, 2012)).  
 
Despite the increasing number of such reports, the exact molecular target of 
salinomycin has not been identified. A number of recent studies have, however, 
reported mechanisms that have increased the understanding of the mode of action of 
salinomycin. One of these mechanisms is the induction of apoptosis and cell death. 
However, there are reports suggesting salinomycin to induce both apoptotic and 
nonapototic cell death depending on the cell types (Fuchs et al., 2009; 2010; Ketola et 
al., 2012; Kim et al., 2011). The increase in apoptosis in certain cancer cells could be 
attributed to the ionophoric potassium efflux activity of salinomycin (Naujokat and 
Steinhart, 2012). Furthermore, salinomycin has been shown to target various 
molecular complexes and pathways that are critical for the development and 
maintenance of CSCs or that confer resistance and survival of CSCs, such as the 
ABC transporter, the Wnt/ β-catenin pathway and acquisition of EMT. There is 
evidence showing that salinomycin is a potent inhibitor of the multidrug resistance 
ABC-transporter P-glycoprotein in cancer cells (Riccioni et al., 2010). Salinomycin 
has also been shown to inhibit Wnt signaling by inhibiting coreceptor LRP6 and 
down-regulating the Wnt target genes in chronic lymphocytic leukemia cells (Lu et 
al., 2011). In addition, oxidative phosphorylation has been linked to mesenchymal 
stem cell transformation, and salinomycin has been shown to inhibit mitochondrial 
oxidative phosphorylation (Mitani et al., 1976). The original finding by Gupta et al, 
also reported that salinomycin induces differentiation of CSCs and up-regulates 
genes involved in breast epithelial cell differentiation (Gupta et al., 2009). Taken 
together, salinomycin may target CSCs and cancer cells via multiple mechanisms.  
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4.4.1.2 Plant-derived	compounds	
Resveratrol is a natural phytoalexin found in red wine grapes and peanuts. It is 
shown to induce p53, cell cycle arrest and apoptosis and to inhibit Wnt and 
Hedgehog signaling pathways (Naujokat and Steinhart, 2012). A number of studies 
have reported the activity of resveratrol against CSCs of medulloblastoma, colon, 
breast and pancreas. Interestingly, resveratrol inhibits pancreatic CSCs in vitro 
through apoptosis, inhibition of EMT, loss of multi-drug resistance and lower self-
renewal capacity (Shankar et al., 2011). These multiple effects lead to inhibition of 
pancreatic tumor formation and growth in K-rasG12D mice that form spontaneous 
PDAC (Shankar et al., 2011). Resveratrol is now being tested by several studies for 
clinical use (Singh et al., 2015).  
 
Curcumin, found in the Indian spice plant turmeric, has been widely studied for its 
anti-inflammatory, anti-cancer, anti-viral and immunomodulatory activities 
(Naujokat and Steinhart, 2012). Initial studies with glioblastoma CSCs reported that 
curcumin treatment lead to differentiation, apoptosis and reduced clonogenicity of 
glioblastoma CSCs. Subsequent studies have shown that curcumin and curcumin 
analogues inhibit breast, colon and pancreatic CSCs, and curcumin is currently 
investigated by various clinical studies (Gupta et al., 2013).  
 
4.4.1.3 Classical	drugs	
In addition to the microbial and plant-derived compounds, a few classical drugs that 
have been used for decades to treat metabolic, immune and psychiatric diseases have 
been found to be active against CSCs.  
 
Metformin is a commonly used drug for treating type II diabetes. The mechanisms 
of action of metformin in reducing insulin and glucose are well known. In cancer 
cells metformin has been shown to inhibit ATP production, activate AMP-Kinase, 
suppress PI3K and mTOR activity and also reverse EMT (Martin-Castillo et al., 
2010). Metformin was also shown to have anti-proliferative properties and inhibit 
growth of several cancer cell lines (Martin-Castillo et al., 2010). A number of recent 
studies have shown that metformin selectively targets breast, pancreatic and thyroid 
CSCs. Particularly, metformin significantly reduces the CD44high/CD24low breast CSC 
populations found in various breast cancer types (Hirsch et al., 2009). Moreover, 
metformin reduces expression of EMT markers such as Twist, Slug and Zeb1, 
together with the stem cell marker Oct4 in breast CSCs (Bao et al., 2012; Jung et al., 
2011; Vazquez-Martin et al., 2010). In pancreatic CSCs, metformin was recently 
shown to inhibit expression of transcription factors, NANOG, Oct4 and Notch1, 
which are associated with CSC self-renewal and maintenance (Bao et al., 2012). 
Consistent with these results, metformin treatment in a K-rasG12D driven 
pancreatic mouse model significantly reduced tumor weight and suppressed the 
expression of the CSC markers CD44, CD133 and ALDH1 (Mohammed et al., 2013).  
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Thioridazine, identified from a HTS for targeting neoplasic human pluripotent stem 
cells (hPSCs) is a well-known anti-psychotic drug (Sachlos et al., 2012). Earlier 
studies have shown that thioridazine targtes PI3K and mTOR signaling and causes 
cell cycle arrest and apoptosis (Kang et al., 2012). Recently thioridazine was shown 
to induce differentiation of hPSCs and AML SCs, and it was shown to be specifically 
active against cells expressing dopamine D2 receptors (Sachlos et al., 2012). These 
studies suggest that dopamine D2 receptors could be a novel anti-CSC target 
(Walsby et al., 2010). It is worth noting that in the original study, thioridazine was 
found to be active at very high concentrations that can not be translated to in vivo 
testing, indicating that thioridazine may work independently of D2 signaling for its 
anti-CSC effect. Nevertheless, it is currently investigated in a phase I study in 
combination with cytarabine for relapsed or refractory AML (Clinical trial ID - 
NCT02096289). 
 
Tranilast is an anti-allergy drug approved for use in Japan. The anti-tumor potential 
of tranilast has gathered considerable interest. Tranilast has been shown to inhibit 
breast CSC tumorspheres, reduce expression of stem cell markers Oct4 and CD133, 
and prevent in vivo lung metastasis of breast CSCs (Prud'homme et al., 2010).  
 
Taken together, these studies highlight the critical role of CSCs and their role in 
cancer. The activation of the EMT and its relationship to CSC has further increased 
our understanding of CSCs. Since CSCs are regarded as the major culprits in therapy 
resistance and relapse following conventional therapy, the CSC drugs and inhibitors 
highlight the possibility of selectively targeting CSCs (Figure 10).  
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5 Therapeutic	strategies	for	targeting	Ras	
R e v i e w 	 o f 	 t h e 	 L i t e r a t u r e 	 – 	 S t r a t e g i e s 	 f o r 	 T a r g e t i n g 	 R a s 	
As earlier described, the Ras proteins are important oncogenes that contribute to the 
formation and maintenance of cancer. Thus finding drugs that specifically target Ras 
has been the focus of intense efforts in the past decades. This section summarizes the 
recent attempts to develop Ras inhibitors in academia and industry (Figure 11, Table 
3).  
 
 
5.1 Inhibiting	the	post-translational	processing	of	Ras	
Ras-dependent signaling requires the correct membrane localization of Ras 
predominantly in the plasma membrane. This critical need for Ras to associate with 
cellular membranes has been appreciated for decades (Jackson et al., 1990; 
Willumsen et al., 1984). As described earlier, nascent Ras proteins undergo a well-
described series of post-translational modifications, which include cysteine S-
farnesylation, proteolysis and carboxy-methylation at the C terminus. In addition,  
H-ras and N-ras are subjected to cysteine S-palmitoylation (Ahearn et al., 2012). 
Therefore, impairment of Ras localization has been explored as a mean to inhibit 
oncogenic Ras signaling, and each of these modifications represents viable targets for 
therapeutic intervention. It was one of the most promising directions towards an 
anti-Ras drug and two decades of extensive research involved targeting Ras 
Figure	11.	Strategies	for	targeting	Ras.	Some	of	the	strategies	to	target	Ras	involve	the	impairment	
of	 Ras	 localization,	 inhibition	 of	 Ras-effector	 interactions	 and	 inhibition	 of	 Ras-GTP	 formation.	
Another	potential	 therapeutic	strategy	 is	 the	perturbation	of	Ras	nanoclusters.	 It	 should	be	noted	
that	 in	addition	to	these	strategies,	major	efforts	so	 far	have	been	directed	towards	targeting	Ras	
downstream	signaling	pathway	members.	
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lipidation. These efforts were, however, followed by their dramatic and 
disappointing results in the clinic. 
  
Farnesylation is the first step of the CAAX processing and farnesyl transferase 
(FTase) has been a target of numerous and intensive rational drug design and 
screening efforts to identify FTase inhibitors (FTIs) (Figure 12). This resulted in the 
development of many FTIs that fall into two categories: non-peptidomimetics such 
as tipifarnib (Beaupre et al., 2004; Zujewski et al., 2000), lonafarnib (Wang and 
Johnson, 2003), and BMS-214662 (Rose et al., 2001), and CAAX peptidomimetics 
including FTI-276 (Sun et al., 1998), FTI-277 (Lerner et al., 1995), L-744832 (Song et 
al., 2000), B956 (Nagasu et al., 1995) and FTI-2153 (Crespo et al., 2001). A number 
of publications have described their pre-clincal efficiency showing inhibition of H-
ras farnesylation, impaired downstream signaling and tumor growth in animal 
models (Adjei, 2001; Berndt et al., 2011; Haluska et al., 2002). Particularly, 
lonafarnib, tipifarnib and BMS-214662 reached advanced clinical trials and were 
tested in over seventy clinical trials, but failed to show clinical efficacy against solid 
tumor such as pancreatic and colon cancer or with AML (Berndt et al., 2011). This 
was shown to be due to a process of alternative geranylgeranylation of K-ras and N-
ras by geranlygeranyl transferase I (GGTase I), in the presence of FTIs. One 
potential solution was treatment with GGTase inhibitors or dual prenylation 
inhibitors to block both FTase and GGTase. The dual prenylation inhibitor (L-
778123) even reached phase III clinical trails and was tested on a variety of 
hematologic and solid tumors (Holstein and Hohl, 2012). Disappointingly, neither 
the agent alone nor in combination, displayed clinical efficacy as the intended target 
K-ras was not affected. However, a number of recent studies have reported 
promising results with FTIs as single agents and in combination with normal 
chemotherapeutics in a subset of elderly patients with hematological malignancies 
(Witzig et al., 2011). An alternative strategy to disrupt Ras prenylation is through 
inhibition of isoprenoid pyrophosphate substrates, which are intermediates in the 
cholesterol biosynthetic pathway. Statins, which are used to treat hyperlipidemia also 
limit global protein prenylation in cells by depleting isoprenoids downstream of 
mevalonate. However, use of statins for anti cancer therapy is limited by the very 
high doses required to block prenylation (Holstein and Hohl, 2012). 
 
Loss of postprenylation processing enzymes RCE1 and ICMT has been shown to 
cause mislocalization of Ras proteins and to reduce Ras-induced transformation in 
cells, making these enzymes attractive drug targets (Bergo et al., 2002; Gysin et al., 
2011). A high-throughput screen with yeast Rcep1, lead to the identification of RCE1 
inhibitors with low micromolar range activity (Manandhar et al., 2007). Moreover, 
studies have also found ICMT inhibitors such as Cysmethyil (Figure 12) (Winter-
Vann et al., 2005). This compound was shown to mislocalize Ras, impair MAPK 
signaling and inhibit cell growth. However, the myriad of other substrates of these 
two enzymes (RCE1 and ICMT1), the lack of sufficiently selective and potent small 
molecule inhibitors, perplexing context dependent roles for RCE1 and ICMT (Bergo 
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et al., 2001; 2002), and toxicity associated with loss of RCE1 (Bergo et al., 2004) have 
hampered the pharmacological development of inhibitors. 
 
 
 
Non-specific palmitoylation inhibitors such as the palmitate analog 2-
bromopalmitate (2BP) have been widely used as a tool compound and its inhibitory 
effects on palmitoylation of H-ras and other proteins have been described (Draper 
and Smith, 2009; Webb et al., 2000). The identification of DHHC9/ GPC16 as the 
protein acyl transferase (PAT) that modifies N-ras and H-ras (Swarthout et al., 2005) 
suggests the possibility of targeting palmitoylation of Ras more selectively. Recent 
evidence implicating the palmitoylated K-ras splice variant, K-ras4a in colorectal 
cancer suggests palmitoylation could indeed be an attractive target for Ras-mutated 
cancers (Tsai et al., 2015). 
 
Recently, depalmitoylation of Ras from cellular membranes was shown to be 
required for dynamic cycling and ultimate enrichment of palmitoylated H- and N-
ras on the plasma membrane (Rocks et al., 2010; 2006). Blocking the 
depalmitoylation machinery breaks the cycle and leads to Ras mislocalization. 
Therefore, inhibiting depalmitoylating acyl protein thioesterase 1 (APT1) and APT2 
with covalent b-lactone inhibitors palmostatins B and M leads to redistribution of 
Figure	 12.	 Schematic	 representation	 of	 selected	 inhibitors	 targeting	 Ras	 post	 translational	
processing	and	signaling.		
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palmitoylated H- and N-ras to the endomembranes (Figure 12).  Palmostatin has 
been shown to inhibit proliferation of myeloid progenitor cells expressing oncogenic 
N-ras in treated mice and partially reverse oncogenic phenotype of H-ras 
transformed MDCK cells (Dekker et al., 2010). In addition to palmostatins, non-
covalent APT1/2 inhibitors have also been identified (Adibekian et al., 2012; 
Zimmermann et al., 2012). Moreover, H-ras depalmitoylation is stimulated by 
FKBP12 that binds rapamycin and other rapalogs (Ahearn et al., 2011). 
Using an analogous approach of interfering with the N-/H-ras palmitoylation cycles, 
K-ras4B shuttling by prenyl-binding protein PDEδ was targeted, and inhibitors of 
the K-ras–PDEδ interaction have recently been identified (Chandra et al., 2012; 
Zimmermann et al., 2013). Deltarasin, a bis-benzimidazole compound with high 
affinity for PDEδ, effectively impairs the K-Ras4B−PDEδ interaction and induces 
relocalization of Ras family proteins (Figure 12). In addition, deltarasin reduces 
proliferation and tumor growth in xenografts of K-ras transformed pancreatic 
cancer cells (Zimmermann et al., 2013). However, further structural optimization of 
deltarasin would be required, considering its nonspecific inhibitory activity toward 
other small GTPases such as Rheb (Chandra et al., 2012). These studies highlight 
that modulation of Ras processing and trafficking can open new opportunities for 
modulating Ras signaling.  
 
Table	3.	Classification	of	inhibitors	targeting	Ras	and	downstream	effectors.		
Compound	 Target/mechanism	of	action	 Ras	specificity	 Reference	
Compounds	that	inhibit	Ras-effector	interactions	
Sulindac	(NSAID)	 Direct	binding	in	vicinity	of	H-ras	
switch	I	
H-ras	 Waldmann	et	al.,	
2004;	Muller	et	
al.,	2004		
Methylcyclopropen
e	(MCP)	
Ras-Raf	interaction	 K-ras	 Kato-Stankiewicz	
et	al.,	2002;	
González-Pérez	
et	al.,	2010	
Cu2+	or	Zn2+	cyclens	 Ras-effector	interaction.	Shifts	H-ras-
GTP	conformational	equilibrium	
towards	state	1	
Ras	 Rosnizeck	et	al.,	
2010	
Kobe-family	
inhibitors	
Stabilizes	Ras	in	open	state	1	
conformation.	
H-ras	(T35S)-
GTP	
Shima	et	al.,	
2013	
Compounds	that	inhibit	exchange	of	GDP	for	GTP	
SCH54292	and	
water-soluble	
SCH54292	
Suggested	to	bind	Ras	between	the	
switch	II	and	helix	4	regions.	
H-ras	 Taveras	et	al.,	
1997;	Palmioli	et	
al.,	2009	
Peptide	HBS3	 Interferes	with	Ras-SOS	interaction	 Ras	 Patgiri	et	al.,	
2011		
4,6-dichloro-2-
methyl-3-
aminoethyl-indole	
(DCAI)	
Blocks	K-ras/SOS	interaction	by	
binding	to	the	hydrophobic	pocket	
located	between	the	switch	II	region	
and	the	core	β-sheet.	
K-ras	 Maurer	et	al.,	
2012	
Indole	derivative	 Blocks	K-ras/SOS	interaction	by	
binding	to	the	hydrophobic	pocket	
K-ras	 Sun	et	al.,	2012		
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located	between	the	switch	II	region	
and	the	core	β-sheet.	
SML-10-70-1	 Mimics	GDP	when	bound	to	K-ras	 K-rasG12C	 Lim	et	al.,	2013	
	
Acrylamide-12	
(AA12)	
Binds	irreversibly	to	K-rasG12C	and	
disrupt	switches	I	and	II	
K-rasG12C	 Ostrem	et	al.,	
2013		
Bisphenol	A	 Inhibits	SOS-mediated	nucleotide	
exchange	by	direct	binding.	
K-ras,	H-ras	 Schopel	et	al.,	
2013		
Cyclorasin	9A	and	
12A	(cyclic	
peptides)	
Bind	K-ras	in	the	switch	I	and	II	
regions.	
K-ras	 Wu	et	al.,	2013;	
Upadhyaya	et	al.,	
2015	
Compounds	that	alter	Ras	plasma	membrane	localization	
Tipifarnib,	
lonafarnib,	and	
BMS-214662	(non-
peptidomimetics)	
FTase	inhibitors.	Inhibits	
farnesylation	of	Ras.	Changes	
localization	of	Ras.	 	
H-ras	 Beaupre	et	al.,	
2004	
FTI-276,	FTI-277,	L-
744832,	B956	and	
FTI-2153	(CAAX	
peptidomimetics)	
FTase	inhibitors.	Inhibits	
farnesylation	of	Ras.	Changes	
localization	of	Ras.	 	 	
H-ras	 Sun	et	al.,	1998;	
Lerner	et	al.,	
1995	
Statins	 Inhibits	Ras	prenylation	through	
inhibition	of	isoprenoid	
pyrophosphate	substrate.	Changes	
localization	of	Ras.	
-	 Hindler	et	al.,	
2006	
RPI,	prenylcysteine	
chloromethylketon
e	derivatives,	S-
adenosylhomocyst
eine,	
prenylcysteine	
derivates	(AFC,	
AGGC)	
Targets	RCE1	and	ICMT.	Changes	
localization	of	Ras.	
Ras	 Hollander	et	al.,	
2000;	
Manandhar	et	
al.,	2007	
2-Bromopalmitate	 Inhibits	palmitoylation,	but	is	not	
specific.	Changes	localization	of	Ras.
	 	 	
H-ras,	N-ras	 Draper	et	al.,	
2009;	Webb	et	
al.,	2000	
Palmostatins	B	and	
M	
B-lactone	inhibitors.	Blocks	
depalmitoylation.	Changes	
localization	of	Ras.	
H-ras,	N-ras	 Dekker	et	al.,	
2010	
Deltarasin	 Inhibits	the	K-ras–PDE6d	interaction.	
Changes	localization	of	Ras.	
K-ras	 Zimmermann	et	
al.,	2013	
Salirasib	
(farnesylcysteine	
mimetic)	
Inhibits	the	prenyl-binding	
interactions	between	Ras	and	
farnesyl-binding	proteins.	Disrupts	
Ras	membrane	anchorage.	
H-ras	 Marom	et	al.,	
1995;	Kloog	et	
al.,	2013	
Compounds	that	target	Ras	downstream	signaling	
LY3009120	 Pan-Raf	inhibitor	 -	 Peng	et	al.,	2015	
PLX8394	 B-Raf	inhibitor	 -	 Zhang	et	al.,	
2015	
PLX7904	 B-Raf	inhibitor	 -	 Zhang	et	al.,	
2015	
CCT196969	 Pan-Raf	and	Src-family	kinase	
inhibitor	
-	 Girotti	et	al.,	
2015	
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Pictilisib	(GDC-
0941)	
Pan-PI3K	inhibitor	 -	 Sarker	et	al.,	
2015	
Buparlisib	 Pan-PI3K	inhibitor	 -	 Maira	et	al.,	
2012	
Alpelisib	(BYL719)	 p110α	selective-PI3K	inhibitor	 -	 Fritsch	et	al.,	
2014;	Furet	et	
al.,	2013	
Taselisib	(GDC-
0032)	
p110α	selective-PI3K	inhibitor	 -	 Ndubaku	et	al.,	
2013	
MLN1117	 p110α	selective-PI3K	inhibitor
	 	
-	 Jenssen	et	al.,	
2011	
AZD8186	 p110β	selective-PI3K	inhibitor	 -	 Hancox	et	al.,	
2015	
Idelalisib	(GS-1101)	 p110δ	selective-PI3K	inhibitor	 -	 Fruman	et	al.,	
2014	
NVP-BEZ235	 Dual	PI3K/mTOR	inhibitor	 -	 Maira	et	al.,	
2008	
(Fritsch et al., 2014; Fruman and Cantley, 2014; Furet et al., 2013; Girotti et al., 2015; Hancox et al., 2015; Jessen et al., 2011; Kato-Stankiewicz et al., 2002; Maira et al., 2012; 2008; Muller et al., 2004; Ndubaku et al., 2013; Peng et al., 
2015; Sarker et al., 2015; Vanessa González-Pérez, 2010; Waldmann et al., 2004; Zhang et al., 2015) 
Finally, a number of farnesyl-derived compounds were designed to inhibit the 
prenyl-binding interactions between Ras and farnesyl-binding proteins. Salirasib, 
also known as farnesylthiosalicylic acid (FTS), a farnesylcysteine mimetic, was 
proposed to target galectins and to compete for interaction with Ras proteins (Elad 
et al., 1999; Elad-Sfadia et al., 2002; Kloog et al., 2013; Paz et al., 2001). Salirasib has 
been shown to disrupt Ras membrane anchorage, leading to an inhibition of tumor 
cell growth (Marom et al., 1995). Although, Salirasib was tested in small clinical 
trials, no objective responses were seen either as monotherapy against advanced K-
ras-mutant lung adenocarcinoma or in combination with gemcitabine in pancreatic 
cancer (Laheru et al., 2012; Riely et al., 2011). 
 
5.2 Drugging	Ras	structurally	
The disappointing results with developing FTIs as anti-Ras drugs, lead to the notion 
that Ras is ‘undruggable’. Designing drugs to bind Ras directly seemed futile due to 
the lack of apparent binding domains or pockets for small molecule binding in the 
Ras tertiary structure (Marcus and Mattos, 2015). However, the recent developments 
with the Ras crystal structures and high-throughput screening have given hope that 
small molecules can bind in Ras pockets. The following section provides an overview 
of some of accomplishments with inhibitors that directly target Ras and its effector 
interactions. 
Vos et al., in 1988 and Pai et al., in 1989 reported the first tertiary structure of H-ras-
GDP and H-ras-GppNHp respectively (de Vos et al., 1988; Pai et al., 1989). H-ras 
consists of a hydrophobic core of 6-stranded β-sheets and five α-helices with ten 
connecting loops. Comparison of the GDP and GTP bound H-ras revealed a guanine 
nucleotide exchange driven conformation change in the predominantly flexible 
regions, Switch I (residues 32-28) and Switch II (residues 60-75). This was followed 
by NMR spectroscopy data that revealed the existence of at least two distinct 
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conformational states that are in dynamic equilibrium. H-ras-GppNHP adopts two 
conformations in solution, state 1 and state 2 (Geyer et al., 1996; Spoerner et al., 
2005) regardless of the presence or absence of the oncogenic mutations. State 1 
corresponds to an inactive conformation with greatly impaired ability to bind 
effectors and it is recognized by GEFs. Effector proteins recognize state 2 and it 
represents the active conformation, due to an effector-binding induced equilibrium 
shift towards state 2. Crystal structures of H-ras GTP alone or bound to effector 
correspond to this state. Crystal structures of H-ras mutants in state 1 (Geyer et al., 
1996) revealed that state 1 corresponds to an open conformation with the loss of 
hydrogen bonding across the switches I and II and guanine nucleotide found in state 
2. This results in the surface pocket suitable for accepting small-molecule 
compounds. Different approaches have been used to directly target Ras: inhibiting 
the exchange of GDP for GTP, increasing GTP hydrolysis rates or inhibiting effector 
interactions. 
 
5.3 Inhibiting	the	exchange	of	GDP	for	GTP	
Some previous studies have reported potential small molecule association with Ras. 
However, there was little knowledge on the binding site of the inhibitors and no 
defined binding pocket was reported. Tavares et al., first highlighted the concept of 
targeting Ras by small molecules when they characterized the Ras-binding 
compounds SCH54292 (Taveras et al., 1997) and its water-soluble derivative 
(Palmioli et al., 2009). In silico mapping suggested that these molecules bind to Ras 
between the switch II and helix 4 regions and do not displace the nucleotide. In the 
cellular context, the exact mechanism of action is not known, hindering 
identification of similar inhibitors. Inhibitors to block the nucleotide exchange 
reaction were developed using modified peptides based on the Ras-binding domains 
of GEFs (Patgiri et al., 2011; Sacco et al., 2012). Peptide HBS3, a cell-permeable 
synthetic α-helix mimic of SOS developed using the hydrogen bond surrogate (HBS) 
approach was shown to interfere with Ras-SOS interaction and down regulate Ras 
signaling in response to epidermal growth factor (EGF)-stimulation in HeLa cells 
(Patgiri et al., 2011).  
 
Ras guanine nucleotide-binding site is a known allosteric site for potential 
modulation. In 2012, two groups independently reported the use of an NMR-based 
fragment screening approach to identify inhibitors that block the K-ras/SOS 
interaction (Maurer et al., 2012; Sun et al., 2012). These inhibitors: 4,6-dichloro-2-
methyl-3-aminoethyl-indole (DCAI) (identified by the Genentech group) and indole 
derivative compound (identified by Fesik’s group) bound to the same hydrophobic 
pocket, located between the α2 helix (switch II region) and the core β-sheet of K-ras 
and thereby interrupted K-ras/SOS association. These fragments make very different 
contacts inside the pocket (Maurer et al., 2012; Sun et al., 2012).  However, there was 
no evidence for their inhibitory effect on Ras mutated cancer cells.  
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Lim et al., and Ostrem et al., found an alternative strategy of inhibiting GDP-
exchange (Lim et al., 2013; Ostrem et al., 2013). Lim et al., used a synthetic chemistry 
approach to design and screen GDP derived analogues. They identified analogue 
SML-10-70-1 that mimics GDP when bound to K-ras and can covalently modify 
cysteine 12 of K-rasG12C. This modification is K-rasG12C specific and not found in 
wild type K-ras. SML-10-70-1 blocked the proliferation of K-rasG12C mutated 
cancer cells (Lim et al., 2013). Ostrem and colleagues used a disulphide-fragment-
based screening approach called tethering, which relies on the formation of a 
disulfide bond between the ligand and a cysteine residue in the protein of interest 
(Erlanson et al., 2000; Ostrem et al., 2013). By taking advantage of the nucleophilicity 
of the cysteine thiols, they used K-rasG12C as a target for identifying small 
molecules. Notably, the mutant cysteine 12 in K-ras sits in the proximity to both the 
nucleotide-binding region and the switch regions that are involved in Ras effector 
interactions. The fragment-based screening led to the identification of inhibitors that 
irreversibly binds to K-rasG12C and disrupt switches I and II. Crystallographic 
studies of the complex revealed a novel drug-binding pocket. Structure based 
optimization resulted in the most potent compound acrylamide 12 (AA12) that is 
specifically active against mutated K-rasG12C, but not wild type K-ras in vitro, and it 
induced apoptosis of lung cancer cells carrying K-rasG12C (Ostrem et al., 2013). 
However, the effect of this compound in either H- or N-rasG12C is not known, 
though the mutations are rare in these Ras isoforms. 
 
By using an NMR-based screening approach against a related GTPase Rheb, it was 
found that Bisphenol A directly binds to Rheb and also K-ras (Schöpel et al., 2013). 
Bisphenol A inhibits the SOS-mediated nucleotide exchange activity of both K- and 
H-ras. Again the binding site of Bisphenol A in K-ras was identical to the one 
described earlier for the structurally different compounds (Schöpel et al., 2013). 
More recently, a combinatorial peptide library screening against K-ras found cyclic 
peptides (cyclorasin 9A and 12A) that strongly bind K-ras (Upadhyaya et al., 2015; 
Wu et al., 2013). The binding site of the cyclorasin was mapped to the switch I and II 
regions, similar to the ones reported before by Genentech and the Fesik group 
(Maurer et al., 2012; Sun et al., 2012).  
 
5.4 Inhibiting	Ras-effector	interactions	
Blocking the interactions of Ras-GTP with downstream effectors is another strategy 
for inhibiting constitutively active Ras. This Ras-effector targeting has produced few 
low-affinity inhibitors. It was first reported using a phenotypic screening approach 
that sulindac, a NSAID (nonsteroidal anti-inflammatory drug) strongly inhibited H-
ras-induced malignant transformation of MDCK-F3 cells and the Ras-dependent 
Raf activation (Muller et al., 2004; Waldmann et al., 2004). NMR analysis of H-ras 
with the inhibitor revealed a direct binding of sulindac in the vicinity of H-ras switch 
I (Muller et al., 2004), however these observations were not studied further. 
Methylcyclopropene (MCP) compounds were identified as inhibitors of Ras-C-Raf 
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interaction using a yeast two-hydrid system. MCP compounds inhibited anchorage-
independent growth of cancer cells harboring a K-ras mutation. However, the direct 
target of the inhibitor has been ambiguous. Rosnizeck et al., showed inhibition of 
Ras-effector protein interactions using Cu2+ and Zn2+ cyclens as a way to deregulate 
over active GTP-bound Ras (Rosnizeck et al., 2010). The authors hypothesized that 
the presence of these metal cyclen derivatives - capable of shifting the 
conformational equilibrium of H-ras-GTP toward state 1 - caused a disruption of 
the nucleotide-binding site in the presence of GTP leading to weak effector 
interactions. However, these cyclen derivatives have low binding affinity for Ras-
GTP, weak inhibitory effect on Ras-Raf and lack evidence for cellular efficacy 
hindering their further optimization (Rosnizeck et al., 2010). 
 
The identification of state 1 of H-ras-GTP lead to the identification of the Kobe-
family inhibitors that block Ras activation by stabilizing Ras in the open state 1 
conformation (Shima et al., 2013). The Kobe0065-family of inhibitors was identified 
using an in silico screening approach coupled with computer docking simulations. 
Kobe0065 and its analogue Kobe2602 compounds inhibited the Ras-Raf-Mek-Erk 
pathways and nucleotide exchange activity of SOS. NMR structure revealed that the 
compound inserted into the surface pocket of H-ras (T35S)-GTP. Furthermore, the 
compounds inhibited Ras-mutated cancer cell lines and reduced tumor growth in a 
xenograft model (Shima et al., 2013).  
 
5.5 Targeting	Ras	downstream	effectors	
Given the difficulties associated with targeting mutant Ras proteins directly, search 
began for drugs targeting the downstream effector pathways, particularly the Raf-
MAPK and PI3K pathways. The Raf-Mek-Erk pathway, was the first Ras effector-
signaling pathway to be identified and is required for Ras-mediated transformation 
and tumorigenesis (Kyriakis et al., 1992). Most of the attempts to target Raf-Mek-
Erk signaling pathway were largely focused on finding Raf and Mek inhibitors. The 
identification of BRAF mutations in cancer (~8% of all cancers and 50% of all 
melanomas) makes it an ideal anti-cancer target (Dong et al., 2003). This lead to the 
identification of several Raf inhibitors and some were clinically approved like 
vemurafenib and dabrafenib. For instance, vemurafenib binds and inhibits all three 
Raf kinases in biochemical assays and it effectively inhibits Erk signaling and 
proliferation of the B-Raf V600E melanoma cell lines and mouse xenograft models. 
These inhibitors also showed unprecedented clinical activity in patients with B-Raf 
V600E or V600K mutant melanomas (Chapman et al., 2011; Hauschild et al., 2012).  
 
However, a notable property of these B-Raf inhibitors is that they lead to paradoxical 
activation of Raf kinase especially in Ras mutant cancers, leading to increased Erk 
signaling precluding their use for Ras mutated cancers (Chapman, 2013; Poulikakos 
et al., 2011). This is because, in the presence of oncogenic Ras, B-Raf inhibitors can 
drive the formation of B-Raf/C-Raf hetero- and homodimers, which contain one 
Review of the Literature – Strategies for Targeting Ras 
 50 
inhibitor-bound partner and one partner that is inhibitor-free. The inhibitor-bound 
partner drives activation of the inhibitor-free partner through scaffolding or 
conformational functions, thus activating C-Raf and, consequently, stimulating Mek 
and Erk activation (Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos et al., 
2010). This ‘Raf inhibitor paradox’ has gathered a lot of research interest in the past 
few years, and it has lead to the recent identification of next-generation Raf 
inhibitors dubbed ‘paradox breakers’. Zhang and colleagues reported that the 
paradox-breaking B-Raf inhibitors PLX7904 and PLX8394 can inhibit downstream 
Erk signaling in cultured cells with B-Raf mutations (Zhang et al., 2015). 
Importantly, these inhibitors suppress Erk phosphorylation in BRAF-mutant 
melanoma cells but do not stimulate Erk signaling in RAS-mutant cells. Moreover, 
PLX7904 did not enhance B-Raf/C-Raf heterodimerization in Ras-mutant cells and 
in vemurafenib-resistant cells. PLX8394 is currently in clinical trials 
(www.clinicaltrials.gov, NCT02428712). These inhibitors are predicted to have 
increased safety and clinical efficacy compared to first-generation and pan-Raf 
inhibitors. Recently, Peng and colleagues characterized a new pan-Raf inhibitor, 
LY3009120, which inhibits all Raf family members with similar potencies. 
LY3009120 inhibits monomeric B-Raf V600E as well as WT and mutant Raf dimers 
with minimal paradoxical activation. In addition, LY3009120 was shown to have 
anti-tumor activity in cancer models carrying oncogenic K-ras, N-Ras, or B-Raf 
mutations (Peng et al., 2015).  
 
Mek and Erk inhibitors do not have this paradoxical activation. Nevertheless, their 
early clinical efficacy was limited by toxicity and failing to select patients with 
tumors containing mutations in the Erk pathway (Samatar and Poulikakos, 2014). 
The first MEK inhibitor to be approved by FDA for clinical use was trametinib, a 
potent Mek1/2 inhibitor that preferentially binds to unphosphorylated Mek1/2 and 
prevents Raf-dependent Mek phosphorylation. It was approved for treatment of 
metastatic melanoma with the B-Raf (V600E/K) mutation and its efficacy was 
proved in a phase III clinical trial of patients with B-Raf mutant melanoma who had 
not received prior B-Raf therapy (Samatar and Poulikakos, 2014). However, 
trametinib treatment was unsuccessful for patients who relapsed after therapy with 
either vemurafenib or dabrafenib. Though the reasons for this acquired resistance 
are not clear, one possibility is the reduced dependence of the resistance tumors on 
Erk signaling for growth. Cobimetinib, another allosteric inhibitor of Mek1/2 with 
sustained inhibition of Erk/MAPK signaling is currently in clinical trials (Choo et al., 
2012). A phase I trial (CoBRIM) trial of cobimetinib combined with B-Raf inhibitor 
(vemurafenib) in patients with B-Raf V600E/K mutations confirmed an improved 
response to combination therapy. This was further confirmed by a phase III trial of 
vemurafenib plus cobimetinib in advanced B-Raf mutant melanoma (Larkin et al., 
2014). Cobimetinib was very recently approved by the FDA for treatment of patients 
with unresectable or metastatic melanoma with a B-Raf V600E/K mutation, in 
combination with vemurafenib 
(www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472193.htm).  
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Cobimetinib is now under regulatory review for the same indication in several 
countries (Garnock-Jones, 2015). Similar to Raf inhibitors, Mek inhibitors are also 
limited by drug resistance that typically involve the loss of Erk-driven negative 
feedback loops. Nevertheless, Mek inhibitors such as GDC-0623, which stabilizes the 
Raf-Mek complex, has shown greater efficacy in K-ras mutated cancers than 
conventional Mek inhibitors.   
 
Until recently, development of Erk inhibitors was lagging behind Raf and Mek 
inhibitors, largely due to the assumption that there is no additional benefit of 
targeting Erk, since inhibition of Raf and Mek would be sufficient to inhibit Erk. 
However, most resistance mechanisms result in reactivation of Erk. Active Erk 
inhibitors, such as VTX-11e and SCH772984, have been described before (Aronov et 
al., 2009; Morris et al., 2013). SCH772984 has been found to be active against both 
N-ras and B-Raf mutated cancer cell lines. In addition, SCH772984 was reported to 
act synergistically with vemurafenib against B-Raf mutant cell lines (Wong et al., 
2014). Moreover, Erk1/2 inhibitors, including CC-90003, GDC-0994, MK-8353 and 
BVD-523 (ulixertinib), are currently in phase I/II clinical studies. GDC-0994 was 
reported to have significant activity in multiple in vivo cancer models, including K-
ras-mutant and B-Raf-mutant human xenograft tumors in mice (Robarge et al., 
2014). Similarly, BVD-523 inhibits tumor growth in B-Raf-mutant melanoma and 
colorectal xenografts as well as in K-ras-mutant colorectal and pancreatic models. 
BVD-523 was found to inhibit the growth of cells resistant to dabrafenib, trametinib, 
or their combination (Germann et al., 2015). The preclinical and clinical studies of 
these inhibitors will help in better understanding whether they may be used as novel 
agents in MAPK directed therapeutic strategies. 
 
The identification and characterization of such clinically available Raf, Mek and Erk 
inhibitors with different biochemical and pharmacologic properties are predicted to 
potently inhibit signaling and avoid toxicities. As mentioned above, which inhibitor 
as single agent or in combination is ‘better’, will depend on tumor type and tumor 
genetic context.   
 
The PI3K pathway is another well-studied signaling cascade that is often up-
regulated in tumor cells, indicating its importance in cancer. Ras mutations drive 
PI3K activity, and mutations in Ras and PI3K often coexist e.g. in colorectal and 
endometrial cancers (Esther Castellano, 2011). Currently there are several classes of 
potent and selective small molecule PI3K inhibitors under development. They are 
classified into pan-PI3K and isoform-selective inhibitors, depending on their 
specificities to the four isoforms of the p110 catalytic domains α, β, γ, and δ (Table 
3). Pictilisib (GDC-0941) was the first oral, potent, pan-PI3K inhibitor shown to be 
active in glioblastoma and ovarian cancer xenograft models (Raynaud et al., 2009). A 
recent first-in-human phase I study confirmed the activity of pictilisib in inhibiting 
PI3K in patients with solid tumors (Sarker et al., 2015). Alpelisib (BYL719) is a 
p110α-selective PI3K inhibitor that has shown activity in a variety of cancer cell 
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lines, especially in those harboring PIK3CA mutations. In vitro studies have 
predicted alpelisib to be most potent in head and neck, hematological, and breast 
cancers and alpelisib is currently investigated in phase I-II clinical trials (Massacesi 
et al., 2015). Synergistic activity of combined binimetinib (Mek1/2 inhibitor) and 
alpelisib was recently reported in human neuroblastoma cell lines. This combined 
treatment suppresses the activation of MAPK, PI3K/Akt and mTOR (Hart et al., 
2015). However, inhibitors targeting the PI3K pathway are generally limited by the 
feedback loops that activate upstream signaling and their poor therapeutic index. In 
vitro data suggest oncogenic Ras to be a strong predictor of resistance to PI3K 
inhibitors (Gysin et al., 2011; Ihle et al., 2009). Therefore, targeting PI3K alone is 
likely insufficient for Ras mutated cancers. In light of the crosstalk between the Raf-
Mek-Erk and PI3K pathways, it has been proposed that dual inhibition of both 
pathways may be necessary to treat Ras-driven tumors (Sabbah et al., 2011). In 
support of this assumption, combined inhibition of Mek (by Selumetinib) and 
PI3K/mTOR (by NVP-BEZ235) has been shown to be effective at suppressing tumor 
growth of mice with K-ras driven lung cancers (Engelman et al., 2008). Moreover, 
there are several ongoing clinical trials testing the dual inhibition of the Raf-Mek-
Erk and PI3K pathways (Britten, 2013; Saini et al., 2013). 
 
5.6 Targeting	Ras	nanoclusters	
Perturbing the spatiotemporal dynamics of Ras nanoclusters disrupts Ras signaling. 
This makes nanoclustering a viable therapeutic target for pharmacological targeting 
and to inhibit aberrant Ras signaling in human cancers. Work from our laboratory 
provided the first proof-of-concept study to identify potential Ras nanocluster 
inhibitors (Köhnke et al., 2012). By using a FRET-based screening approach, Köhnke 
et al., identified ionophoric antibiotic macrotetrolides to specifically disrupt H-ras 
nanoclustering and EGF-induced Ras signaling (Köhnke et al., 2012). However, the 
mechanism of action of these macrotetrolides or similar ionophoric compounds on 
Ras nanoclustering and signaling is unknown. Recent work from John Hancock and 
colleagues has further validated Ras nanoclusters as anti-cancer drug targets. Using a 
high-content imaging based screening method, they identified two known 
compounds, fendiline and staurosporine (STS) to mislocalize K-ras (Cho et al., 
2012b; van der Hoeven et al., 2013). Fendiline is an FDA approved drug, originally 
found as a L-type calcium channel blocker. Fendiline specifically decreases K-ras but 
not H-ras nanoclustering, leading to impaired downstream signaling and growth of 
K-ras mutated cancer cells. Though the exact molecular mechanism for this is not 
completely characterized, it is unrelated to the activity of fendiline as a calcium 
channel blocker (van der Hoeven et al., 2013). STS and its analogues are well-known 
PKC-inhibitors that were found to deplete PS from the inner leaflet of the plasma 
membrane to the endomembranes, thus disrupting K-ras nanoclustering and 
signaling (Cho et al., 2012b). These effects were unrelated to STS-mediated 
inhibition of PKC.  
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In addition to drugs that change plasma membrane lipid composition, drugs that 
change lipid and membrane properties have also been found to affect Ras 
nanoclustering (Zhou et al., 2010). Nonsteroidal anti-inflammatory drugs (NSAIDs), 
such as aspirin, ibuprofen and indomethacin have been reported to specifically 
stabilize cholesterol-dependent H-ras-GDP and N-ras-GTP nanoclusters, but they 
have no effect on cholesterol-independent nanoclusters (Zhou et al., 2012). 
However, this stabilization of cholesterol-domains leads to formation of heterotypic 
clustering between H-ras-GDP and H-ras-GTP resulting in lower MAPK signaling. 
It is therefore suggested that the chemo-preventive action of NSAIDs could be partly 
related due to the effect on Ras nanoclustering. It is now understood that Raf-
inhibitors, in a Ras-dependent manner, can lead to paradoxical activation of the Raf-
Mek-Erk pathway by inhibitor-induced homodimerization of B-Raf or 
heterodimerization of B- and C-Raf (Hatzivassiliou et al., 2010; Heidorn et al., 2010; 
Poulikakos et al., 2011). It was recently shown that Raf inhibitors like sorafenib and 
SB590885 specifically enhance K- and N-rasG12V but not H-rasG12V 
nanoclustering (Cho et al., 2012a). Mechanistically, Raf inhibitor-treated cells form 
stable Raf dimers with two RBDs that drive Ras dimerization that leads to higher K- 
and N-rasG12V nanoclustering (Cho et al., 2012a). 
Ras membrane lipid composition and lipid interactions with Ras are critical for 
nanoclustering and proper lateral segregation, suggesting that nanoclustering and 
lateral segragation must be a general characteristic of all lipid-anchored proteins. 
However, this possibility remains to be investigated. Given the importance of Ras 
nanoclusters in signal transduction and cancer,  targeting Ras nanoclustering and 
lateral segregation is an attactive therapeutic target for drug development. 
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AIMS	OF	THE	STUDY	
A i m s 	 o f 	 t h e 	 S t u d y 	
Due to their eminent role in cancer, Ras proteins have been considered a major drug 
target for more than 30 years. Numerous attempts have been made to find a true 
anti-Ras drug, yet not a single drug has emerged from these efforts. These past 
failures in the search for drugs to target Ras have driven some researchers to jump 
ship, deeming Ras ‘undruggable’. Nevertheless, there is currently a growing 
optimism that this could change in the near future as we gain new insights into Ras 
function. Now it is clear that Ras forms nanoscale signaling complexes on the plasma 
membrane, termed nanocluster. Ras nanoclustering is essential for oncogenic Ras 
signaling. The focus of my PhD thesis was to explore nanoclusters as novel anti-
cancer drug targets and to identify chemical modulators of nanoclustering. For the 
identification of nanocluster inhibitors a cell-based high-throughput amenable Ras 
FRET-biosensor screening platform was established. Diverse chemical libraries were 
acquired and screened for potentially novel chemical modulators of Ras. Potential 
hit molecules were validated on full-length oncogenic proteins using a combination 
of imaging methods such as FLIM-FRET, confocal and super resolution microscopy, 
and biochemical methods. The selected hit compounds were then functionally 
validated on different Ras isoforms using cellular transformation and tumor growth 
assays.  
 
 
The specific aims of the thesis were: 
 
• To utilize FRET-biosensors as a small molecule screening platform to 
identify nanoclustering and lipid modification inhibitors. 
 
• To perform a small molecule chemical screen to identify H-ras nanocluster 
modulators. 
 
• To perform differential screens with H- and K-ras biosensors to find novel 
inhibitors of K-ras nanoclustering. 
 
• To design and validate FRET-biosensors that report on membrane targeting 
of N-myristoylated proteins. 
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EXPERIMENTAL	PROCEDURES	
E x p e r i m e n t a l 	 P r o c e d u r e s 	
 
More detailed information on the experimental procedures is available in the 
original publications. For more information on the use of the flow cytometry-based 
Fluorescence Resonance Energy Transfer (FRET)-biosensors assays see 
(Najumudeen et al., 2015). 
 
Cell lines  
Name	(company)	 Publication	
BHK21,	baby	hamster	kidney	cells	(Sigma-Aldrich)	 I,	II,	III	
HEK293-EBNA,	HEK293	cells	expressing	the	EBNA-1	gene	 I,	II,	III	
MEF,	wild-type	mouse	embryonic	fibroblasts	 I	
Du-315-6	(H-ras-/-,	N-ras-/-)	mouse	embryonic	fibroblasts	 I	
PC12,	rat	adrenal	pheochromocytoma	cells	 I	
MDA-MB-231,	Human	breast	adenocarcinoma	cells	 I,	II	
MDCK,	Madin-Darby	canine	kidney	cells,	stably	expressing	either	
mGFP-K-	or	H-	rasG12V	(gift	from	J.	Hancock)	
II	
NCI-H1395,	OVSAHO,	NCI-H1975,	Calu-6,	A2780,	SK-MEL-2,	SNU-398,	
COLO320,	MeWo,	NCl-H196,	A375,	U-2OS,	HGC27,	MDA-MB-231,	
HS675T	(GenScript)	
II	
 
Antibodies 
Name	 Application	 Publication	
Erk1/2	(Cell	Signaling	Technology,	Cat.	No.	9102)	 WB	 I,	II	
phospho-	ppErk1/2	(T202/Y204;	Cell	Signaling	
Technology,	Cat.	No.	9101)	
WB	 I,	II	
Akt	(Cell	Signaling	Technology,	Cat.	No.	9272)	 WB	 I	
phospho-pAkt	(T308;	R&D	Systems,	Cat.	No.	658320)	 WB	 I	
β-actin	(Sigma	Aldrich,	Cat.	No.	A1978)	 WB	 I,	II	
Pan-Ras		 WB	 I	
Cav-1	(BD	biosciences,	Cat.	No.	610060)	 STED	 II	
GFP	(BioVision,	Cat.	No.	3999-100)	 WB	 	II	
APC-conjugated	anti-CD44	(clone	G44-26,	BD	
Biosciences)	
Flow	
cytometry	
II	
PE-conjugated	anti-CD24	antibody	(clone	ML5,	BD	
Biosciences)	
Flow	
cytometry	
II	
 
Methods 
Name		 Publication	
Chemical	library	screening	with	H-ras-NANOPS,	K-ras	NANOPS	and	
Yes-NANOMS	
I,	II,	III	
Immuno-electron	microscopy		 I	
Confocal	microscopy	 II	
Fluorescence	resonance	energy	transfer	(FRET)	confocal	microscopy	 III	
Flow	cytometric	FRET	on	BD	LSRII	(BD	Biosciences)	 I,	II,	III	
Flow	cytometric	analysis	of	stem	cell	markers	LSRII	(BD	Biosciences)	 II	
Fluorescence	lifetime	imaging	microscopy	(FLIM)-FRET	 I,	II	
Fluorescence	recovery	after	photobleaching	(FRAP)	 I	
STED	microscopy	 II	
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FACS	and	FRAP	data	analysis	with	IGOR	Pro	6	(WaveMetrics)	 I,	II	
Image	analysis	using	ImageJ	 I,	II	
Western	blotting	(WB)	 I,	II	
Quantification	of	immunoblot,	ImageLabTM	software	(BioRad)	 I,	II	
PC12	cell	differentiation	assay	 I	
Mammosphere	assay	 I	
In	ovo	tumor	growth	assay	 I	
Cell	proliferation	assay	 II	
Drug	sensitivity	profiling	(performed	through	GenScript)	 II	
siRNA	knockdown	 I,	III	
Quantitative	reverse	transcription	PCR		 III	
In	silico	analysis	of	co-expressed	genes	(conducted	by	Aittokallio	
group)	
II	
In	silico	analysis	of	cell	lines	(conducted	by	Aittokallio	group)	 II	
In	silico	analysis	of	clinical	samples	(conducted	by	Aittokallio	group)	 	
Dose-response	analysis	(nonlinear	regression	analysis)	with	GraphPad	
PRISM	software	
I,	II	
Statistical	analysis	(t-test,	ANOVA)	with	GraphPad	PRISM	software	 I,	II,	III	
 
Chemical libraries 
Name	and	description	 Publication	
Enzo®	Screen-Well®	Natural	Product	library	(Enzo	Life	Science	Inc.),	
502	naturally	derived	compounds	
I	
In	house	collection	of	157	natural	compounds	(Brunhofer	et	al.,	2012;	
Narwal	et	al.,	2012)	
I	
Ionophore	collection	(Cherry-picked)	 II	
Microbial	Screening	Technologies	(MST)	Library	 II	
 
Reagents 
Reagents	(manufacturer)	 Application	 Publication	
jetPRIME	(Polyplus	transfection)	 Cell	transfection	 I,	II,	III	
FuGene6	(Roche)	 Cell	transfection	 III	
Lipofectamine	3000	(Thermo-Fischer	Scientific)	 Cell	transfection	 I	
Lipofectamine	RNAiMax	(Invitrogen)	 Cell	transfection	 III	
DMEM,	Dulbecco’s	modified	Eagle’s	Medium	
(Invitrogen,	Sigma-Aldrich)	
Cell	culture	 I,	II,	III	
RPMI-1640,	Roswell	Park	Memorial	Institute	
medium	(Invitrogen)	
Cell	culture	 I	
FBS,	fetal	bovine	serum	(Invitrogen)	 Cell	culture	 I,	II,	III	
Horse	serum	(Invitrogen)	 Cell	culture	 I	
L-glutamine	(Sigma-Aldrich)	 Cell	culture	 I,	II,	III	
Penicillin	(Sigma-Aldrich)	 Cell	culture	 I,	II,	III	
Streptomycin	(Sigma-Aldrich)	 Cell	culture	 I,	II,	III	
DMSO	(Sigma-Aldrich)	 Compound	solvent	 I,	II,	III	
Rat	tail	collagen	I	(Gibco)	 Cell	culture	 I	
B27	supplement	(Gibco)	 Cell	culture,	sphere	 I	
Epidermal	growth	factor	(EGF;	Sigma)	 Cell	culture,	sphere	 I	
Fibroblast	growth	factor	(FGF;	Sigma)	 Cell	culture,	sphere	 I	
PFA,	paraformaldehyde	(Sigma-Aldrich)	 Microscropy	 I,	II,	III	
Mowiol	4–88	(Sigma)	 Microscopy	 I,	II,	III	
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4.5	nm	gold	nano-particles	coupled	to	anti-GFP	 Electron	microscopy	 I	
Fluorescein	 FLIM-FRET	standard	 I,	II	
FITC	beads	(Bangs	Laboratories)	 FRET	standard	 I,	II,	III	
Ringers	buffer	 FRAP	 I	
ClarityTM	Western	ECL	blotting	(BioRad)	 WB	 I	
Matrigel	(BD	Biosciences)	 In	ovo	tumor	
growth	
I	
AlamarBlue	(Invitrogen)	 Cell	proliferation	
and	viability	
II	
 
Inhibitors (used in the thesis) 
Name	 Concentrations	 Publication	
Cycloheximide	(Fischer	Scientific)	 0.18	μM,	10	μM	 I	
Anisomycin	(Fischer	Scientific)	 2	μM,	10	μM	 I	
Harringtonine	(Fischer	Scientific)	 2	μM,	10	μM	 I	
Doxorubicin	(Sigma-Aldrich)	 100	ng/ml,	2	
μM	
I,	II	
Salinomycin	(BioAustralis)	 1.3	μM,	2	μM	 I,	II	
Nigericin	(BioAustralis)	 1.3	μM	 II	
Lasalocid	sodium	(BioAustralis)	 1.7	μM	 II	
Staurosporine	(STS)	(BioAustralis)	 10	nM	 II	
Avermectin	(BioAustralis)	 0.2,	2	μM	 II	
Ivermectin	(BioAustralis)	 0.2,	2	μM	 II	
Congoblatin	A	(BioAustralis)	 0.2,	2	μM	 II	
Ophiobolin	A	(BioAustralis)	 0.2,	2	μM	 II	
Leptomycin	B	(BioAustralis)	 0.2,	2	μM	 II	
Kazusamycin	B	(BioAustralis)	 0.2,	2	μM	 II	
Streptonigrin	(BioAustralis)	 0.2,	2	μM	 II	
DDD85646		 4	μM	 III	
Myristoleic	Acid	(Sigma-Aldrich)	 0.3	μM	 III	
Tris	(dibenzylideneacetone)	dipalladium	(TDP;	
SantaCruz)	
1.0	μM	 III	
FTI-277	(Calbiochem)	 0.3	μM	 III	
2-bromopalmitate	(Sigma	Aldrich)	 100	μM	 III	
2-fluoropalmitate	(United	Bioresearch)	 100	μM	 III	
 
Plasmid constructs 
Name		 Publication	
mCFP	and	mCitrine-CTH	or	H-ras-NANOPS	(Kohnke	et	al.,	2012),	C-	
terminal	hypervariable	region	of	human	H-ras		
I,	II	
pmGFP-H-rasG12V	(Abankwa	et	al.,	2008),	mutated	human	H-ras		 I,	II	
pmGFP-K-ras4BG12V	(Abankwa	et	al.,	2010),	mutated	human	K-ras	 I,	II	
mRFP-C-Raf-RBD	(Abankwa	et	al.,	2008),	Ras-binding	domain	of	C-Raf		 I,	II	
pcDNA3-Gal-1	(Paz	et	al.,	2001),	Galectin-1		 I	
pcDNA3-asGal-1	(Paz	et	al.,	2001),	Galectin-1	knockdown		 I	
pmCherry-H-rasG12V	 I,	II	
pmCherry-K-rasG12V		 I,	II	
pmGFP-wt-H-ras,	wild-type	H-ras	 I	
mCFP	and	mCitrine-CTK	or	K-ras-NANOPS,	C-terminal	hypervariable	
region	of	human	K-ras	
II	
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mGFP-LactC2,	mRFP-LactC2	(gift	from	J.	Hancock)		 II	
PTRF-Flag	(Hill	et	al.,	2008),	Polymerase	I	And	Transcript	Release	
Factor		
II	
Cav1-HA	(Hill	et	al.,	2008),	Caveolin-1	or	Cav-1	 II	
pN_Src16_mCit-N1	and	pN_Src16_mCFP-N1	or	Src-NANOMS,	N-
terminus	from	human	c-Src		
III	
pN_mutSrc16_mCit-N1	and	pN_mutSrc16_mCFP-N1	or	mutant	Src-
NANOMS,	glycine	2	mutated	to	alanine	in	N-terminus	of	c-Src		
III	
pN_Yes17_mCit-N1	and	pN_Yes17_mCFP-N1	or	Yes-NANOMS,	N-
terminus	from	Yes1		
III	
pN_mut	Yes17_mCit-N1	and	pN_mutYes17_mCFP-N1,	mutated	
Glycine	2	to	Alanine	and	Cysteine	3	to	Serine	in	N-terminus	of	Yes1		
III	
pN_Gi2.mCit-N1	and	pN_Gi2.mCFP-N1	or	Gi2-NANOMS	(Abankwa	&	
Vogel,	2007)		
III	
pmCherry-H-rasG12V	and	pmCherry-K-rasG12V	
(Constructed	by	replacing	pmGFP	from	the	pmGFP-H-rasG12V	and	
pmGFP-K-rasG12V	plasmids	with	pmCherry	from	the	pmCherry-C1	
vector	(Clontech	Laboratories	Inc.,	CA,	USA).	
I,	II	
Yes-	and	Src-NANOMS	(Constructed	by	adding	specific	N-terminal	
membrane	targeting	regions	to	the	N-termini	of	the	pmCit-N1	or	
pmCFP-N1	vectors)	
III	
 
siRNA 
Name	(manufacturer)	 Publication	
H-ras	(Life	technologies)	 I	
NMT1		 III	
NMT2		 III	
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RESULTS	AND	DISCUSSION	
R e s u l t s 	 a n d 	 D i s c u s s i o n 	 – 	 C e l l u l a r 	 F R E T - b i o s e n s o r s 	 a s 	 a 	 S c r e e n i n g 	 P l a t f o r m 	 	
1 Cellular	FRET-biosensors	as	a	screening	platform	to	identify	
nanoclustering	and	lipid	modification	inhibitors	(I-III)	
Ras controls signaling pathways important for cell growth, differentiation, and 
survival. Ras has been shown to initiate cancers and the continued expression of Ras 
is necessary for tumor maintenance, as shown in model organisms. This has paved 
the way for targeting Ras, and there is significant amount of evidence to suggest that 
therapeutic targeting of Ras is a viable strategy. However, so far the attempts to find 
a safe drug to inhibit Ras activity have failed. Nanoclustering of proteins has 
emerged as a novel anti-cancer target as drugs targeting nanoclusters can hamper 
their activation and signaling. As a part of my thesis project I set out to identify new 
inhibitors of Ras-nanoclustering by using a FRET-based screening approach. The 
following chapter describes the results from screening different chemical libraries (I-
III). The functional validation and characterization of the hits from these screens is 
described in chapters 2 and 3 of Results and Discussion. 
 
1.1 Ras-derived	FRET	biosensors	report	on	nanoclustering	and	
membrane	anchorage	(I-II)	
We have previously reported the application of cytometric FRET measurements for 
detecting nanoclustering and lipid modification of membrane bound proteins 
(Abankwa and Vogel, 2007; Najumudeen et al., 2015). In this method, lipid anchors 
of membrane proteins are genetically fused to the fluorescent proteins mCFP 
(donor) and mCit (acceptor), and expressed in mammalian cells. We exploit the fact 
that these lipid-modified proteins in cellular membranes organize into nanoclusters 
and display high FRET, which is measured using a BD LSRII flow cytometer 
equipped with a 96-well high-throughput sampler. The FRET measured on a two-
dimensional membrane or on biological membranes depends on the ratio of donor-
acceptor fluorophores and the concentration of these fluorophores. In our 
cytometer-based method, FRET is measured in a high throughput fashion by 
adapting the sensitized acceptor-emission method (Gordon et al., 1998). In this 
method, at a constant donor-acceptor ratio of 1:1, the FRET efficiency increases with 
the increase in the acceptor expression levels, towards a maximal FRET value termed 
FRET Emax (Abankwa and Vogel, 2007). This Emax is characteristic for different 
membrane bound proteins and it can be used to report on functional membrane 
targeting and nanoclustering.  
 
H- and K-ras FRET-biosensors report on the functional membrane anchorage and 
nanoclustering of H- and K-ras, respectively. These biosensors are designed with the 
C-terminal hypervariable region (HVR) of H- and K-ras, genetically fused to the 
fluorescent proteins mCFP and mCit, and named as H- and K-ras-NANOPS 
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(Nanoclustering and Prenylation Sensor), respectively (Abankwa et al., 2008; 
Köhnke et al., 2012). The HVR has been used as a surrogate marker to report on the 
nanoclustering of the full-length proteins (Abankwa et al., 2008; Köhnke et al., 2012; 
Rotblat et al., 2010). The Ras-NANOPS undergoes the same post-translational 
modifications (i.e., farnesylation and/or palmitoylation) in the C-terminus like the 
full-length protein (Figure 5). Thus, they can also report on the steady-state activity 
of prenyltransferases and acyltransferases in the cell. The close packing of the 
prenylated Ras into nanoclusters on the membrane is measured as FRET Emax. A 
reduction in this FRET value corresponds to either loss of membrane anchorage due 
to inhibition of the protein prenylation machinery, or due to inhibition of 
nanoclustering of the Ras-NANOPS. This makes our Ras-NANOPS FRET-assay a 
highly sensitive and robust system to search for chemical modulators of Ras lipid 
modification, membrane localization and nanoclustering (Figure 13). 
 
 
1.2 Small	molecule	chemical	screen	with	H-ras-NANOPS	identifies	
H-ras	nanocluster	modulators	(I)	
In order to identify novel chemical modulators of H-ras nanoclustering, we 
performed a chemical screen of 659 small-molecules from two chemical libraries 
(Enzo Natural Product library (Enzo Life Science Inc.) and a chemically diverse in-
house natural compound collection). The compounds were used at an average 
concentration of 10 μM on BHK cells expressing the H-ras NANOPS (I: Figure 1A). 
A good dynamic range for the screens was observed with qualitative parameters such 
as a Z’ value of 0.6 and coefficient of variation (% CV) of 5%. By setting the hit 
selection criteria or hit limit at >15% change in FRET from the average we identified 
38 primary hits (I: Figure 1B). These hits were filtered out of auto-fluorescent 
molecules and then cross-validated in a human cell line (HEK293). Results obtained 
from both HEK and BHK cells showed a good correlation (I: Supplementary Figure 
1a). We confirmed twelve hits after cross-validation (I: Figure1C), with six 
compounds that decreased (negative deviators) the FRET Emax. Surprisingly, we also 
Figure	 13.	 Schematic	 representation	 of	 the	 nanoclustering-based	 FRET	 biosensors.	 	 Centre,	 Tight	
packing	 of	 membrane	 anchors	 with	 fluorescently	 tagged	 donor	 (mCFP)-	 and	 acceptor	 (mCit)-
fluorophores	 (blue	 and	 yellow	 cylinders,	 respectively)	 in	 nanocluster	 leads	 to	 FRET.	 Left,	 FRET	 can	
decrease	 due	 to	 loss	 of	membrane	 anchorage	 due	 to	 changes	 in	 lipid	 modification	 and	 subcellular	
distribution.	Right,	FRET	can	decrease	due	to	inhibition	of	nanoclustering	of	lipid-modified	proteins.	
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identified six hits that increased (positive deviators) the FRET Emax. The negative 
deviators mevastatin, dihydrotanshinone (DHTS), dihydroxyacetophenone, 
tubericidin, b-lapachone and A23187 reduced the Emax of H-ras-NANOPS. The loss 
of FRET with the Ras-NANOPS could for most part be attributed to either loss of 
membrane anchorage due to inhibition of the protein prenylation machinery, or to 
inhibition of nanoclustering of H-ras-NANOPS on their cognate membranes 
(Köhnke et al., 2012). Not surprisingly, two of these negative deviators – mevastatin 
and DHTS - have already been identified to inhibit farnesyl transferases. These two 
inhibitors block farnesylation and thereby inhibit the membrane anchorage of H-
ras-NANOPS, leading to the loss of FRET (Figure 13).  
 
Mevastatin - found in the early 1970s from microbial metabolites- was ‘a blockbuster 
drug’ approved for clinical use for treating hypercholesterolemia (Clendening and 
Penn, 2012). Mevastatin is a well-established hydroxymethylglutaryl coenzyme A 
reductase (HMGCR) inhibitor (Brown et al., 1978; Endo et al., 1976). HMGCR is the 
rate-limiting enzyme of the mevalonate pathway that is crucial for generation of 
cholesterol and other lipid precursors. It has also been observed that statin-use 
reduced the risk of cancers in many patients (Nielsen et al., 2012). Now, it is well 
established that some anticancer properties of statins are related to the inhibition of 
the mevalonate pathway. With respect to Ras signaling, the key isoprenoid 
intermediates necessary for Ras lipid modification – farnesyl pyrophosphate and 
geranylgeranyl pyrophosphate - are products of the mevalonate pathway. As Ras and 
other small GTPases require isoprenylation for proper membrane anchorage, loss of 
HMGCR activity impairs Ras function. Although a number of clinical trials have 
been conducted to test the efficacy of statins in anticancer therapy, it is now clear 
that the statin anticancer efficacy is dependent on many factors including the cancer 
tissue type and type of statin used. For example, lipophilic statins such as fluvastatin, 
are potent against breast cancers, whereas the hydrophilic pravastatin is active 
against hepatic cancers (Clendening and Penn, 2012). However, statins in 
combination with approved anticancer agents have shown variable results in Ras-
mutated cells. A recent study showed that Atorvastatin-treatment can overcome 
gefitinib (EGFR inhibitor) resistance of K-ras mutated non-small cell lung 
carcinoma cells both in vivo and in vitro (Chen et al., 2013). A drug combinations 
study from National Cancer Institute suggested that statins in drug combinations 
with B-Raf therapeutics were sensitive towards K-ras mutant melanomas (Held et al., 
2013). Statin therapy has also been suggested to have therapeutic benefit for thyroid 
cancers (Bifulco, 2008). On the other hand, statin therapy for patients with colorectal 
cancers treated with Cetuximab (EGFR inhibitor) showed no improvement in 
patient survival (Krens et al., 2014). It is noteworthy that lovastatin was found to 
specifically inhibit leukemia stem cells (LSCs) while sparing normal hematopoietic 
stem and progenitor cells (HSPCs) via inhibition of HMGCR (Hartwell et al., 2013). 
The authors concluded that the anti-LSC effect of lovastatin could be independent of 
Ras function. 
Results and Discussion – Cellular FRET-biosensors as a Screening Platform 
 62 
 
Dihydrotanshinone (DHTS) – a tanshinone isolated from Salvia miltiorrhiza –is 
another known FTase inhibitor (Lee et al., 1998). DHTS has been reported to have 
FTase inhibitory activity with an in vitro assay using purified FTase from Rat brain 
(Lee et al., 1998). Nevertheless, this activity of DHTS had not yet been reported in 
cells. Our identification of DHTS as a negative regulator of H-ras-NANOPS 
corroborates the original finding from Lee et al., and suggests that DHTS could have 
potent FTI activity also in cells.  Even though the mechanism of action of DHTS on 
FTase is unknown, it is interesting to speculate that DHTS may have a similar 
mechanism of action as nonpeptidomimetic FTIs, such as tipifarnib and lonafarnib. 
Since DHTS-like plant-derived FTIs have been found to inhibit the binding of 
farnesyl diphosphate to the FTase (Khan et al., 2010; Shaikenov et al., 2001). In 
addition, a number of other molecular targets have been reported for the action of 
DHTS, such as activation of the apoptosis cascade, inhibition of hypoxia-inducible 
factor-1 (HIF-1) and inhibition of topoisomerase I (Chen et al., 2014). DHTS has 
been shown to have anti-cancer properties with dose and time-dependent inhibition 
of cancer cell growth, invasion and migration (Dong et al., 2011). These data suggest 
that the anti-cancer potential of DHTS could be a combination of these activities, 
which warrants further characterization. However, the identification of these known 
Ras FTase inhibitors validates the sensitivity of the assay and the possibility to 
identify novel Ras lipid modification and membrane trafficking inhibitors. 
Furthermore, it highlights the potential of the Ras-NANOPS screening assay to 
identify not only pharmacologically relevant inhibitors, but also compounds that can 
help us better understand Ras functioning.  
 
A surprising finding from this screen was the identification of 6 compounds that 
increased the FRET Emax of H-ras-NANOPS (I: Figure 1C). Intriguingly, 5 out of 
these 6 compounds were structurally divergent protein synthesis inhibitors (PSI). 
The effect of protein synthesis inhibition on Ras is not known.  The functional 
characterization and validations of these positive deviators is discussed in chapter 2 
of Results and Discussion. 
 
1.3 Differential	screen	with	H-	and	K-ras-NANOPS	identifies	novel	
CSC	inhibitors	(II)	
Cancer stem cells (CSC) possess the capacity to self-renew and to cause the 
heterogeneous lineages of cancer cells that comprise the tumor. These CSCs are 
believed to contribute to anti-cancer therapy resistance and relapse after therapy 
(Kreso and Dick, 2014). However, given the importance of Ras signaling in cancers, 
the role of Ras in CSC is not well understood. Our laboratory had previously utilized 
the Ras-NANOPS assay described above to identify macrotetrolides as potential Ras 
nanocluster inhibitors (Köhnke et al., 2012). Macrotetrolides are ionophoric 
antibiotics that can insert into cellular membranes and alter the membrane 
organization. Here, we postulated that such inhibitors or compounds that affect 
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membrane organization could have potential nanocluster inhibitor properties. We 
therefore made a small collection of 13 known ionophoric compounds (II: 
Supplementary Table 1). We performed a differential screen with these compounds 
using two Ras-derived biosensors H-ras-NANOPS (Köhnke et al., 2012) and K-ras-
NANOPS (K-ras4B derived) (Abankwa et al., 2008) expressed in mammalian cells 
(II: Figure 1B). From this chemical screen, we identified three hit compounds that 
specifically altered the nanoclustering associated FRET Emax of K-ras but not H-ras-
NANOPS (II: Figure 1C). These hit compounds; salinomycin, nigericin and lasalocid 
were used for further validation. Salinomycin and nigericin are potent K+ 
ionophores that are commonly used in poultry for their antibiotic and anticoccidal 
(against intestinal parasites) activities. Nonetheless we found that other compounds 
in the library with similar ionophoric activity do not affect K-ras-NANOPS in the 
same manner, suggesting a mechanism of action that does not involve the 
ionophoric activity. Interestingly, salinomycin and nigericin have already been 
reported by Weinberg and colleagues to target breast CSCs (Gupta et al., 2009). This 
has lead to repurposing these inhibitors as potential anti-cancer agents; however, 
their mechanism of action is not well understood. Our efforts to understand the K-
ras specific activity of these inhibitors are described and further discussed in detail in 
chapter 3 of Results and Discussion. 
In addition to the above screen, we performed a small molecule screen of ~400 
diverse microbial metabolites and related semi-synthetics from the MST library, to 
identify novel K-ras specific nanocluster inhibitors. We screened these metabolites 
using both H-ras-NANOPS and K-ras-NANOPS expressed in BHK cells (II: 
Supplementary Figure 5a). With a hit selection of >10% change in FRET from the 
average, we identified 39 primary hits (II: Supplementary Table 5). In accordance 
with the previously published Ras targeting compounds (Köhnke et al., 2012), we 
identified nactins/macrotetrolides as H-ras-NANOPS specific hits. We also found 
the recently described K-ras localization inhibitors antimycin and neoantimycin 
(Salim et al., 2014). In addition, we also confirmed that the tool compound 
staurosporine (STS), and a number of STS analogues, oxostaurospoine, stauprimide 
and UCN-01 that affect phosphatidylserine (PS) and PS/Ras clustering (Cho et al., 
2012b). The identification of these already reported inhibitors, together with 
established HMG-CoA inhibitors, such as lovastatin and simvastatin further 
corroborates and highlights the potential of our Ras-NANOPS screening platform. 
Among the primary hits, we also found avermectin and its derivative ivermectin to 
specifically affect K-ras-NANOPS. Interestingly, Weinberg and colleagues had 
previously identified avermectin as Abamectin (a mixture of avermectin B1a and 
B1b) to target breast CSCs (Gupta et al., 2009). From these screening efforts we 
identified conglobatin A and ophiobolin A as two potential CSC inhibitor 
candidates. The functional validation, characterization and anti-CSC property of 
these compounds are discussed in detail in chapter 3 of Results and Discussion. 
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1.4 Myr-NANOMS	report	on	membrane	targeting	of	N-
myristoylated	proteins	(III)	
The essential role of Ras nanoclustering in cell signaling and cancers is now well 
demonstrated (Solman et al., 2015; Tian et al., 2007; Zhou and Hancock, 2015). It is 
postulated that nanoclustering might be a more common, or even the dominant 
feature of plasma membrane protein organization (Garcia-Parajo et al., 2014). 
Similar to Ras proteins, Rho and heterotrimeric G proteins have been shown to 
laterally segregate into distinct membrane nanodomains (Abankwa and Vogel, 2007; 
Crouthamel et al., 2010). Lipid modifications of these proteins are critical for their 
anchoring to the membrane and nanoclustering. In addition to farnesylation and 
palmitoylation, many membrane proteins are myristoylated by N-myristoyl 
transferases (NMT) (Selvakumar et al., 2007). N-myristoylation is the irreversible 
co-translational addition of a myristoyl group to the N–terminal glycine by NMT, 
which is preceded by proteolysis of the N-terminal methionine by methionine 
aminopeptidases (Met-AP1 and 2) (Wright et al., 2010). Some of the well-
characterized myristoylated proteins include the oncogenic Src family kinases, Gα 
proteins and apoptosis regulator BID (Selvakumar et al., 2007; Wright et al., 2010).  
 
Despite the importance of myristoylated proteins in cancer, there is a lack of suitable 
assays to identify specific myristoylation inhibitors. Using the principle of the Ras-
NANOPS FRET assay, we developed FRET-biosensors to detect nanoclustering and 
membrane anchorage of myristoylated proteins. To design biosensors that report on 
the functional membrane anchorage of myristoylated proteins, we utilized the N-
terminal membrane targeting sequences of three myristoylated proteins: 
heterotrimeric G protein subunit Gαi2, Yes- and Src-kinases. Similar to the Ras-
biosensors, these sequences were fluorescently tagged and were named Gαi2, Yes- or 
Src- NANOMS (NANOclustering and Myristoylation Sensors) (III: Figure 1). When 
expressed in cells, these NANOMS become lipid modified and display high FRET.  A 
comparison of the FRET values of the three NANOMS in BHK cells revealed that 
Yes-NANOMS have a high FRET Emax of >0.4, followed by Src- (~0.3) and by Gi2-
NANOMS (~0.2), indicating comparatively strong nanoclustering of Yes-NANOMS 
(III: Figure 2a). Treatment of Yes-NANOMS expressing cells with the N-myristoyl 
transferase (NMT) inhibitor DDD85646 (Frearson et al., 2010) resulted in the 
cytoplasmic redistribution of the biosensor and in a significant loss of FRET Emax 
(III: Figure 2a). This value was similar to the Emax values of a mutant non-
myristoylatable Yes-biosensor, where myristoylated glycine is replaced by alanine 
(III: Figure 2a). Consistent with the Yes-NANOMS, the other biosensors Src- and 
Gi2 also showed a significant decrease in FRET Emax values after treatment with 
DDD85646 (III: Figure 2a). To confirm the specificity of the biosensor response to 
NMT inhibitors, we tested FTI and statins that did not induce a response (III: 
Supplementary Figure 3a).  Furthermore, weaker NMT inhibitors such as 
myristoleic acid (MA) and Tris (dibenzylideneacetone) dipalladium (TDP) or 
palmitoylation inhibitors had little or no effect on the biosensors in BHK or HEK 
cells (III: Supplementary Figure 2b, c, 3b-d). We further validated that the Yes- and 
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Gi2-NANOMS report on NMT by siRNA mediated knockdown of the human 
NMT1 and NMT2, which lead to a significant loss of Emax for both biosensors (III: 
Figure 3). These data confirm that NANOMS respond potently to chemical and 
genetic loss of NMT or inhibition of myristoylation, and it is a suitable system to 
monitor myristoylation in cells.  
 
Next we explored whether the Yes-NANOMS is a suitable system for chemical 
screening to identify novel membrane targeting inhibitors of myristoylated proteins. 
To this end, we collected compounds that are chemically similar to the previously 
reported Met-AP inhibitors fumagillin and bengamide and derivatives (III: Figure 
4a) and tested their efficacy with Yes-NANOMS expressed in BHK cells. These 
inhibitors have been successfully used to block membrane anchorage and activity of 
myristoylated proteins. The chemical screen with Yes-NANOMS had a good 
dynamic range with a Z’-score of 0.60 and DDD85646 as a positive control. From 
this screen we identified fumagillin, homoserine lactones and reveromycin B to 
reduce the FRET Emax values. Consistent with its effect against Met-AP2, only 
fumagillin significantly decreased the Emax (III: Figure 4b).  
 
1.5 Conclusions	and	future	perspectives:	FRET-biosensors	are	
valuable	tools	for	screening	molecules	that	alter	membrane	
targeting	and	nanoclustering	(I-III)	
In conclusion, the data on the FRET-biosensors designed and employed above 
indicate that they are a suitable platform for screening chemical libraries (I: Figure 1; 
II: Figure 1). The FRET-biosensor assay integrates the essential features of most 
high-content imaging based screening approaches that is subcellular localization 
(Cho et al., 2012b) and it is customizable to be done at high-speeds needed for large 
screens. Compared to imaging methods, this method allows monitoring of the full 
expression range of the biosensors on cells and combines the subcellular distribution 
of membrane anchors into a single, quantitative FRET-parameter Emax. Our 
screening results with Ras-NANOPS (I-II) clearly demonstrate the capacity of the 
NANOPS-assay to identify novel Ras nanoclustering and signaling inhibitors. 
Furthermore, the identification of already known FTase inhibitors, HMG-CoA 
inhibitors (mevastatin and simvastatin), together with Ras localization inhibitors 
such as STS and analogues, further corroborates the accuracy and reproducibility, 
and highlights the potential of the relatively simple Ras-NANOPS screening 
platform. Our results with the Myr-NANOMS (III) show that the FRET-biosensor 
assay principle could be applied for other lipid-modified membrane proteins. For 
instance, we have previously developed Rab-NANOPS to provide first evidence that 
Rab GTPases also form nanoclusters (Köhnke et al., 2012; Najumudeen et al., 2015). 
These Rab-NANOPS have also been utilized to identify novel RabGGTase inhibitors 
that inhibit Rab membrane localization (Coxon et al., 2014). The assay can be 
adapted for other cell lines with high expression levels for the biosensors to measure 
Emax (II: Figure 1). As future perspectives, the Ras-NANOPS screening platform has 
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the potential for application in genetic screening or RNAi-library applications. Our 
screening results here show the advantage of using both H- and K-ras-NANOPS for 
performing differential RNAi screens in detecting isoform-specific upstream 
modulators of H- and K-ras. Both these biosensors respond to known and novel 
nanocluster modulators in a similar manner as the full-length Ras proteins. In the 
context of genetic screens, our preliminary results with H-ras-NANOPS show that 
RNAi mediated knockdown of Galectin-1 can specifically disrupt H-ras-NANOPS 
(unpublished results), which is consistent with the role of Gal-1 as a H-ras 
nanocluster scaffold. Such observations, and the critical role of nanocluster 
modulators in MAPK signaling, suggest that the NANOPS-assay has a strong 
potential for future application in RNAi-screening. 
2 Protein	synthesis	inhibitors	increase	H-ras	nanoclustering	
and	tumor	growth	(I)	
R e s u l t s 	 a n d 	 D i s c u s s i o n 	 – 	 P r o t e i n 	 S y n t h e s i s 	 I n h i b i t o r s 	 I n c r e a s e 	 H - r a s 	 N a n o c l u s t e r i n g 	
2.1 Protein	synthesis	inhibitors	enhance	H-ras	but	not	K-ras	
nanoclusters	
From the chemical screen with H-ras-NANOPS, along with the negative deviators 
discussed above, we identified six compounds – cycloheximide, anisomycin, 
harringtonine, emetine dihydrochloride, diacetoxyscirpenol and actinomycin D - 
that positively up regulated H-ras nanoclustering (I: Figure 1 C). Intriguingly, five 
out of these six compounds were structurally divergent protein synthesis inhibitors 
(PSI). A table of known activities and targets of these PSIs is shown in (I: 
Supplementary Table 3). Many of these PSIs are routinely used as tool compounds in 
cell biological research to block protein translation initiation, elongation and RNA 
synthesis (I: Supplementary Table 4). Moreover, these inhibitors affect cell signaling 
and have been reported to induce neuronal differentiation (Greenberg et al., 1986; 
Grollman, 1967; Louis et al., 1994). Nevertheless, a Ras isoform specific effect of 
protein synthesis inhibition is not known; therefore, we decided to further 
understand the specific effect of PSIs on Ras nanoclustering using cycloheximide 
(CHX) as a representative PSI. 
 
We examined the effect of CHX on the nanoscale organization of Ras using electron 
microscopy (EM). This method allows for high-resolution quantification of Ras on 
the membrane and enables the direct visualization of the distribution of mGFP-
tagged Ras on intact apical plasma membrane sheets using EM combined with 
spatial mapping (Prior et al., 2003). BHK cells transiently expressing mGFP-tagged 
constitutively active H-rasG12V, wild-type H-ras and K-rasG12V were treated with 
CHX for 24 h and their membrane sheets were labeled using anti-GFP 5 nm gold 
nanoparticles and imaged using EM. This EM spatial analysis showed that CHX 
significantly increases the nanoclustering of both constitutively active and wild-type 
full length H-ras (I: Figure 2A). However, CHX does not affect the nanoscale spatial 
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distribution of K-rasG12V (I: Figure 3A). These EM data indicate that the effect of 
CHX is H-ras isoform specific.  
 
We next validated the EM results using FLIM-FRET measurements between mGFP- 
and mCherry tagged H-rasG12V and K-rasG12V. The FRET emerging due to the 
dense packing of mGFP- and mCherry-tagged Ras into nanoclusters is used as 
readout for nanoclustering. Cells expressing these fluorescent FRET-pairs were 
treated with CHX and the changes in fluorescence lifetimes were expressed as 
apparent FRET efficiency (%). These FRET measurements show that CHX treatment 
at both high (10 μM) and low concentrations (0.18 μM) significantly increased H-ras 
nanoclustering (I: Figure 2B). Moreover, this effect was comparable to Gal-1 
overexpression, which was used as a positive control for H-ras nanoclustering  (I: 
Figure 2B). Similarly to CHX, two other PSI (anisomycin and harringtonine) also 
significantly increased H-ras nanoclustering (I: Supplementary Figure 3A). 
However, nanoclustering of K-rasG12V was not affected by CHX treatments (I: 
Figure 3B). We found that Gal-1 overexpression could have a negative effect on K-
ras nanoclustering (I: Figure 3B) indicating a Gal-1 independent effect of CHX on K-
ras.  
 
We next investigated CHX effects on H-ras nanoclustering using FRAP 
(Fluorescence recovery after photobleaching). FRAP is used to the measure lateral 
diffusion and mobility of fluorescently tagged Ras proteins (Guzmán et al., 2014a). It 
is known that at steady state, 40% of Ras proteins on the plasma membrane exist as 
immobile clusters (Zhou and Hancock, 2015). Gal-1 overexpression has previously 
been shown to specifically stabilize cholesterol-independent H-ras nanoclusters 
(Prior et al., 2003) and to increase the immobile fraction of H-rasG12V (Rotblat et 
al., 2010). An increase in the immobile fraction of Ras quantified using FRAP 
therefore corresponds to an increase in Ras being immobilized in nanoclusters. 
Consistent with EM and FLIM-FRET data, CHX significantly increased the 
immobile fraction of H-rasG12V (I: Figure 2C). This increase is at a similar and 
comparable level to that of Gal-1 overexpression (I: Figure 2C). Taken together, EM 
immunogold spatial mapping, FLIM-FRET and FRAP data firmly establish that 
CHX specifically increases H-ras nanoclusters and has no effect on K-ras 
nanoclusters.  
 
It is surprising to find small molecules that increase Ras nanoclustering from screens 
for nanocluster inhibitors. However, this is an important observation from a 
signaling standpoint, as recent studies have shown that Raf-inhibitors could lead to 
‘paradoxical activation’ of Raf.  This Raf activation leads to increased proliferation 
and in some cases induce tumorigenesis in vivo of Ras-mutated cells (Hatzivassiliou 
et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2010). In fact, these Raf inhibitors 
have been shown to increase K- and N-ras nanoclustering and signaling, but not H-
ras nanoclustering (Cho et al., 2012a). Therefore, characterization of inhibitors that 
specifically activate H-ras warrants further investigation. Notably, H-ras is mutated 
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in cancers of the skin, bladder and salivary glands (Table 1) and it also been 
implicated in differentiation of adipocytes and neuronal cells (Bar-Sagi and 
Feramisco, 1985; Qui and Green, 1992).  Moreover, active H-ras has been shown to 
specifically mediate F9 stem cell differentiation leading to cessation of proliferation 
(Quinlan et al., 2008; Yamaguchi-Iwai et al., 1990). However, the role of wild-type 
H-ras in stem cells is not known. Gal-1 also positively and specifically regulates H-
ras nanoclustering (Belanis et al., 2008; Paz et al., 2001; Rotblat et al., 2010). Our 
results here show that Gal-1 overexpression has a negative effect on K-rasG12V 
nanoclustering. This could be attributed to the phosphatidylserine (PS) mediated 
negative impact that H-ras on K-ras nanoclustering, as H-ras can sequester plasma 
membrane PS and consequently affect K-ras nanoclustering (Zhou et al., 2014). This 
negative effect would be therefore further increased by Gal-1 overexpression. 
 
It is well known that cholesterol plays an important role in the proper lateral 
segregation of H-ras nanoclusters (Prior et al., 2003). H-ras-GDP forms cholesterol 
dependent nanoclusters, whereas H-ras-GTP is cholesterol independent. Drugs that 
affect this segregation such as indomethacin and aspirin (non-steroidal anti 
inflammatory drugs) have been shown to increase H-ras-WT but decrease H-
rasG12V nanoclustering (Zhou et al., 2010; 2012). However, our results with EM 
clearly show that CHX treatment specifically increases nanoclustering of H-ras-WT, 
H-rasG12V and tH (a surrogate marker for H-ras-GDP nanoclusters), but not K-
rasG12V. This suggests that the CHX effects on H-ras nanoclustering are very likely 
cholesterol independent and H-ras specific. However, changes in other lipids that 
affect nanoclustering cannot be ruled out. On the other hand, it could be reasoned 
that the increase in nanoclustering of H-ras found with CHX could be due to loss of 
H-ras depalmitoylation. It has been shown earlier that CHX inhibits FKBP12 
stimulated H-ras depalmitoylation (Ahearn et al., 2011). This loss of FKBP12 activity 
corresponds to an increase in H-ras membrane residence and signaling. Considering 
the role of palmitoylation on H-ras nanoclustering (Roy et al., 2005), it is plausible 
that the increase in H-ras nanoclustering seen with CHX could be due to increased 
palmitoylated H-ras on the PM. However, all other PSIs found in our screen are 
structurally diverse and have different mechanism of action for protein synthesis 
inhibition (I: Supplementary Table 4). Moreover, we show that blocking protein 
translation (I: Supplementary Figure 2) is the common denominator of these 
compounds that increase H-ras nanoclustering (I: Supplementary Figure 3a). These 
results suggest that protein translation inhibition through a yet unknown 
mechanism feedbacks specifically towards H-ras nanoclustering.  
 
2.2 Increased	H-ras	nanoclustering	drives	differentiation	and	tumor	
growth	(II)	
Ras activation and nanoclustering is transmitted as downstream signaling through 
the activation of downstream effectors. Active GTP-bound Ras nanoclusters on the 
plasma membrane act as signaling platforms to facilitate effector recruitment and 
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activation. This Ras-effector interaction reports directly on the Ras nanocluster 
function and rate of effector recruitment from cytoplasm to the membrane bound 
Ras (Tian et al., 2007). To investigate whether the induction of H-ras nanoclustering 
by CHX correlates with the recruitment of downstream effectors, we used our well-
established effector-recruitment FLIM-FRET assay to analyze the interaction of 
mGFP-tagged Ras and mRFP-tagged RBD of c-Raf in BHK cells treated with CHX 
(Abankwa et al., 2010; Guzmán et al., 2014b). Using this assay we could show that 
CHX treatment significantly increases effector recruitment of H-rasG12V but not of 
K-rasG12V (I: Figure 4A and B). This is in line with our EM and nanoclustering-
FLIM data indicating that only H-ras nanocluster mediated signaling is affected by 
CHX. Since effector recruitment initiates the MAPK signaling cascade, we 
performed western blot analysis of the MAPK cascade and found that CHX and 
other PSIs such as anisomycin and harringtonine significantly increased ppErk and 
pAkt signaling in BHK cells (I: Figure 4B, Supplementary Figure 3). Nevertheless, it 
could be contended that the increase in MAPK signaling is unassociated to increased 
H-ras activity. To corroborate the H-ras specificity, we compared ppErk and pAkt 
levels on MEFs and their Rasless counterparts that lack H-ras-/- and N-ras-/- (Drosten 
et al., 2010). Indeed, CHX failed to activate ppErk and pAkt signaling in Rasless 
MEFs, whereas Rasless MEFs transiently expressing H-ras-WT show a significant 
increase in ppErk and pAkt signaling.  Collectively these signaling data indicate that 
H-ras has a distinct role in CHX- and PSI-mediated increase in MAPK signaling.  
 
However, increase in MAPK (ppErk) signaling is mostly, but not always, associated 
with increased cellular proliferation and tumorigenicity. Oncogenic Ras is known to 
induce morphological differentiation of pheochromocytoma (PC12) cells by 
inducing neurite formation (Bar-Sagi and Feramisco, 1985). Ras activity can induce 
PC12 cell differentiation independent of growth factor stimulation and this makes 
the PC12 differentiation assay one of the widely used model system for MAPK 
activity (Bar-Sagi and Feramisco, 1985). We used the PC12 differentiation assay to 
investigate whether CHX induced H-ras activation increases differentiation. 
Interestingly, previous studies have reported protein synthesis inhibitors to induce 
differentiation in primary culture of neurons from the central nervous system (Louis 
et al., 1994) but the mechanism of action has been unclear. Expression of H- and K-
rasG12V induces differentiation of PC12 cells, as seen by neurite formation, and the 
addition of CHX significantly increased the percentage of differentiated cells 
expressing H-rasG12V (I: Figure 4C) but not K-rasG12V (I: Figure 4C). This is 
concordant with our results that CHX augments H-ras nanoclustering and signaling, 
leading to differentiation.  
 
We then examined whether CHX induced H-ras nanoclustering and signaling would 
also increase tumorigenicity or tumor growth in a H-ras dependent manner. To 
determine the CHX induced tumorigenicity, we tested CHX on tumorsphere 
formation. The tumorsphere or mammosphere assay is a standard clonogenic assay 
for the detection of self-renewal and tumorigenic capacity of cancer stem cells (CSC) 
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that are enriched in the non-adherent spheres (Clarke et al., 2006; Dontu et al., 
2003). MDA-MB-231 breast cancer cells are naturally enriched for CSCs and form 
mammospheres in non-adherent conditions. Compared to treatment with 
chemotherapeutic like doxorubicin or CSC inhibitor salinomycin that decreased 
tumorsphere formation, CHX treatment significantly increased the number of 
spheres suggesting that CHX increases the tumorigenicity of these cells (I: Figure 
5B). Since CHX increases the number of tumorspheres, we questioned whether this 
is H-ras dependent. Surprisingly, siRNA mediated loss of H-ras together with CHX 
treatment significantly reduces the number of spheres (I: Figure 5C). These data 
suggest that H-ras is essential for CHX mediated action and that depletion of H-ras 
fully reverses the response compared to control treated cells. This corroborates the 
idea that H-ras exclusively effects CHX mediated Ras signaling activation. To further 
validate the increase in mammospheres, we utilized an in ovo tumor growth assay as 
a surrogate xenograft model. In this assay, MDA-MB-231 cells are grown on the 
chorion allantois membrane (CAM) of a chicken embryo and treated with CHX. 
Concurrent with the mammosphere data, CHX treatment significantly increased the 
tumor mass as compared to the control (I: Figure 5D).  
 
 
Protein synthesis, is the most energy-consuming process in the cell and it is 
frequently dysregulated in cancers. Results from this study show PSIs such as CHX 
could specifically increase H-ras nanoclustering, signaling and drive tumor growth 
(Figure 14). These results are reminiscent of the recently identified paradoxical Raf 
activation by Raf inhibitors (Cho et al., 2012a; Poulikakos et al., 2010). As with Raf 
inhibitors, protein synthesis inhibitors might have these effects only under certain 
cellular or genetic context, as seen with the mammospheres derived MDA-MB-231 
cells. These cells are K-ras mutated and enriched in CSC-like populations with 
increased drug resistance and self-renewal capacity (Kreso and Dick, 2014). Little is 
known about the role of the different Ras isoforms and their associated signaling in 
CSC. Others and we (II) have provided evidence for the divergent role of Ras 
isoforms in CSC. Interestingly, our results here show CHX treatment increases H-ras 
signaling, mammospheres and tumor growth. However, depletion of H-ras and 
Figure	14.	Schematic	abstract	showing	protein	synthesis	 inhibitors	 increase	H-ras	nanoclustering	
and	induce	tumor	growth	(Najumudeen	et	al.,	2015).	
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CHX treatment leads to synthetic lethality in the K-ras mutant MDA-MB-231 
mammospheres. Others have shown that loss of wild-type H-ras and N-ras can 
sensitize K-ras mutant cells to DNA damaging agents (Grabocka et al., 2014). Our 
data indicate the significance of PSI and similar inhibitors as tool compounds to 
investigate synthetic lethality.  
 
Protein metabolism is controlled and maintained by the rates of protein synthesis 
and degradation in cells. Previous reports have indicated the half-live of endogenous 
Ras proteins to be ∼9-12 hours under CHX (Kim et al., 2009). However, the 
observed changes in H-ras nanoclustering by PSIs are unlikely to be related to 
changes in Ras stability or de novo Ras synthesis, since our results with Rasless MEFs 
overexpressing wild-type H-ras show no significant changes in pan Ras levels after 
24 hour CHX treatment (I: Figure 5a). This suggests that CHX and PSI induced 
increase in H-ras nanoclustering is unrelated to changes in the steady-state Ras 
levels. Activation of the Ras/Erk or Ras/PI3K/Akt pathway activates mechanisitic 
target of rapamycin (mTOR). mTOR is activated by different cues such as amino 
acids, insulin and growth factors. mTOR controls various cellular processes and 
protein synthesis is one of the well-characterized effect of mTORC1.  mTORC1 
controls lipid and protein synthesis, which is required for cell growth, proliferation 
and survival (Laplante and Sabatini, 2009). For instance, mTORC1 to a large extent 
controls lipid biogenesis to generate membranes for proliferating cells, by activating 
SREBP1/2 (sterol regulatory element-binding protein 1) transcription factors that 
control genes involved in lipid and cholesterol synthesis. Deregulation of mTORC1 
leads to reduced SREBP levels that disrupts expression of genes required for 
lipogenesis (Laplante and Sabatini, 2012b). Membrane lipids such as 
phosphatidylserine and cholesterol play an essential role in proper lateral 
segregation of Ras nanoclusters and changing the compositon on the plasma 
membrane has been shown to affect Ras nanoclustering (Cho et al., 2012b; Prior et 
al., 2003; Zhou et al., 2014). It is plausible that changes in protein synthesis rates and 
mTOR activity could alter the plasma membrane lipid profile and thereby affect Ras 
nanoclustering.  
 
Activation of the Ras/Erk or Ras/PI3K/Akt pathway activates mTORC1 that 
phosphorylates eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1) 
and the p70 ribosomal S6 kinase 1 (S6K1). Phosphorylation of 4E-BP1 leads to 
activation of eIF4E, which leads to cap-dependent translation. Activation of S6K1 
leads to translation initiation and elongation (Laplante and Sabatini, 2012a). 
Phosphorylated eIF4E is associated with oncogenic signaling (Hsieh and Ruggero, 
2010). Previous studies and our unpublished results show that blocking protein 
synthesis results in hyperphosphorylation of S6K1 (Krieg et al., 1988). It is known 
that oncogenic stress-induced cellular senescence (OIS) stops overactive MAPK 
signaling. OIS is a permanent cell growth arrest caused by an activated oncogene in 
primary untransformed cells and it acts as an in vivo tumor suppression mechanism 
(Adams, 2009). However, it is likely that non-oncogene induced stresses like high 
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intracellular amino acid levels, deregulation of mTOR could elevate S6K1 or eIF4E 
levels and bypass OIS.  It has already been shown that ectopic expression of eIF4E in 
primary HMECs could bypass senescence (Avdulov et al., 2004), this together with a 
cooperating second-hit induces neoplastic-like properties in immortalized HMECs 
(Larsson et al., 2007). In fact, our unpublished data suggest that signaling stresses 
such as increased intracellular amino acid levels (as seen with PSI treatment) or 
inhibition of components downstream of the mTORC1 complex can specifically 
increase H-ras nanoclustering and signaling. How this specific feedback with H-ras 
is achieved is not yet understood. Interestingly, recent reports have indicated an 
association between the translation machinery and MAPK signaling in cancer drug 
resistance. Several mechanisms of resistance towards therapies targeting the MAPK 
or PI3K pathways are known to converge on mRNA translation (Lito et al., 2013; 
Silvera et al., 2010). One such mechanism involves the formation of the eIF4F 
complex (Boussemart et al., 2014). Boussemart et al. show that an increase in eIF4F 
complex-formation significantly associated with the resistance to anti-B-Raf, anti-
Mek, and combination therapy. However, inhibition or loss of eIF4F complex 
synergises with B-Raf inhibition to act on cancer cells. A comprehensive 
understanding of the coupling between the Ras pathway and the protein synthesis 
machinery could create novel drug targeting opportunities.  
 
3 Cancer	stem	cell	inhibitors	target	K-ras	signaling	in	a	
stemness	context	(II)	
R e s u l t s 	 a n d 	 D i s c u s s i o n 	 – 	 C a n c e r 	 S t e m 	 C e l l 	 I n h i b i t o r s 	 t a r g e t 	 K - r a s 	 s i g n a l i n g 	
3.1 CSC	inhibitors	affect	K-ras	nanoscale	organization	and	signaling	
(II)	
The differential screen with H- and K-ras-NANOPS identified three hit compounds 
that specifically altered the nanoclustering associated FRET Emax of K-ras-NANOPS 
(II: Figure 1C). The hit compounds: salinomycin, nigericin and lasalocid were 
selected for further analysis. To understand the K-ras specific mechanism of these 
inhibitors, we performed further validation with the constitutively active full length 
K- or H-rasG12V. We used the consitutively active full-length Ras isoforms for 
further validation as nanoclustering of active Ras is most relevant in the context of 
signaling output (Tian et al., 2007).  The isoform-specific nanoclustering of H- and 
K-ras was quantified using FRET from FLIM-FRET measurements between mGFP- 
and m-Cherry tagged K- or H-rasG12V. BHK cells transiently overexpressing the 
FRET-pairs treated with the compounds showed that all three hit compounds 
significantly reduced nanoclustering FRET of K-rasG12V, but nigericin also affected 
H-rasG12V nanoclustering (II: Figure 2A). This indicated that some of these 
compounds reduced the nanoclustering-FRET in a K-ras specific manner. This loss 
of FRET observed from the nanoclustering-FRET assays could be attributed to either 
loss of membrane anchorage or inhibition of K-ras nanoclustering on the membrane 
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(II: Figure 1A). To check whether this reduced nanoclustering-FRET is due to 
changes in subcellular Ras localization, we did confocal imaging with MDCK cells 
stably expressing and BHK cells transiently expressing H- or K-rasG12V treated 
with the hit compounds. This revealed that all compounds induced a loss of plasma 
membrane localization of both H- and K-ras (II: Figure 2D, Supplementary Figure 
1A). From these observations one can extrapolate that these hit compounds induce 
changes to Ras localization and nanoscale membrane organization.  
To understand the implications of the reduced nanoclustering and plasma 
membrane localization by the hit compounds we followed the downstream signaling 
events. Ras nanoclusters act as signaling platforms to facilitate effector recruitment 
and activation. Using our well-established Ras-effector recruitment FRET assay 
between fluorescently tagged Ras and RBD of C-Raf in cells, we quantified that all 
three hit compounds significantly reduced the RBD recruitment to K-rasG12V (II: 
Figure 3A) measured as loss of FRET; and they had no effect on the FRET between 
RBD and H-rasG12V (II: Figure 3B). This data is in line with our nanoclustering-
FLIM data indicating that all the hit compounds affect K-ras nanoclustering and 
RBD recruitment. Since effector activation initiates the MAPK cascade, we measured 
the downstream signaling output of BHK cells transiently overexpressing K- and H-
rasG12V and treated with the hit compounds. In accordance with the K-ras specific 
activity of the compounds, we observed a significant reduction in downstream 
MAPK signaling in K-rasG12V (II: Figure 3C) and not in H-rasG12V (II: Figure 3D) 
transfected cells. This decrease in K-ras mediated downstream MAPK signaling is 
reflected as significant reduction in proliferation of BHK cells by salinomycin and 
nigericin (II: Figure 3E). Using Ras-transformed 3T3 cells we could show that K-ras 
transformed cells were more sensitive to salinomycin treatment than H-ras 
transformed cells (unpublished data). These results are consistent with previously 
reported activity of salinomycin and nigericin in arresting cell growth and 
proliferation. However, our results indicate a previously unknown specificity of 
these inhibitors towards K-ras activity. 
Taken together our data show that the CSC inhibitor salinomycin most specifically 
disrupts K-ras nanoclustering and effectively reduces MAPK signaling and 
proliferation. This is in agreement with the fact that K-ras is involved in stem-cell 
self-renewal (Quinlan et al., 2008). With respect to CSCs, salinomycin has been 
shown to be active against many different CSC types (Naujokat and Laufer, 2013), 
however the exact molecular target has not been determined. There is accumulating 
evidence showing the importance of K-ras in stem cells; early studies on colonic 
epithelial cells of mice with activated K-rasG12D expressed are locked in a poorly 
differentiated state and express stem-cell markers. This results in widespread 
hyperplasia (no benign adenomas), and it cooperates with loss of Apc to induce 
adenocarcinomas (Haigis et al., 2008). However, expression of N-rasG12D in these 
mice does not induce hyperplasia or cooperates with loss of Apc (Haigis et al., 2008). 
More recent reports show that K-rasG12D expression in Lgr5+ stem cells leads to 
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clonal expansion and competition with the normal crypt cells (Snippert et al., 2013); 
yet, these mice do not develop neoplasias. Thus suggesting different roles for K- and 
N-ras in colon cancers. Recent work from Kevin Haigis and colleagues shows that 
similar to N-rasG12D in hematopoietic stem cells (Li et al., 2013), K-rasG12D has a 
bimodal activity on quiescent intestinal stem cells (Gierut et al., 2015). Bimodal 
activity refers to the ability of mutant Ras to increase the proliferation kinetics of one 
subset of stem cells, and increase the self-renewal potential of another subset (Gierut 
et al., 2015). In this context, it would be interesting to know if this ‘bimodal’ 
response of Ras activation is specific to the Ras family of genes or also found in other 
oncogenic mutations.  
 
3.2 Salinomycin	targets	K-ras	and	PS	nanoscale	organization	(II)	
It is well known that lipid composition of the plasma membrane is critical for Ras 
membrane anchorage and clustering (Zhou et al., 2014). Specifically, the negatively 
charged phosphatidylserine (PS), which is a common constituent of all Ras 
nanoclusters was shown to be an essential structural component of K-ras 
nanoclusters (Zhou et al., 2014). Recently, staurosporine (STS) was shown to 
strongly redistribute PS from the plasma membranes affecting K-ras nanoclustering 
and localization (Cho et al., 2012b). Furthermore, it was reported that Fendiline - a 
FDA approved calcium channel blocker - reduces K-ras4B nanoclustering by 
mislocalizing K-ras from the plasma membrane. Though, the exact molecular 
mechanism is not currently known, it is shown to be independent of its calcium 
channel blocking activity (van der Hoeven et al., 2013). The activity of these 
inhibitors is reminiscent to that of our hit compounds. These studies also indicate 
that changing the lipid composition of the plasma membrane affects Ras 
nanoclustering and localization and this leads to changes in MAPK signaling and 
can have biological implications (Zhou and Hancock, 2015). PS interacts with the 
polybasic region of K-ras and it is required for the structural stability of K-ras 
nanoclusters (Plowman et al., 2008; Zhou et al., 2014). Using the fluorescently tagged 
C2 domain of lactadherin (LactC2) as probe for subcellular PS, we examined the PS 
nanoscale organization and coclustering with Ras using FLIM-FRET. All the hit 
compounds and STS significantly reduced PS nanoclustering-FRET (II: 
Supplementary Figure 1B). However, our unpublished data show that salinomycin 
and nigericin do not induce a clearly predominant intracellular pool of PS, as seen 
after STS treatment (Cho et al., 2012b), suggesting that the Ras mislocalization by 
these inhibitors is not a direct consequence of loss of PS from the plasma membrane. 
Interestingly, only salinomycin specifically reduced PS-K-rasG12V coclustering 
FRET, while the other compounds affected PS coclustering to both H- and K-
rasG12V. These data collectively suggest that the hit compounds perturb Ras-
nanoscale organization by decreasing PS-clustering and salinomycin specifically 
affects K-ras/PS coclustering. This specific effect on K-ras is significant; as it has 
been shown that H-rasG12V can negatively affect assembly and segregation of K-ras 
nanoclusters remotely via PS (Zhou et al., 2014).  
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Moreover, PS is known to be enriched particularly in sites abundant in caveolae 
(Fairn et al., 2011). In the context of Ras nanoclustering and plasma membrane lipid 
composition, Ariotti et al., recently proposed that caveolae can remotely control Ras 
nanoclustering and signaling (Ariotti et al., 2014). They show that loss of caveolae 
results in an increase in PS-clustering and as a consequence leads to increase in K-
ras nanoclustering and signaling, while H-ras remains unaffected (Figure 15) 
(Ariotti et al., 2014).  
 
It is also shown that PS binds to all four cavin members in vitro (Bastiani and 
Parton, 2010; Fairn et al., 2011; Hill et al., 2008). While trying to understand the cell 
type dependent activities of salinomycin and other hits using Ras-NANOPS, we 
identified that the hit compounds lost activity in HEK cells. We therefore focused on 
the possible role of caveolae in this context, as the quantitative comparison of 
caveolae with STED super resolution microscopy suggested that HEK cells have a 
significantly lower caveolae density than BHK cells (II: Figure 4A, B). Transient 
overexpression of the caveolae structural proteins Cav1 and PTRF together in HEK 
cells significantly increased the caveolae density, close to the same level as BHK cells 
(II: Figure 4A, B). Consistent with Ariotti et al., HEK cells reexpressing the caveolar 
proteins showed significantly reduced K-rasG12V nanoclustering-FRET and RBD 
recruitment (II: Figure 4C, E). This would be attributed to the enrichment of PS in 
the caveolae that negatively affects K-ras nanoclustering (Figure 15). Furthermore, 
salinomycin significantly reduced the K-rasG12V nanoclustering and RBD 
recruitment in HEK cells reexpressing the caveolar proteins; whereas H-rasG12V 
Figure	 15.	 Schematic	 representation	 of	 the	 model	 of	 K-ras	 activity	 modulation	 by	 presence	 or	
absence	 of	 caveolae,	 based	 on	work	 from	Ariotti	 et	 al.,	 2014.	 Left,	Absence	or	 loss	 of	 caveolae	
increases	 the	 plasma	 membrane	 PS	 (in	 yellow)	 clustering.	 Consequently,	 this	 increase	 in	 PS	
clustering	 increases	 K-ras	 clustering	 and	 signaling.	 Right,	 Increase	 in	 caveolae	 levels	 leads	 to	 PS	
enrichment	in	caveolae	that	lowers	PS	and	K-ras	clustering.	
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nanoclustering and RBD recruitment were unaffected by caveolar reexpression or 
inhibitor treatments (II: Figure 4D, F). Consistent with the above results, Cav1 and 
PTRF expression also desensitized HEK but not BHK cells to salinomycin (Figure 
4G, H). Taken together our results show that caveolae reexpression in HEK cells can 
restore salinomycin activity towards K-ras and it can differentiate between caveolae 
expression levels.  
The proper lateral segregation of the Ras isoforms is maintained within a very 
narrow PS concentration range (Zhou et al., 2014). Therefore, increasing caveolae 
density sequesters the mobile PS from the plasma membrane, resulting in lower PS 
levels in the membrane and therefore an overall reduction in K-ras nanoclustering. 
This is reflected as reduced salinomycin sensitivity, as there is less PS and K-ras for 
salinomycin activity. This is similar to the effect of activated H-ras that negatively 
regulates PS and thereby K-ras nanoclustering (II: Figure 3E). Thus, one could 
speculate that the PS-mediated K-ras inhibitory activity of H-ras could also affect 
cell sensitivity and cell fate. The most important implication from the above results 
is that caveolae can modulate the sensitivity of cells in certain contexts to the CSC 
drug salinomycin. Interestingly, low caveolae and Cav-1 levels have been implicated 
in stem cells and differentiation (Baker and Tuan, 2013). Studies with Cav-1 null 
mice show that loss of Cav-1 leads to an increased adult mammary stem cell 
population and high expression of stem cell markers Sca-1, keratin-5 and keratin-6 
(Sotgia et al., 2005). The same group also provided evidence showing that Cav-1 loss 
leads to hyper-proliferation and expansion of intestinal crypt stem cells, with a 
simultaneous upregulation of β-catenin (Li et al., 2005). In addition, Cav-1 deletion 
has recently been shown to impair hematopoietic stem cell self-renewal and 
differentiation (Bai et al., 2014). Interestinly, a recent study from Lawson et al., 
utilizing a single-cell gene expression analysis identified Cav-2 expression to be 
specifically repressed in low-burden metastatic cells (Lawson et al., 2015).  
Consistent with these studies, loss of Cav-1 has been associated with poorer 
prognosis (Witkiewicz et al., 2009). A similar role has been associated with PTRF in 
prostate cancer (Nassar et al., 2013b). These studies support a more critical role of 
caveolae (via PS) in cancer and stem cells. In accordance with these studies, our 
results show that caveolae play a significant role in the sensitivity of cancer cells to 
the CSC drug salinomycin. 
 
3.3 K-ras	nanoclustering	associated	gene	signature	predicts	
salinomycin	sensitivity	and	patient	survival	(II)	
In addition to the K-ras specificity of salinomycin and the differences in caveolae 
levels between BHK and HEK cells, we found that the lack of caveolae – that leads to 
free-PS and high dependence on K-ras signaling – makes the HEK cells almost 8-
fold more sensitive to salinomycin (IC50 – 0.63 μM) than BHK cells (IC50 – 4.9 μM). 
Therefore, it seems very likely that there is a relationship between salinomycin 
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potency and components of K-ras nanoclustering. Along with caveolae, there are a 
number of other known proteins that impact K-ras nanoscale organization and 
signaling (Review of literature 3.3, II: Supplementary Table 2). We therefore 
analyzed the available gene expression patterns of H-, K- and N-ras isoforms, six 
known nanoclustering modulators and EGFR (II: Supplementary Table 2) in 
embryonal stem cells (ESCs) from the stem cell database ESTOOLS (Kong et al., 
2013). Interestingly, this analysis revealed that the expression of these genes in ESCs 
is basically inversed to the expression in fibroblasts. Moreover, we could find three 
distinct sets of ESC expression signatures that are characteristic of naïve and primed 
ESC, and those in transit between these two states (II: Supplementary Figure 3a).  
We expanded the initial ten gene set by searching ESTOOLS for co-regulated genes 
(II: Methods for details). From this analysis, we identified vimentin (VIM), caveolin-
2 (CAV-2) and integrin α5 (ITGA5) to be among the co-regulated genes. Vimentin 
is an intermediate filament protein that is a well-known EMT marker (Thompson et 
al, 1992). During EMT epithelial cells undergo complex reprogramming to lose 
epithelial markers and gain expression of mesenchymal markers like N-cadherin and 
vimentin among others. Vimentin expression is specifically associated with 
mesenchymal stem cells and in the invasive metastatic properties of cancer cells (Ye 
et al., 2015). Cav-2 is a caveolin isoform that is expressed together with Cav-1 in a 
wide range of tissues (Bastiani and Parton, 2010). Importantly, Cav-2 positively 
regulates Cav-1 mediated caveolae formation, suggesting that Cav-2 plays a 
regulatory role in caveolae dynamics (Kirkham et al., 2008; Mora et al., 1999; Sowa et 
al., 2003). Integrin α5 is implicated in cancer and its expression is correlated with 
cancer progression in many tissue types (Seguin et al., 2015). Integrin α5 forms 
heterodimers with β1 subunit to mediate adhesion to the extracellular matrix protein 
fibronectin. It is upregulated in various cancer types and it is crucial for 
angiogenesis. These studies suggested that vimentin, cav-2 and ITGA5 to be the 
most plausible genes to be associated with K-ras and stemness regulation. 
Interestingly, unsupervised clustering of these genes was consistent with high K-ras 
expression in ESC and low in differentiated cells (II: Figure 5a). This motivated us to 
check whether salinomycin targets K-ras in cancer cells with a gene expression 
similar to ESCs. If this were true, it is predicted that cells that respond to 
salinomycin would be resistant to standard chemotherapeutics (Gupta et al., 2009). 
To derive cancer cell lines that have an ESC-like or fibroblast-like signature, we 
correlated the expression of these 13 genes predominantly associated with K-ras 
nanoclustering (hereafter K-ras-nanoclustering signature) in cancer cell lines, ESCs 
and fibroblasts. From this we identified a panel of cancer cell lines that have a K-ras 
nanoclustering signature either more like ESCs or fibroblasts (II: Figure 5b).  
We then tested this panel of cancer cell lines for sensitivity to the CSC inhibitor 
salinomycin compared to the conventional chemotherapeutic Staurosporine (STS). 
Consistent with our prediction, cancer cell lines that have an ESC-like signature 
showed higher sensitivity to salinomycin (II: Figure 5c), whereas the fibroblast-like 
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cells were more sensitive to STS (II: Figure 5d). Correlating the drug response 
profiles with the gene expression further confirmed that responsiveness to 
salinomycin positively correlated with K-ras expression and negatively with caveolae 
genes (II: Figure 5e). Standard chemotherapeutic STS mostly showed opposite 
association. Taken together these data suggest that our K-ras-nanoclustering-
signature could be used to predict cancer cell lines responsiveness to CSC inhibitor 
salinomycin. 
Though the idea of CSC is still contentious, the evidences from others and our data 
here indicate that a K-ras centric mechanism in the context of CSCs is very plausible. 
Several reports have shown that EMT induction can generate breast cancer cells with 
CSC-like characteristics (Ansieau, 2013; Gupta et al., 2009; Mani et al., 2008). EMT 
induction has also been linked to drug-resistance (Singh and Settleman, 2010). 
Recently, mutant K-ras has been implicated to promote mesenchymal features in 
basal-breast cancers through EMT. Moreover, K-ras is shown to be preferentially 
activated in basal-breast cancer cells compared to luminal-breast cancer cells (Kim et 
al., 2015). Therefore, it is very likely that our K-ras centric mechanism would also be 
relevant in the context of CSC and CSC characteristics.  
Besides, other reports suggest that some K-ras mutated cells can be independent on 
K-ras signaling, while some K-ras wild-type cells are K-ras dependent and there is a 
differential K-ras dependency in K-ras mutated cancer cells. These reports also 
suggest that gene expression signature of the Ras pathway is a better predictor of Ras 
dependency and signaling compared to K-ras mutation status (Loboda et al., 2010; 
Singh et al., 2009). These studies further support the notion that a measure of all 
Ras-associated signaling is a better measure of Ras dependent signaling compared to 
just Ras mutation statuses. In this context, our K-ras nanoclustering gene signature 
integrates information transmitted upstream of K-ras nanoclustering and activation, 
and correlates with drug sensitivity, and it is able to predict response to inhibitors 
targeting K-ras in CSCs.  
Interestingly, almost 8% (605 / 7536) of all the patient tumor samples in the The 
Cancer Genome Atlas (TCGA) database have an ESC-like K-ras-nanoclustering 
signature that, according to our data, would be sensitive to CSC inhibitors. This 
signature was associated with poor overall survival of patients with this fraction of 
tumors (II: Figure 5f). Interestingly, this poor patient survival was more significant 
using ESC-like cancer cell line expression data. This confirms our assumption that 
tumors with the K-ras-nanoclustering-signature contain a high number of CSCs or 
CSC-like cells. This might be of particular importance to stratification of these 
patients that have low overall survival and would be high responders to salinomycin 
and other CSC inhibitors. Moreover, analysis of the actual tumor types that had the 
ESC-like signature revealed an enrichment of this signature in cancers of the female 
reproductive tissue such as breast invasive carcinoma, ovarian serous 
cystadenocarcinoma and uterine corpus endometrial carcinoma (II: Supplementary 
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Table 4). This was followed by a relatively high enrichment of ESC-like signature in 
acute myeloid leukemia. This is significant as our K-ras-nanoclustering signature is 
conserved across a number of tumor types, including tumors that generally have low 
Ras mutation frequencies, such as breast cancer. The identification of breast cancer 
enrichment is in line with the original observation by Weinberg and colleagues who 
identified salinomycin by using transformed mammary cells (Gupta et al., 2009). 
The enrichment of AML cancer types is consistent with the reported activity of 
salinomycin against AML SCs (Fuchs et al., 2009). Our data shows that salinomycin 
targets CSC with low caveolae, and this could be the reason behind the general 
toxicity observed with salinomycin. However, the understanding of such CSC 
susceptibilities would be of great importance for future cancer therapy. 
 
3.4 Ophiobolin	A	is	a	novel	candidate	CSC	inhibitor	(II)	
Salinomycin has gathered lot of research interest due to its strong activity against 
CSCs (Naujokat et al., 2010). However, the pleiotropic effects of salinomycin have 
hindered its application in the clinic. To demonstrate the suitability of our K-ras-
nanoclustering focused screening platform to identify novel CSC inhibitors. Among 
the primary hits, we identified previously reported CSC inhibitor avermectin and its 
derivative ivermectin (Gupta et al., 2009) and stauprimide a highly selective inducer 
of ESC differentiation (Zhu et al., 2009) to have activity towards K-ras FRET-
NANOPS.  The identification of these compounds further support the link between 
K-ras and stemness.  
From the primary hits, we identified five substance classes that were largely 
represented (leptomycins, avermectins, ophiobolins, conglobatin and streptonigrin) 
with some selectivity towards K-ras-NANOPS (II: Supplementary Table 5). One 
representative compound from each class was taken for further validation, giving a 
total of seven new compounds that were analyzed as potential CSC inhibitors (II: 
Supplementary Table 6). We next validated these inhibitors using FLIM-FRET 
measurements between mGFP- and mCherry tagged K- or H-rasG12V. These 
FLIM-FRET analyses show that all compounds significantly reduced K-rasG12V 
nanoclustering-FRET (II: Figure 6a), however only leptomycin and streptonigrin 
also affected H-ras nanoclustering-FRET (II: Figure 6b). We then analyzed whether 
these compounds affected the Ras effector-recruitment through our effector-
recruitment FRET-assay. Using this analysis we found that all the compounds 
significantly reduced K-rasG12V-RBD recruitment FRET, but not H-rasG12V-RBD 
(II: Supplementary Figure 5b). The reduction in K-ras nanoclustering quantified in 
these FRET assays could be also due to perturbation of Ras membrane anchorage. 
To check whether the hit compounds induce changes in subcellular Ras localization, 
we did confocal imaging with MDCK cells stably expressing H- or K-rasG12V and 
treated with the hit compounds. These imaging experiments revealed that these hit 
componds do not affect H- and K-ras subcellular distribution (II: Supplementary 
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Figure 5c).  
 
We then analyzed the anti-CSC potential of these compounds in breast CSC using 
the well-studied CD44+/CD24- enriched CSC population found in breast cancer cell 
lines. We used flow cytometry to analyze the CD44+/CD24- CSC-population of 
MDA-MB-231 breast cancer cells treated with the inhibitors. Using this analysis, we 
established that conglobatin A and ophiobolin A significantly reduced the 
CD44+/CD24- population, similarly to salinomycin (II: Figure 6C, D). Testing of the 
other ophiobolin analogues ophiobolin B and C on CD44+/CD24- populations 
showed that ophiobolin A and B are highly active and dose dependently reduced the 
CD44+/CD24- cells, whereas ophiobolin C is inactive. Structural comparison of these 
ophiobolin analogues suggested that the oxygen 13 is required for the activity of 
ophiobolin A and B (II: Supplementary Figure 6B).  
 
To conclude, from this second screen we have identified two compounds that 
specifically affect K-ras-nanoclustering and signaling, which facilitated the 
identification of two new potential CSC inhibitors. The MST library used in the 
second screen consists of a diverse collection of compounds with antibiotic, 
antifungal, nematocidal and anti-tumor properties. It is interesting to note that some 
of the hits from this second screen such as leptomycin and staurosporine analogues 
have already been reported to be highly toxic against mammalian cells. However, our 
results also show that metabolites with little or no toxicity such as avermectins and 
conglobatin are active against K-ras nanoclustering. This suggests that toxicity per se 
is not sufficient for a compound to be found as active in the screen.  
 
Our results also show that of all the validated hits, Ophiobolin A is found to be the 
most effective breast CSC inhibitor. These results are supported by the specific effect 
of ophiobolin A on K-ras nanoclustering and effector recruitment. Corroborating 
the effect on CD44+/CD24- breast CSCs, our unpublished data show that ophiobolin 
A treatment significantly affects the self-renewal and tumorgenicity of breast CSCs 
(MDA-MB-231) measured using mammospheres assay. Our data also show that 
Ophiobolin A dose-dependently reduces the mammosphere formation in other 
breast cancer cells with high CSC populations (data not shown). Concurrent with 
this effect on CSCs, ophiobolin A is less potent against breast cancer cells (like 
MCF7) that have a low CSC population (data not shown). 
 
Although at this moment the exact mechanisms underlying the elimination of CSCs 
by ophiobolin A are poorly understood, our results above show that one potential 
mechanism could be the perturbation of K-ras nanoclustering and signaling. It is 
also evident that the effects of ophiobolins on K-ras are not due to changes in the 
subcellular localization or distribution. This suggests that ophiobolin could be 
targeting a K-ras specific interaction. Interestingly, previous studies have shown that 
ophiobolin A is a strong calmodulin (CaM) antagonist that covalently binds 
calmodulin on lysines on position 75 or 77 and 148 thus inhibiting CaM activity (Au 
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et al., 2000; Kong Au and Chow Leung, 1998). The Lys-75 was shown to be the 
primary inhibitory site that is responsible for all the inhibitory activity of ophiobolin 
A binding. The Lys-75 CaM mutant is partially resistant to ophiobolin A, whereas 
mutation on all three Lys renders the CaM completely resistant to ophiobolin A 
(Kong Au and Chow Leung, 1998). Other reports have shown ophiobolin A to 
induce apoptosis in mouse leukemia cells and inhibit growth of human cancer cells 
(Au et al., 2000; Bencsik et al., 2014). Recently, ophiobolin A was shown to induce 
cell death in glioblastoma cells (Bury et al., 2013). However, the precise mechanism 
of action on CaM inhibition and the action on mammalian cancer cells has remained 
unclear. In the context of Ras signaling, CaM is already shown to specifically bind to 
active K-ras4B and not H- or N-ras (Villalonga et al., 2001). Moreover, it has been 
shown that the HVR of K-ras provides the major CaM binding site, but both the 
HVR and catalytic domain are involved in CaM binding affinity (Abraham et al., 
2009). The binding of CaM to K-ras4B is shown to be mutually exclusive with the 
S181 phosphorylation of K-ras4B and this modulates oncogenic and non-oncogenic 
K-ras activity and functions (Alvarez-Moya et al., 2010; 2011). Therefore, it is likely 
that ophiobolin A exhibits its anti-CSC properties through inactivation of CaM, 
leading to a deregulated K-ras nanoclustering and signaling. In fact, we have 
preliminary experimental evidence showing that loss of CaM by siRNA can lead to 
loss of tumorspheres or CSCs. The exact molecular mechanism behind these 
observations and the relationship to K-ras still needs to be worked out. Nevertheless, 
these observations are consistent to the very recent report from the McCormick 
group that proposed blocking the K-ras/CaM interaction as a novel approach to 
specifically interfere with K-ras stemness signaling in cancer cells (Wang et al., 
2015). The results above could lead to a better understanding of the mode of action 
of ophiobolin in CSC.  
 
3.5 Future	perspectives 
Ras proteins play a critical role in normal cell cycle, growth and differentiation. They 
cluster into nanoscale complexes on the plasma membrane called nanoclusters. 
Nanoclustering of oncogenic Ras proteins has emerged as a novel therapeutic target. 
The results obtained from this thesis suggest that nanoclusters indeed could be a 
potential avenue to find novel drugs that modulate activity of oncogenic proteins. 
There is now a growing understanding that not all Ras isoforms are created equal 
and that the different isoforms have distinct roles and function in normal and cancer 
cells. Consequently, strategies targeting Ras need to be specific for the different 
isoforms. The work presented in this thesis suggests that a nanocluster-directed 
differential screening approach could identify compounds that are able to 
specifically modulate the distinct Ras isoforms. In the context of K-ras, our 
identification of previously known CSC drugs and potentially novel CSC inhibitors 
from a small library of microbial metabolites suggests that natural products and 
metabolites could be rich sources of similar compounds. Although the clinical 
relevance of these compounds is currently unclear, they can be chemically modified 
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to generate analogues with specific activity towards CSCs that are well tolerated. 
Moreover, several compounds and natural products are being repurposed and 
clinically tested for activity against CSCs. However, the goal of future cancer therapy 
should be to eradicate all cancer cells in a patient, including CSCs. Similarly to 
cancer cells, CSCs, may also show various cell specific mutations. Since the CSCs 
represent a heterogeneous population, finding a “silver bullet” that kills all CSCs 
might prove difficult. CSCs that are not targeted by a particular CSC-directed 
therapy might escape, and subsequently therapy-resistant CSC clones might arise. 
Therefore, finding new molecular pathways and gene signatures to successfully 
target CSCs is important. The finding of gene signatures similar to our K-ras 
nanoclustering associated gene signature would be of clinical relevance in the 
selection of patients that would respond maximally to a specific CSC-directed 
therapy.  
 
As cancer therapy becomes more individualized, it also underlines the need for 
better mechanistic understanding of molecular drivers and molecular mechanisms 
involved in cancer. For instance, the reason for high frequency of K-ras mutations 
compared to N- and H-ras mutations in various cancer types is still not resolved. 
Several studies argue for different reasons behind this. One of the reasons for this 
preponderance of K-ras mutations is attributed to the unique property of K-ras in 
bestowing cells with stem cell properties. The work presented in this thesis and work 
from others suggests that K-ras, indeed, plays an important role in CSCs. The 
advances in genetically engineered mouse models now offer ways to tissue-
specifically delete genes. These models could offer new insights into the role of K-ras 
in adult stem cells in tissues such as stomach and colon. What is the K-ras 
dependency of these stem cells in vivo and what would be the fate of these cells if 
they were to lose the K-ras allele? These are some of the questions that need to be 
answered. 
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CONCLUDING	REMARKS	
C o n c l u d i n g 	 R e m a r k s 	
Since their discovery three decades ago, Ras proteins have been widely studied and 
implicated in human cancers, but therapeutic targeting of Ras remained elusive. 
When I began my PhD thesis project, efforts to therapeutically target Ras in cancers 
were making a coming back. This was largely due to the developments made in the 
past decade on computer modeling, crystallography and novel ways of screening for 
drug compounds. In addition, recent years have enabled a better understanding of 
the complexity in Ras subcellular regulation and function. The combination of this 
and afore mentioned tools have now renewed the hope of finding a safe drug to curb 
Ras activity. It has become clear in recent years that not all Ras isoforms are created 
equal. Particularly, studies pointing to the important role of K-ras in conferring stem 
cell properties had started to accumulate, however, how this is regulated is not fully 
understood. It was now widely accepted that the Ras proteins form nanoscale-
signaling complexes called nanoclusters on the plasma membrane that dictate 
downstream signaling. The work from others and us has confirmed the importance 
of Ras nanoclustering in cancers, and nanoclusters have emerged as potential anti-
cancer drug targets. In this thesis, a FRET-based small molecule screening approach 
is used for finding novel chemical modulators of Ras nanoclustering. This screening 
method was previously shown to identify potential nanocluster inhibitors. In the 
first study, we utilized this method to screen for H-ras specific nanocluster 
modulator compounds and found that PSIs such as CHX and others, specifically 
induced H-ras nanoclustering, effector recruitment and downstream signaling. 
Interestingly, CHX also increased the CSC-enriched mammospheres and tumor 
growth of breast cancer cells. Depletion of H-ras and CHX treatment significantly 
reduced mammospheres, suggesting an exquisite synthetic lethality. These results 
provides insights into the possibility of identifying Ras-isoform specific modulators 
using nanocluster-directed screening, as we also show that PSI do not increase K-ras 
nanoclustering or signaling. In the second study, we used this nanocluster-directed 
differential screening approach to show that the CSC inhibitor salinomycin 
specifically inhibits K-ras nanocluster organization and this activity is sensitive to 
the presence of caveolae. We use this insight to derive a K-ras nanoclustering 
associated and stem cell derived gene signature that predicts the sensitivity of cancer 
cells to salinomycin. We show that 8% of samples in TCGA database with the above 
gene signature have a significantly higher mortality. Using this mechanistic insight, 
we identify ophiobolin A and conglobatin A to specifically inhibit K-ras 
nanoclustering and act as potential breast CSC inhibitors. The third study 
investigates the application of the above FRET-based assay to design biosensors that 
can report on the membrane anchorage of N-myristoylated proteins. We show that 
these biosensors can potentially report on inhibitors of membrane anchorage and 
nanoclustering of myristoylated proteins.  
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Figure	16.	Schematic	summary	of	all	results	presented	in	this	thesis.	
 
The results presented in this thesis and its original publications (Figure 16), provide 
valuable insights into targeting nanoclusters of different oncogenic proteins and the 
perturbation of nanoclustering as a tractable new therapeutic target. It gives new 
understanding to the role of PSI and CSC inhibitors on different Ras isoforms. The 
future years hold great promises and challenges for understanding and targeting Ras 
in the context of Ras isoforms, membrane architecture, cell type and tissues. 
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This thesis describes a new approach to disrupting signaling of oncogenic proteins, 
specficially of Ras proteins. Ras is one of the major oncogenes, and it is mutated 
in 20% of all human cancers. Despite numerous efforts, targeting Ras directly 
in cancer has proven unsuccessful. We have taken a new approach to targeting 
Ras, namely targeting its localization and organization into nanoclusters in the 
cell membrane. By utilizing Förster resonance energy transfer (FRET)-based 
methods, we have screened chemical libraries to identify compounds that affect 
Ras nanoclustering. One of the main findings is that known cancer stem cell 
(CSC) inhibitors affect K-ras nanoclustering. We identify a K-ras-associated gene 
signature predicts response of cancer cells to CSC inhibitors. In addition, we were 
also able to identify novel compounds that target CSCs. The results give new 
insights into the role of Ras nanoclusters as promising new molecular targets in 
cancer and in stem cells.
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